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Abstract 
A Disintegrin and Metalloproteinase with ThromboSpondin Motif (ADAMTS)-5 is 
considered to play a key role in degradation of aggrecan during the progression of osteoarthritis 
(OA). Thus, ADAMTS-5 inhibitors are emerging as potential disease-modifying OA drugs. The 
generation of small molecule inhibitors of metalloproteinases has not achieved successful outcomes 
primarily due to the lack of selectivity. On the other hand, monoclonal antibodies were proved 
potent and selective binders of many biologically relevant targets. We therefore aimed to isolate 
inhibitory antibodies against ADAMTS-5. 
A human naïve single-chain variable fragment library was used to select and isolate anti-
ADAMTS-5 antibodies. Among the isolated antibodies, clones 2D3 and 2D5 inhibited ADAMTS-5 
cleavage both of a peptide substrate (Ki app values of 2 nM and 18 nM, respectively) and bovine 
aggrecan (Ki app values of 30 nM and 300 nM, respectively). Antibody 2B9 did not inhibit 
ADAMTS-5 activity against the peptide substrate, but it inhibited the cleavage of aggrecan (Ki app: 
300 nM). Surface plasmon resonance studies with a series of deletion mutants of ADAMTS-5 
indicated that 2D3 and 2D5 bind to the catalytic/disintegrin domain (KD values of 3 nM and 55 nM, 
respectively), whereas 2B9 binds to the spacer domain of this enzyme (KD value of 6 nM), thus 
being an exosite inhibitor. Kinetic studies indicated that the anti-ADAMTS-5 antibodies described 
here do not act through a zinc-chelating mechanism of inhibition. Moreover, inhibition and co-
immunoprecipitation data suggested that for some antibodies, such as 2D5, the binding site is 
different from that of TIMP-3.  
The efficacy of ADAMTS-5-blocking antibodies was investigated using model systems of 
aggrecan degradation (IL-1α/oncostatin M-stimulated porcine and human articular cartilage 
explants). The results indicated that antibodies 2D3 and 2B9 effectively inhibited aggrecanase 
activity in these systems. These antibodies may therefore be useful as chondroprotectant agents in 
OA. 
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1.1. Protease-mediated degradation of articular cartilage 
Osteoarthritis (OA) and rheumatoid arthritis (RA) are the two most common joint disorders, 
affecting a significant proportion of the human population. In particular, symptomatic knee OA 
occurs in 10% men and 13% women aged 60 years or older (Zhang and Jordan, 2010) and pain 
related to this pathology is the leading cause of impaired mobility in the elderly population in the 
USA (Helmick et al., 2008). Twenty-seven million individuals have been diagnosed with OA in the 
USA alone (Lawrence et al., 2008) and this number is expected to rise to 67 million by 2030 
(Hootman and Helmick, 2006). Although they differ in aetiology, both OA and RA are 
characterised by destruction of articular cartilage, which ultimately leads to pain and disability.  
Articular cartilage is composed of chondrocytes embedded in an extracellular matrix (ECM) 
which bestows the biomechanical properties (elasticity and compressibility) that are essential for 
movement. The two major ECM components are type II collagen fibrils and aggrecan 
proteoglycans; other less abundant macromolecules are fibromodulin, decorin, biglycan, cartilage 
oligomeric matrix protein (COMP), fibronectin, hyaluronan (HA), link protein, type VI, IX, and XI 
collagens and cell surface proteoglycans (Figure 1.1). Collagen is the main structural component of 
cartilage and provides tensile strength to the tissue; aggrecan provides flexibility, elasticity and 
compressibility and these functions are mediated by the negatively-charged glycosaminoglycans 
(GAG) chains attached to its core which ultimately are responsible for the high osmotic pressure in 
cartilage (Vertel and Ratcliffe, 2000). Multiple aggrecan molecules associate with a single HA 
filament (an unsulphated GAG), and each interaction is further stabilised by link protein. 
Proteoglycans and collagens interact with each other: perlecan proteoglycan enhances fibril 
formation (Kvist et al., 2006) and collagen VI microfibrils connect to collagen II and aggrecan via 
complexes of matrilin-1 and biglycan or decorin (Wiberg et al., 2002). 
The development of OA is related to genetic and environmental factors, metabolic disorders, 
and biochemical and/or biomechanical abnormalities. Under physiological conditions, cartilage 
homeostasis is maintained by a balance between the synthesis and degradation of aggrecan and 
collagen, but in OA and other joint disorders this equilibrium shifts towards catabolism. Enzymes 
involved in catabolism of collagens and proteoglycans are produced primarily by chondrocytes after 
inductive stimuli such as mechanical stress, injury, oxidative stress, etc. 
Loss of aggrecan is an early event in the onset of cartilage destruction, occurring initially at 
the joint surface and progressing to deeper zones (Pond and Nuki, 1973; Pratta et al., 2003). It has 
been hypothesised that aggrecan protects the collagen fibrillar network from proteolytic attack by 
collagenases due to steric and charge hindrance by its GAG chains (Pratta et al., 2003). In fact, no 
detectable levels of collagen release in interleukin-1 (IL-1)-stimulated bovine articular cartilage 
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explants have been noted until after 14 days of culture, when most of the aggrecan had been 
depleted from the ECM (Billinghurst et al., 2000).  
 
Figure 1.1. Schematic representation of articular cartilage ECM. 
 
Aggrecan breakdown which occurs at the earlier stages of OA is compensated by new 
synthesis (Lorenzo et al., 2004) and represents a reversible stage of cartilage degradation (Karsdal 
et al., 2008). Once collagen breakdown begins, OA becomes irreversible (Karsdal et al., 2008). It is 
noteworthy that a collagenase selective inhibitor (Ro-32-3555, Trocade, Cipemastat), developed by 
Roche, did not prevent progression of joint damage in patients with RA (Close, 2001) despite the 
favourable preclinical data (Lewis et al., 1997) and pharmacokinetics (Brewster et al., 1998). 
The term “aggrecanase” was coined to define operationally the enzymatic ability to cleave 
aggrecan at the Glu392↓393Ala bond (Sandy et al., 1991). Cleavage at this site represents a primary 
event in the proteolysis of aggrecan since fragments with the 393Ala N-terminus are the major 
products in catabolism of aggrecan by both chondrosarcoma cells and primary bovine chondrocytes 
(Lark et al., 1995). In 1999, aggrecanases have been identified as two members of A Disintegrin 
and Metalloproteinase with Thrombospondin Motifs (ADAMTS) family of metalloproteinases, 
aggrecanase-1 (ADAMTS-4) and aggrecanase-2 (ADAMTS-5, which was originally coined 
ADAMTS-11) (Tortorella et al., 1999; Abbaszade et al., 1999).  
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1.2. ADAMTSs 
 
1.2.1. The ADAMTS family 
The ADAMTS proteases belong to family M12 in clan MA of the metallopeptidases 
according to the MEROPS database (Rawlings et al., 2004). Other peptidases in family M12 
include astacins, the adamalysin peptidases (ADAMs) and the snake venom metallopeptidases 
(reprolysins). To date, 19 distinct ADAMTS gene products have been identified in humans 
(http://degradome.uniovi.es/met.html), as well as 7 ADAMTS-like (ADAMTSL) proteins lacking 
the catalytic domain (Figure 1.2). 
 
 
 
Figure 1.2: Schematic representation of the structural and evolutionary relationship of human ADAMTS and 
ADAMTSL gene products. 19 ADAMTS and 7 ADAMTSL protein sequences (from UniProt) were aligned with 
ClustalW 1.83 (Aiyar, 2000) and the resulting dendrogram was visualised with TreeView 1.6.6. Where applicable, the 
long form of splice variant is shown. There is no ADAMTS-11 because early reports of ADAMTS-11 (Abbaszade et 
al., 1999) were later found to describe ADAMTS-5. ADAMTSL-4 presents a large insertion in the first 
thrombospondin- type 1 domain. vWF, von Willebrand Factor, COMP, cartilage oligomeric matrix protein. ADAM-10 
is reported as out-group. Note that domains are not to scale. For details about the creation of the phylogram see Section 
2.2.8. 
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On the basis of the sequence homology and substrate specificity, ADAMTSs can be grouped 
into 7 subdivisions: 1) ADAMTS-1, -4, -5, -8 and -15; 2) ADAMTS-2, -3 and 14; 3) ADAMTS-9 
and -20; 4) ADAMTS-6, -7, -10 and -12; 5) ADAMTS-16 and -18; 6) ADAMTS-17 and -19; 7) 
ADAMTS-13 (Nicholson et al., 2005). Under a broad ClustalW analysis, ADAMTSL proteins fall 
in the same cluster as ADAMTS-13 (Figure 1.2) (Brocker et al., 2009).  
 
1.2.2. Biological role of ADAMTSs 
The (patho)physiological roles of the ADAMTSs have been defined for only few members. 
Members of the subgroup comprising ADAMTS-1, -4, -5, -8, -15, are also called “aggrecanases” or, 
more broadly, “hyalectanases”, to indicate their ability to cleave a family of large-aggregating 
proteoglycans (“hyalectans”, namely aggrecan, versican, brevican and neurocan) (Gao et al., 2002). 
Further studies have demonstrated that this activity is shared with ADAMTS-9, -16, and -20 
(Somerville et al., 2004; Zeng et al., 2006).  
Versican is the main proteoglycan in many tissues where it provides a loose and highly 
hydrated ECM and plays a role in cell adhesion, proliferation, migration and ECM assembly 
(Wight, 2002). Hyalectanases are able to cleave versican in vivo and are therein involved in several 
developmental processes where versican cleavage has been proved pivotal: ovulation (Russell et al., 
2003; Brown et al., 2006; 2010) and urogenital system development (ADAMTS-1) (Mittaz et al., 
2004); interdigital web regression (ADAMTS-5, -9 and -20) (McCulloch et al., 2009a); endocardial 
cushion remodelling during valve development (ADAMTS-5, -9) and myocardial compaction (Kern 
et al., 2010; Dupuis et al., 2011; Stankunas et al., 2008); myoblast fusion (ADAMTS-1, -9) (Stupka 
et al., 2013); palatogenesis (ADAMTS-9, 20) (Enomoto et al., 2010); melanoblast colonisation of 
skin (ADAMTS-20) (Silver et al., 2008). 
McCulloch et al. (2009a) showed an operational model in which several ADAMTSs 
(ADAMTS-5, -20, and -9, with a pivotal role exerted by ADAMTS-5) work cooperatively to 
influence apoptosis during the regression of the interdigital webs in mammalian limb 
morphogenesis through the production of pro-apoptotic versican fragments. Adamts-5-/-/Adamts-  
20-/- double knock-out mice exhibit soft tissue syndactyly since the interdigital webs have reduced 
apoptosis and decreased cleavage of versican (McCulloch et al., 2009a). Cooperation by ADAMTS-
9 and ADAMTS-20 in versican cleavage plays a role also in palatogenesis, since Adamts-9+/-
/Adamts-20-/- mice show cleft palate as a result of decrease of cell proliferation (Enomoto et al., 
2010). Also, mutations in Adamts-20 gene have been found to cause the belted white-spotting 
mutation in mice, resulting from a defect in melanocyte development or migration during 
embryogenesis (Rao et al., 2003). 
Chapter 1  Introduction 
23 
ADAMTS-5 and -15 contribute to the formation of multinucleated myotubes during 
myogenesis by remodelling a versican-rich pericellular matrix and facilitating the myoblast fusion 
(Stupka et al., 2013). The universal importance of versican cleavage by hyalectanases during 
development has been shown by GON-1, an orthologue of ADAMTS-9 and -20 in Caenorhabditis 
elegans, which is required for migration of distal tip cells during gonadal morphogenesis (Blelloch 
et al., 1999). Versican is the primary proteoglycan in vasculature (Salter et al., 2010) and can form a 
complex with multiple Low-Density Lipoprotein (LDL) molecules. Positively-charged lipoproteins 
interact with sulphated negatively-charged GAG chains of versican and other proteoglycans and this 
complex can increase lipoprotein uptake in both vascular smooth muscle cells (VSMCs) and 
macrophages (Hurt-Camejo et al., 1992; Llorente-Cortés et al., 2002). Both biglycan and versican 
accumulate in atherosclerosis-prone arteries, where they trap LDL molecules (Skalén et al., 2002); 
LDL lipoproteins then aggregate and elicit an inflammatory response, involving alterations of 
VSMCs and remodelling of ECM (Chait and Wight, 2002). 
ADAMTS-4 and -8 have been implicated in the formation of atherosclerotic plaques and 
atherosclerotic disease (Wågsäter et al., 2008). ADAMTS-1, -4, -5 and -8 are present within human 
carotid lesions and advanced coronary atherosclerotic plaques (Wågsäter et al., 2008; Jönsson-
Rylander et al., 2005). In particular, ADAMTS-4, -5 and -8 are localised in macrophages, whereas 
ADAMTS-1 is localised in endothelial and VSMCs (Wågsäter et al., 2008; Jönsson-Rylander et al., 
2005). Cleavage of versican by ADAMTS-1 may promote VSMC migration (Jönsson-Rylander et 
al., 2005). On the other hand, ADAMTS-5 activity is needed for proteoglycan-mediated lipoprotein 
retention (Didangelos et al., 2012) (See Section 1.3.5).  
Other than versican, another main substrate of hyalectanases is aggrecan, one major 
component of articular cartilage. Studies with Adamts-5-null mice showed that the lack of 
ADAMTS-5 is sufficient to protect from cartilage destruction when OA (Glasson et al., 2005) or 
inflammatory arthritis (Stanton et al., 2005) was induced (See Section 1.3.5.). ADAMTS-4 and 
ADAMTS-5 play a role in the form of arthritis occurring in Lyme disease (Behera et al., 2006). 
Products formed by cleavage at Glu392↓393Ala of aggrecan are detected in synovial fluid (SF) from 
patients affected by this form of arthritis (Hu et al., 2001). Active ADAMTS-4 levels are also 
increased in SF from these patients and human chondrocytes infected with Borrelia burgdorferi, the 
etiologic agent of Lyme disease, show highly induced levels of ADAMTS-4 but not ADAMTS-5 
(Behera et al., 2006). ADAMTS-5 expression is associated with herniated disc and cervical disc 
degeneration pathology, suggesting a role in intervertebral disc degeneration (Zhao et al., 2011). In 
this case, IL-1β-induced expression of ADAMTS-5 is mediated by nitric oxide through induction of 
inducible nitric oxidase (Stradner et al., 2008; Zhao et al., 2011). 
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Adamts-4 is transcriptionally induced in rat astrocytes treated with β-amyloid, suggesting it 
may be involved in Alzheimer’s disease (AD), possibly through cleavage of brevican, a 
proteoglycan specific to the central nervous system (Satoh, 2000). Proteoglycans such as brevican, 
neurocan and phosphacan inhibit neural plasticity under physiological and pathological conditions 
and this is mainly due to their GAG groups (Silver and Miller, 2004). ADAMTS-4 can reverse 
inhibition of neurite outgrowth by cleaving these proteoglycans in vitro and administration of 
exogenous ADAMTS-4 promotes motor function recovery after spinal cord injury in rats (Tauchi et 
al., 2012). However, inactive ADAMTS-4 promotes neurite outgrowth extension through activation 
of extracellular-signal-regulated kinase (ERK), thus catalytic activity is not strictly required (Hamel 
et al., 2008). Activation of ERK kinases is possibly mediated by binding to heparan-sulphate-
containing proteins such as syndecans on the cell surface (Gao et al., 2004). Thus ADAMTSs 
promote neurite extension by two mechanisms: 1) they cleave proteoglycans which inhibit neurite 
outgrowth; 2) they enhance neurite outgrowth directly by activating ERK cascade (Hamel et al., 
2008). To support a role in neural regeneration, expression of both Adamts-4 and Adamts-1 is up-
regulated following neuronal injuries (Yuan et al., 2002; Cross et al., 2006). 
Reelin is a secreted glycoprotein that is mainly expressed in the brain where it is essential 
for proper neurodevelopment and synaptic plasticity (Hisanaga et al., 2012). Reelin binds to 
apolipoprotein E receptor 2 and very low-density lipoprotein receptor, and then activates 
intracellular signalling events that eventually regulate normal development and function of the 
central nervous system (Honda et al., 2011). Proteolytic processing of Reelin decreases its 
signalling activity and promotes its aggregation in vitro; dysfunction of this processing is involved 
in AD and schizophrenia (Kohno et al., 2009). Cleavage of Reelin produces one N-terminal and one 
C-terminal fragment (Lambert de Rouvroit et al., 1999). The N-terminal cleavage fragment is prone 
to aggregate (Utsunomiya-Tate et al., 2000). ADAMTS-4 and ADAMTS-5 (but not ADAMTS-1 
nor ADAMTS-8) can cleave in vitro Reelin, but only ADAMTS-5 is able to degrade the N-terminal 
fragment (Hisanaga et al., 2012; Krstic et al., 2012) (see Section 1.3.5). AD mice show decreased 
expression of Adamts-5 in the hippocampus, therefore decreased processing of the N-terminal 
fragment by ADAMTS-5 may be responsible for accelerated Reelin aggregation in the 
hippocampus of AD mice (Krstic et al., 2012). 
ADAMTS-2, -3, and -14 have been characterised as procollagen N-propeptidases. These 
enzymes cleave the N-terminal propeptides of type I, II, and III procollagens and mutations in the 
human ADAMTS-2 gene cause Ehlers-Danlos Syndrome type VII C (EDS-VIIC), a recessively-
inherited disorder characterised by the presence in the skin of procollagen incompletely processed 
at the N-terminus, and dermatosparaxis in bovine (Colige et al., 1999). Adamts-2 is specifically co-
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expressed with collagen III in the lung and aorta and Adamts-2-/- mice had abnormal lungs with 
decreased parenchymal density (Le Goff et al., 2006). 
Null mutations in ADAMTS-10 have been associated with a recessive form of Weill-
Marchesani syndrome (Dagoneau et al., 2004; Morales et al., 2009) and primary open angle 
glaucoma in dogs (Kuchtey et al., 2011), and mutations in ADAMTS-17 have been identified in 
patients affected by a “Weill-Marchesani-like” syndrome (Morales et al., 2009). ADAMTS-10 
promotes fibrillin-1 deposition in ECM of cultured fibroblasts, supporting a role for this enzyme in 
microfibril biogenesis (Kutz et al., 2011). On the other hand, fibrillin-1 (FBN1) mutations can cause 
dominant Weill-Marchesani syndrome and associated ectopia lentis (dislocation of ocular lens), a 
condition caused by disruption of the zonular fibres supporting the lens (Faivre et al., 2003).  
ADAMTS-18 has been found mutated in patients affected by Knobloch syndrome, a 
developmental disorder characterised by eye abnormalities including high myopia, cataracts, 
dislocated lens, vitreoretinal degeneration and retinal detachments, and occipital skull defects 
(Aldahmesh et al. 2011).  
ADAMTSL proteins, devoid of a catalytic domain, appear to exert regulatory roles in ECM. 
A homozygous mutation in ADAMTSL-4 was identified in autosomal recessive ectopia lentis et 
pupillae (Ahram et al., 2009; Christensen et al., 2010). In summary, these observations suggest that 
ADAMTSL-4, ADAMTS-10 and ADAMTS-17 play a critical role in crystalline lens zonule and 
connective tissue formation. 
ADAMTSL-2 is involved in geleophysic dysplasia (GD), an autosomal recessive disorder 
characterised by short stature, brachydactyly, thick skin and cardiac valvular anomalies (Le Goff et 
al., 2008). The presence of very high levels of active transforming growth factor (TGF)-β in GD 
strongly suggests that this protein is important in sequestering TGF-β in ECM (Le Goff et al., 
2008). ADAMTSL2 interacts with latent TGF-β-binding protein 1 and fibrillin-1 and is expressed 
in heart, skin and pulmonary arteries, as well as in chondrocyte columns in the hypertrophic and 
reserve zones of the proximal femoral growth plate (Le Goff et al., 2008). An ADAMTSL-2 
mutation causes Musladin-Lueke syndrome, a fibrotic disorder in beagle dogs (Bader et al., 2010).  
ADAMTS-7 and ADAMTS-12 play a role in degradation of COMP (Liu CJ et al., 2006a; 
Liu CJ et al., 2006b), a prominent non-collagenous component of cartilage which catalyses and 
promotes collagen fibre formation (Halasz et al., 2007). 
ADAMTS-13 mediates the catabolism of von Willebrand Factor (vWF), a glycoprotein 
involved in platelet adhesion to injured vessel walls under high-shear stress (Zimmerman and 
Ruggeri, 1987). ADAMTS-13 attenuates thrombus formation and growth on injured neointima 
(Moriguchi-Goto et al., 2009). Mutations in ADAMTS-13 and auto-antibodies against ADAMTS-13 
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correlate with the occurrence of the hereditary and sporadic forms, respectively, of thrombotic 
thrombocytopenic purpura (TTP) disease, a rare disorder of the blood coagulation system (Levy et 
al., 2001; Soejima et al., 2003; Scheiflinger et al., 2003). 
Finally, dysregulated expression and activity of several ADAMTSs have been associated 
with different forms of cancer (See Section 1.2.4.5). 
 
1.2.3. ADAMTS domain structure 
ADAMTSs belong to the metallopeptidase family M12 and are evolutionarily and 
structurally related to the matrix metalloproteinases (MMPs) (family M10) (Rawlings et al., 2004). 
A common feature of these metallopeptidase families is the presence of a zinc-binding motif in the 
catalytic domain, containing the consensus sequence HEXXHXXGXXH, in which the three 
histidine residues coordinate a zinc atom and the glutamate residue exerts a catalytic role. This 
motif is followed C-terminally by a conserved methionine residue which constitutes a tight turn 
(“Met-turn”) acting as a constraint in the topology of active site (Bode et al., 1993). The zinc-
binding motifs and the Met-turn are also found in astacins, pappalysins, bacterial serralysins and 
enterotoxin (Bode et al., 1993; Goulas et al., 2011). All these families are collectively called 
“metzincins” (Bode et al., 1993). 
Unlike ADAMs, which are transmembrane proteins, ADAMTSs are secreted proteins, and 
some of them bind to the ECM (Kuno and Matsushima, 1998; Kashiwagi et al., 2004; Gendron et 
al., 2007). They share a common domain composition consisting of a signal peptide, a prodomain, a 
metalloproteinase catalytic domain (Cat), followed by non-catalytic ancillary domains such as a 
disintegrin-like (Dis) domain, a thrombospondin-type I motif (TS) domain, a cysteine-rich (CysR) 
domain, a spacer (Sp) domain, and a various number of TS domains in the C-terminus (with the 
exception of ADAMTS-4, which has only the TS domain preceding the CysR region; TS domains 
are numbered here from the N-terminus TS-1, TS-2, etc) (Figure 1.2). Some of the ADAMTSs 
have further C-terminal domains, such as a mucin domain (present in ADAMTS-7 and ADAMTS-
12), a GON domain (in ADAMTS-20 and ADAMTS-9), and a PLAC (protease and lacunin) 
domain (in ADAMTS-2, -3,-6, -10, -12, 14, -16, -17, -18, and -19) (Porter et al., 2005). Moreover, 
ADAMTS-13 is unique among ADAMTs since it presents two CUB [complement subcomponent 
C1r/C1s/embryonic sea urchin protein Uegf (urchin epidermal growth factor)/bone morphogenic 
protein 1] domains (Soejima et al., 2001; Zheng et al., 2001).  
For the ADAMTS family members, crystal structures have only been resolved for the Cat 
domains of ADAMTS-1, -4, and -5 (Gerhardt et al., 2007; Shieh et al., 2008; Mosyak et al., 2008) 
and for TS-1, CysR and Sp domains of ADAMTS-13 (Akiyama et al., 2009).  
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The Cat domain of ADAMTS-5 contains the active site (with the zinc-binding sequence 
HEIGHLLGLSH), the catalytic zinc ion, and two calcium-binding sites and has an α/β structure 
characteristic of the metzincin family (Shieh et al., 2008; Mosyak et al., 2008). There are two 
calcium-binding sites which have a structural role: one of them contains a single calcium ion 
whereas the other one comprises two calcium ions in a calcium cluster (Shieh et al., 2008). The 
latter calcium-cluster is not present in any known metalloproteinase structure. The Cat domain is 
stabilised by four disulphide bonds (Mosyak et al., 2008; Shieh et al., 2008); five cysteine residues 
are upstream of the zinc-binding sequence, and three residues are downstream of it. Downstream of 
this sequence is also present the methionine residue of the “Met-turn”. The overall fold of the Cat 
domain of ADAMTSs is similar to that of other metzincins, with a central five-stranded β-sheet of 
which four strands are in a parallel configuration and a fifth one is in an antiparallel configuration 
(Shieh et al., 2008). This β-sheet is flanked with two helices on its concave side and one helix on its 
convex side. The main differences compared with the MMPs are the outward facing S2’and the 
inward facing S1’ pockets (terminology is after Schechter and Berger, 1967). The S2’ pocket is 
defined by a short disulphide-containing loop (containing the motif CGxxxCDTL) not present in 
any of the MMPs, called S2’ loop (residues 371-379 in ADAMTS-5) (Mosyak et al., 2008). Unlike 
the large loop present in all the MMPs, this loop adopts a compact β-turn structure quite far from 
the catalytic zinc ion, which could impede sterically access of substrates into the S1’ and 
S2’pockets (Mosyak et al., 2008). The S1’-loop (residues 437-451 in ADAMTS-5) occupies about 
half of the inner face of the S1’ pocket, whereas in the MMPs it occupies almost the whole S1’ 
pocket. The S1’ pocket of ADAMTS-5 is smaller than ADAMTS-4 owing to more bulky side 
chains present in ADAMTS-5 (Leu301, Leu438, Leu443, and Ile446 in ADAMTS-5 instead of Ala252, 
Val390, Met395, and Val398 in ADAMTS-4) (Mosyak et al., 2008). 
The disintegrin (Dis) domain of ADAMTSs does not share homology with disintegrins, a 
family of proteins from viper venoms, but it is very similar in structure to part of the CysR domain 
of P-III snake venom metalloproteinases in which it is involved in binding to platelet integrin 
receptors (Gerhardt et al., 2007; Mosyak et al., 2008; Akiyama et al., 2009). This prevents the 
association of platelets with their natural ligands such as fibrinogen, and results in a block of 
platelet aggregation at the wound site. In ADAMTS-5, the Dis domain lacks any integrin binding 
sequence and does not interact with integrin (Mosyak et al., 2008). It forms a unique fold of two α-
helices, two β-sheets, and several loops throughout, connected to the Cat domain by a flexible 
linker 9 amino acids-long (Mosyak et al., 2008). The Dis domain lies on the prime side of the active 
site, where it shields the S1’ pocket and, to a lesser extent, the S3’ pocket from solvent (Mosyak et 
al., 2008). On the basis of their close proximity in the three-dimensional structure (Mosyak et al., 
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2008) and the activity studies of ADAMTS-5 deletion mutants (Kashiwagi et al., 2004; Lauer-
Fields et al., 2007; Gendron et al., 2007) (See Section 1.3.3), Cat and Dis domains can be 
considered as a structural and functional unit. 
The TS-1 domain is highly conserved within the ADAMTS family, including the 
CSR(T/S)C pentapeptide (Hurskainen et al., 1999). This pentapeptide is consistently different from 
the corresponding sequence (CSVTC) present in thrombospondins (Hurskainen et al., 1999). The 
CysR domain contains 10 conserved cysteine residues, whereas the Sp region does not contain 
cysteine residues, which could make this region quite flexible. In ADAMTS-13, the Sp domain has 
a β-sandwich structure where surface-exposed variable loops are potentially able to interact with 
target proteins (Akyama et al., 2009). Ancillary non-catalytic domains are involved in substrate 
binding and cleavage as well as ECM-binding. They comprise substrate-binding sites (exosites) 
which interact specifically with the substrate. For example, the four TS domains of ADAMTS-7 
(Liu CJ et al., 2006a) and -12 (Liu CJ et al., 2006b) are necessary for binding to COMP. A critical 
step in both vWF binding and proteolysis by ADAMTS-13 is the docking of the Sp domain onto the 
C-terminal end of the VWF A2 domain (Zheng et al., 2003). The Dis domain of ADAMTS-13 also 
plays an essential role by enabling specific proteolysis (Gao et al., 2008; de Groot et al., 2009). 
Without these ancillary domains, the Cat domain of ADAMTS-13 binds to vWF with very low 
affinity and poor cleavage site specificity. The functions of non-catalytic ancillary domains of 
aggrecanases are described in Section 1.3.3. 
 
1.2.4. ADAMTS regulation 
ADAMTS activity is regulated by multiple interacting processes such as promoter activity, 
epigenetic modifications, regulation by microRNA (miRNA), alternative splicing, prodomain 
removal, post-translational modifications (e.g. C-terminal processing), presence of endogenous 
inhibitors and cofactors, and endocytosis. Since the ancillary domains are important in substrate 
recognition and cleavage efficiency, mechanisms able to produce variants lacking one or more of 
these domains (alternative splicing, C-terminal processing) could represent a potent strategy to 
modulate ADAMTS activity in vivo. 
 
1.2.4.1. Regulation of expression 
Expression of ADAMTSs has been shown to be regulated by cytokines, hormones, and 
epigenetic modifications. The effects produced by cytokines on ADAMTS expression vary greatly 
depending on the specific tissue/cell types examined. Major up-regulators of ADAMTS expression 
are interleukin-1 (IL-1) and tumour necrosis factor-α (TNF-α). ADAMTS-1 messenger RNA 
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(mRNA) is up-regulated by IL-1 (Kuno et al., 1997), and ADAMTS-1, -6, and -9 mRNA levels are 
up-regulated in response to TNF-α in retinal pigment epithelium-derived cells (Bevitt et al., 2003). 
Levels of pro-inflammatory cytokines are increased in arthritic joints and cartilage (Mills and 
Dunne, 2009). These cytokines are produced by mononuclear cells, chondrocytes and synoviocytes 
(Fernandes et al., 2002). Aggrecanase activity in bovine (Arner et al., 1998) and porcine (Powell et 
al., 2007) cartilage explants is inhibited by the inclusion of cycloheximide, thus indicating a 
requirement for de novo protein synthesis in IL-1 and TNF-α-mediated up-regulation. ADAMTS-12 
is induced by interferon-alpha (IFN-α) and IL-1β (Liu CJ et al., 2006b; Llamazares et al., 2007). 
ADAMTS-4 mRNA expression by human synoviocytes is significantly inhibited by the TNF-α 
blocker etanercept and an anti-IL-1β neutralising antibody, whereas the expression of ADAMTS-5 
in the same cells was not affected by neutralisation of IL-1β and/or TNFα (Bondeson et al., 2006). 
An additive effect of combination treatment with oncostatin M (OSM) and either IL-1α or TNF-α in 
human chondrocytes or cultured human cartilage explants led to a marked induction of ADAMTS-4 
gene expression and some induction of ADAMTS-5 (Song et al., 2007). 
ADAMTS-5 mRNA is constitutively expressed in human chondrocytes (Bau et al., 2002; 
Moulharat et al., 2004) and synovial fibroblasts (Vankemmelbeke et al., 2001; Yamanishi et al., 
2002; Blaney Davidson et al., 2006). In mouse knee joint explants stimulated with IL-1α and TNF-
α, Adamts-5 mRNA was found induced in tenocytes, synovium, and in patellar, but not femoral or 
tibial articular cartilage (Wylie et al., 2012). In fibroblast-like synoviocytes the expression of 
ADAMTS-4 mRNA was increased by IL-6 and soluble IL-6 receptor, whereas that of ADAMTS-5 
was decreased (Mimata et al., 2012). This regulation is mediated by both mitogen-activated protein 
kinase (MAPK)/ERK and the JAK/STAT signalling pathways (Mimata et al., 2012). IL-4 inhibits 
the expression of MMPs and ADAMTS-4, thus exerting protective effects on cartilage in animal 
models of OA (Yorimitsu et al., 2008). TGF-β strongly up-regulates ADAMTS-4 mRNA and protein 
expression in human synovial fibroblasts, but does not affect ADAMTS-5 (Yamanishi et al., 2002). 
The stress-induced calcium-binding protein, S100A8, enhances IL-1-induced ADAMTS-5 
expression in mouse cartilage (van Lent et al., 2008). Fibroblast growth factor-2 (FGF-2) 
specifically inhibits IL-1-induced expression of ADAMTS-4 and -5 in primary human chondrocytes 
(Sawaji et al., 2008). ADAMTS-5 activity and aggrecan cleavage have been found increased in 
fgf2-null mice (Chia et al., 2009). The immunosuppressant drug cyclosporin A down-regulates 
ADAMTS-4 and ADAMTS-5 at mRNA levels (Little et al., 2002a) while a suppressive effect of n-3 
fatty acids was observed for ADAMTS-4 mRNA but not for ADAMTS-5 (Curtis et al., 2000; Curtis 
et al., 2002).  
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The human ADAMTS-4 promoter has two putative binding sites for the transcription factor 
nuclear factor of activated T cells-p (NFATp) and eight putative binding sites for the Runt-related 
transcription factor (RUNX) family of transcription factors (Thirunavukkarasu et al., 2006), and 
human ADAMTS-5 promoter has four putative binding sites for the family of RUNX transcriptions 
factors (Thirunavukkarasu et al., 2007). ADAMTS-5 promoter activity is up-regulated in response to 
RUNX-2 over-expression in primary bovine chondrocytes and human chondrosarcoma cells 
(Thirunavukkarasu et al., 2007). The human ADAMTS-4 promoter contains at least one specificity 
protein-1 (Sp1) transcription factor-binding site (Mizui et al., 2000) which mediates induction by 
IL-1β (Sylvester et al., 2013). Sp1 regulates also TIMP-3 (Tissue Inhibitor of Metalloproteinase-3), 
an endogenous inhibitor of aggrecanases (Qureshi et al., 2005) (See Section 1.2.4.4), and 
transcription factor SRY-box-containing gene 9 (SOX9), a master regulator of chondrocyte 
differentiation (Piera-Velazquez et al., 2007). Nuclear factor-κB (NF-κB) plays a role in inducible 
expression of ADAMTS-4 (Chockalingam et al., 2007; Bondeson et al., 2007; Ahmad et al., 2009). 
Hormones play also a regulatory role in ADAMTS expression. In osteopenic mice, estradiol 
and pamidronate decrease ADAMTS-4 and ADAMTS-5 expression (Funck-Brentano et al., 2012). 
The thyroid hormone tri-iodothyronine (T3) up-regulates mRNA expression of ADAMTS-5, but not 
ADAMTS-4, with subsequent aggrecan degradation, in growth plate cartilage during endochondral 
ossification (Makihira et al., 2003). 
Expression and/or activity of ADAMTS-4 and -5 can be regulated by mechanical loading in 
chondrocytes (Ding et al., 2010; Tetsunaga et al., 2011). Uni-axial cyclic tensile strain induced 
expression of RUNX-2, MMP-13, ADAMTS-4, -5, and -9 by SW1353 chondrocytes-like cells 
(Tetsunaga et al., 2011). In this study, over-expression of RUNX-2 up-regulated expression of 
MMP-13 and ADAMTS-5, but did not have any effect on expression of ADAMTS-4 and ADAMTS-9 
(Tetsunaga et al., 2011). A ~40-fold increase of ADAMTS-5 has been observed in cartilage explant 
cultures after mechanical injury (Lee JH et al., 2005). 
ADAMTS-5 expression can be regulated by epigenetic modifications such as histone 
acetylation and changes in the methylation status of CpG sites in the gene promoter. Histone 
acetylation and deacetylation are generally associated with transcriptional activation and repression, 
respectively, and these modifications can be reversed by histone deacetylases (Kouzarides, 2000). 
In SW1353 chondrosarcoma cells and primary human chondrocytes, histone deacetylases inhibitors 
sodium butyrate and trichostatin A inhibited IL-1α/OSM-induced ADAMTS-5 expression (Young et 
al., 2005). Methylation of CpG islands is associated with gene silencing. The percentage of non-
methylated sites in ADAMTS-4 promoter increased to 50% in OA cartilage from 0% in control 
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cartilage (Roach et al., 2005). Epigenetic modifications of ADAMTSs are involved in several types 
of cancer (See Section 1.2.4.5). 
 
1.2.4.2. Post-transcriptional regulation 
ADAMTS transcripts have been shown to be regulated by alternative splicing, alternative 
promoter usage, and miRNAs. In human, alternative splicing has been reported for ADAMTS-4 (2 
isoforms) (Wainwright et al., 2006; Wainwright et al., 2013), -6 (4 isoforms), -9 (3 isoforms) 
(Bevitt et al., 2003; Bevitt et al., 2005), -2 (2 isoforms), -13 (3 isoforms), -14 (2 isoforms) 
(Apweiler et al., 2004), -12 (3 isoforms), -16 (2 isoforms), -17 (2 isoforms), -18 (2 isoforms), -20 (2 
isoforms) and alternative promoter usage for ADAMTS-14 (2 isoforms) (Uniprot database). The full 
5’untranslated region (UTR) of ADAMTS-6 mRNA contains multiple upstream ATG initiation 
codons followed by very short open reading frames which may decrease translation rate by 
recruiting ribosomes to non-productive sites (Bevitt et al., 2005); conversely, alternative transcripts 
lacking these 5’UTR codons may increase translation.  
Another potential post-transcriptional regulation seems to be miRNA-mediated. miRNAs 
are a class of non-coding RNAs that negatively regulate genes involved in numerous biological 
processes. Mice with deletion of miRNA140, a miRNA specifically expressed in mouse cartilage 
and down-regulated in OA (Tuddenham et al., 2006; Miyaki et al., 2009), have significantly 
increased levels of ADAMTS-5 mRNA and increased aggrecan loss in vitro, compared with wild-
type mice (Miyaki et al., 2010). 
 
1.2.4.3. Post-translational regulation 
ADAMTSs can be regulated post-translationally by activation, C-terminal processing and 
endocytosis. In addition to N and O-glycosylation, which are common in secreted proteins, specific 
residues in the TS domains, occurring within conserved motifs, are modified by C-mannosylation 
and O-fucosylation (Ricketts et al., 2007; Wang et al., 2009). 
ADAMTSs are synthesised as inactive zymogens. The mechanism by which the prodomains 
maintain ADAMTS latency is currently unknown. The “cysteine switch” mechanism has been 
proposed for pro-MMPs (Van Wart and Birkedal-Hansen, 1990), but only ADAMTS-1, -6, -7,-10, -
12, and -15 contain a motif similar to the cysteine switch sequences found in the pro-MMPs (Porter 
et al., 2005). ADAMTSs are activated following proteolytic removal of the N-terminal propeptide 
by proprotein convertases (PC), a family of Ca2+-dependent subtilisin-type serine proteases which 
include furin and paired-basic amino acid converting enzyme-4 (PACE-4) (Bergeron et al., 2000). 
These enzymes recognise a multibasic consensus sequence RXR/KR within the propeptide of 
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ADAMTSs (208RRAKR212 in human ADAMTS-4 and 257RRRRR261 in human ADAMTS-5) 
(Tortorella et al., 1999; Abbaszade et al., 1999).  
PCs are located in the trans-Golgi network, in endosomes, at cell surface and in the ECM 
(Thomas, 2002). Consequently, activation of ADAMTSs may happen intracellularly as well as on 
the cell surface, although some PCs such as furin are more abundant inside the cell than on the cell-
surface (Klimpel et al., 1992). Intracellular furin-dependent processing of ADAMTS-4 has been 
observed (Wang et al., 2004). It has also been proposed that ADAMTS-4 and ADAMTS-5 
zymogens are deposited in cartilage ECM, where they may be activated by secreted PCs such as 
PACE4 (Malfait et al., 2008). Glucosamine interferes with ADAMTS-5 activation by impairing 
post-translational modification of furin (McCulloch et al., 2009b), and this could explain the 
suppression of aggrecan catabolism by hexosamines in cartilage explants cultures (Sandy et al., 
1998; Sandy et al., 1999). 
MMPs have been reported also to activate ADAMTSs. For example, ADAMTS-4 can be 
activated by MMP-9 (Tortorella et al., 2005) or can be processed on the cell membrane by the GPI-
anchored membrane type 4 MMP (MT4-MMP/MMP-17), in partnership with the transmembrane 
proteoglycan syndecan-1 (Gao et al., 2004). The latter mechanism is similar to the activation of 
ADAMTS-5 by MMP-3 in conjunction with syndecan-4 (Echtermeyer et al., 2009), although the 
exact biochemical mechanism is not known. ADAMTS-1 presents four MMP cleavage sites in the 
Sp domain (Rodriguez-Manzaneque et al., 2000). The serine protease trypsin has been shown to 
activate ADAMTS-4 (Tortorella et al., 2005). 
Cleavage in the C-terminal ancillary domains of ADAMTSs is a further regulatory level of 
ADAMTS activity which can affect both catalytic efficiency and binding to the ECM. Full-length 
ADAMTS-4 undergoes intramolecular autocatalytic C-terminal truncation to generate two isoforms, 
one lacking most of the Sp domain, the other lacking the Sp domain and most of the CysR domain, 
two regions which are essential for binding to GAGs (Flannery et al., 2002). A low molecular 
weight (37-kDa) form of ADAMTS-4 is prevalent in porcine chondrocyte-agarose cultures (Powell 
et al., 2007). C-terminal processing, with removal of the PLAC domain, has been observed for 
ADAMTS-2, resulting in an increase in procollagen peptidase activity (Colige et al., 2005). On the 
other hand, the same activity decreases after removal of the TS-2 and TS-4 domain (Colige et al., 
2005). ADAMTS-5 is further regulated by endocytosis (Yamamoto et al., 2013). Low-density 
lipoprotein receptor-related protein-1 (LRP-1) is the main receptor which mediates ADAMTS-5 
uptake by chondrocytes (Yamamoto et al., 2013).  
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1.2.4.4. Regulation by endogenous inhibitors and cofactors 
TIMP-3 is a potent endogenous inhibitor of both ADAMTS-4 and ADAMTS-5, with Ki 
values in the nanomolar range (Hashimoto et al., 2001; Kashiwagi et al., 2001). TIMP-3, like many 
ADAMTSs, is normally bound to GAGs associated with ECM and cell surfaces and the biological 
function of this localisation may be inhibition of cell-surface or ECM-bound proteases (Yu et al., 
2000). Other TIMPs (TIMP-1, -2, and -4) are ineffective inhibitors of these ADAMTSs, with Ki 
values in the high nanomolar range (Hashimoto et al., 2001). TIMP-3 also inhibits ADAMTS-1 
(Rodriguez-Manzaneque et al., 2000), and ADAMTS-2 (Wang et al., 2006). 
α2-macroglobulin (α2M) is a large plasma protein and is also present in the SF at 
concentrations of 1-2 mg/ml (Hadler et al., 1981). Most endopeptidases are inhibited by this 
macromolecular inhibitor and there is evidence that α2M may be an important inhibitor of 
ADAMTS-4 and -5 (Tortorella et al., 2004), as well as of ADAMTS-7 and ADAMTS-12 in the 
fluid phase (Luan et al., 2008). Other potential endogenous inhibitors reported so far are papilin for 
ADAMTS-2 (Kramerova et al., 2000) and the C-terminal domain of fibronectin for ADAMTS-4 
(Hashimoto et al., 2004). 
Interaction of ADAMTSs with cell surface or ECM molecules could enhance their 
aggrecanase activity. The interaction of ADAMTS-1 and ADAMTS-5 with fibulin-1, a secreted 
glycoprotein present in elastic matrix fibres and basement membranes, increases catalytic activities 
towards aggrecan or versican, respectively (Lee NH et al., 2005; McCulloch et al., 2009c). Fibulin-
1 does not represent a substrate for both enzymes but it could mediate ADAMTS-5 localisation on 
aggrecan via interaction of its epidermal growth factor (EGF)-like repeats in domain II with 
aggrecan (Aspberg et al., 1999). In kidney, fibulin-1, aggrecan and ADAMTS-1 colocalise in apical 
epithelial tubules and in the basement membrane (Lee NH et al., 2005). Direct interactions with 
syndecan-4 (Echtermeyer et al., 2009; Wang et al., 2011) and syndecan-1 (Gao et al., 2004) can 
recruit ADAMTS-5 and ADAMTS-4, respectively, to the cell surface, where these enzymes 
undergo extracellular activation. During intervertebral disc degeneration, elevated levels of 
cytokines TNF-α and IL-1β, as well as syndecan-4 and ADAMTS-4 and -5 are observed (Wang et 
al., 2011). Treatment with TNF-α and IL-1β increases syndecan-4 expression through NF-κB 
signalling pathway and promotes syndecans-4 interaction with ADAMTS-5 but not with 
ADAMTS-4 (Wang et al., 2011). 
 
1.2.4.5. ADAMTSs in cancer 
In the last decade, increasing evidence for a role of ADAMTSs in cancer has emerged 
(Table 1.1). The role played by ADAMTSs in this complex pathology is a result of unregulated 
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expression as well as aberrant C-terminal processing (Liu YG et al., 2006). In particular, different 
effects on angiogenesis and metastasis have been observed for the same enzyme in different cancer 
types or even within the same cancer type, and several findings suggest that ancillary C-terminal 
domains play a crucial role in determining the pro- or anti-tumorigenic properties of these 
molecules. 
 
ADAMTS Cancer type Role in cancer Reference 
1 Breast, colorectal cancers, 
pancreatic cancer, LLC 
 
NSCLC 
Anti- or pro-
angiogenic, 
oncogenic 
Tumour suppressor 
Vazquez et al., 1999; Liu YG et al, 
2006;  
Masui et al., 2001 
Lind et al., 2006 
2 Not known Anti-angiogenic  Dubail et al., 2010 
4 Not known 
Melanoma 
 
Glioblastoma 
Anti-angiogenic  
Anti- or pro-
angiogenic 
Oncogenic 
Hsu et al., 2012 
Rao et al., 2013 
 
Held-Feindt et al., 2006 
5 Prostate cancer, HNSCC, breast cancer, 
colorectal cancer 
 
 
 
LSCC 
Gliobastoma 
Anti-angiogenic 
 
 
 
 
Oncogenic 
Oncogenic 
Cross et al., 2005; 
Demircan et al., 2009; Stokes et al., 
2010; Porter et al., 2006; Kim et al., 
2011; Kumar et al., 2012; Sharghi-
Namini et al., 2008 
Filou et al., 2013 
Held-Feindt et al., 2006; Nakada et al., 
2005 
8 Brain cancer, NSCLC 
Breast cancer 
Tumour suppressor 
Oncogenic 
Vazquez et al., 1999; Dunn et al., 2004 
Porter et al., 2006 
9 Not known Anti-angiogenic in 
vitro 
Koo et al., 2010 
12 Colon cancer Anti-angiogenic, 
tumour suppressor 
Llmazares et al., 2007; Moncada-Pazos 
et al., 2009; El-Hour et al., 2010 
13 Several types of cancer Tumour suppressor Koo et al., 2002; Oleksowicz et al., 1999 
15 Breast cancer 
Colorectal cancer 
Tumour suppressor 
Tumour suppressor 
Porter et al., 2006 
Viloria et al.. 2009 
18 Several types of cancer 
Melanoma 
Tumour suppressor 
Oncogenic 
Jin et al., 2007 
Wei et al., 2010 
20 Brain, colon, breast cancer Oncogenic Llamazares et al., 2003 
 
Table 1.1: Associations between ADAMTSs and several types of cancer. HNSCC, head and neck squamous cell 
carcinoma; LLC, Lewis lung carcinoma; LSCC, laryngeal squamous cell carcinoma; NSCLC, non-small lung cell 
carcinoma.  
 
The pro-tumorigenic effects are generally mediated by cleavage of proteoglycans such as 
versican (Silver et al., 2008), brevican (Held-Feindt et al., 2006) or aggrecan (Filou e al., 2013) 
which promotes invasion. So far, the susceptibility of Adamts-1, -4 and -5-null mice to tumour 
growth and metastasis has not been investigated.  
ADAMTSs can act as tumour suppressors by different mechanisms. ADAMTS-1, -2, -4, -5, 
-8, -9 and -12 were shown to have anti-angiogenic activity. In the case of ADAMTS-2 (Dubail et 
al., 2010), -4 (Rao et al., 2013), -5 (Kumar et al., 2012), and -12 (Llamazares et al., 2007; El Hour 
et al., 2010) the catalytic activity is not required for the tumour suppressor and anti-angiogenic 
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activity. In the case of ADAMTS-9 the catalytic activity is required to exert anti-angiogenic effects 
in vitro (Koo et al., 2010). Inhibition of angiogenesis by ADAMTS-1 (Liu YG et al., 2006), -4 (Rao 
et al., 2013) and -5 (Kumar et al., 2012) is mediated by their TS domains, although the mechanisms 
are not fully elucidated. The TS-1 domain of ADAMTS-5 acts as an anti-angiogenic and pro-
apoptotic peptide (Sharghi-Namini et al., 2008; Kumar et al., 2012). Suppression of angiogenesis is 
mediated by down-regulation of pro-angiogenic factors such as VEGF, placenta growth factor, 
plasminogen activator inhibitor-1 (PAI-1), insulin-like growth factor binding protein-3 (IGFBP-3), 
and platelet-derived endothelial cell growth factor (Kumar et al., 2012). The mechanism by which 
the TS-1 domain modulates transcriptions of these genes is not known. ADAMTS-5 expression is 
down-regulated in breast cancer (Porter et al., 2004) and in head and neck squamous cell carcinoma 
(HNSCC) (Demircan et al., 2009; Stokes et al., 2010). Moreover, ADAMTS-5 promoter has been 
found to be hyper-methylated in colorectal cancer (Kim et al., 2011) and T-cell acute lymphoblastic 
leukaemia (Roman-Gomez et al., 2005).  
ADAMTS-4 and -5 have also been shown to play a pro-tumorigenic role. Both enzymes are 
over-expressed in human glioblastomas and, through cleavage of brevican, may contribute to 
invasiveness of glioblastoma cells (Gary et al., 1998; Held-Feindt et al., 2006; Viapiano et al., 
2008). In glioblastoma ADAMTS-5, but not ADAMTS-1 nor ADAMTS-4, are up-regulated (Nakada 
et al., 2005). In stimulation experiments performed with glioblastoma cells, ADAMTS-4 is 
transiently up-regulated by TGF-β, and ADAMTS-5 by IL-1β (Held-Feindt et al., 2006).  
ADAMTS-4 is involved in aggrecan turnover in normal larynx, with its expression levels 
being 2.5- and 10-fold higher compared to those of ADAMTS-1 and -5, respectively (Filou et al., 
2013). On the other hand, ADAMTS-5 is the main aggrecanase present in laryngeal squamous cell 
carcinoma (LSCC), both at the mRNA and at protein level (Filou et al., 2013). In human laryngeal 
cartilage aggrecan is the main ECM component (Skandalis et al., 2004a) and about 90% loss of 
aggrecan content compared to the normal was observed in late stage of laryngeal cancer (stage IV) 
(Skandalis et al., 2004b). 
ADAMTS-1 is highly expressed in the colon 26 cachexigenic tumour in vivo (Kuno et al., 
1997) and is inactivated through promoter hyper-methylation in colorectal cancer (Lind et al., 
2006). Its expression is down-regulated in pancreatic tumours, but patients displaying higher levels 
of ADAMTS-1 are subject to more retroperitoneal invasion and lymph node metastasis associated 
with poor survival (Masui et al., 2001). ADAMTS-1 plays a dual role in pulmonary metastasis. 
Full-length ADAMTS-1 promotes tumour progression by stimulating the shedding of amphiregulin 
and heparin binding-epidermal growth factor (HB-EGF), and activation of EGF receptor (Liu YG et 
al., 2006). Binding of ADAMTS-1 to these factors is mediated by CysR/Sp domains. On the other 
Chapter 1  Introduction 
36 
hand, an autocatalytically-truncated fragment of ADAMTS-1 containing TS domains inhibits 
bioactivity of amphiregulin and HB-EGF (Liu YG et al., 2006). An autocatalytic cleavage within 
the CysR/Sp domains also disrupts binding of ADAMTS-1 to both amphiregulin and EGF, thus 
abolishing its pro-tumorigenic activity (Liu YG et al., 2006). ADAMTS-1 acts also as an anti-
angiogenic molecule. By binding to vascular endothelial growth factor (VEGF), ADAMTS-1 
attenuates VEGF receptor 2 (VEGFR2) activation (Iruela-Arispe et al., 2003; Luque et al., 2003). A 
similar mechanism has been proposed to explain the anti-angiogenic activity of ADAMTS-4 (Hsu 
et al., 2012). ADAMTS-1 can also cleave thrombospondin-1 (TSP-1), an adhesive glycoprotein that 
mediates cell-cell and cell-matrix interactions, thus releasing anti-angiogenic peptides (Lee et al., 
2006).  
ADAMTS-1 and -8 are both down-regulated in non-small cell lung carcinoma (NSCLC) 
(Rocks et al., 2006; Dunn et al., 2004). ADAMTS-8 displays reduced expression levels in brain 
tumours (Dunn et al., 2006). Patients displaying high levels of ADAMTS-8 and low levels of 
ADAMTS-15 have a general poor clinical outcome in breast carcinoma (Porter et al., 2006). 
Genetic inactivation of ADAMTS-15 in mice increases colony formation or invasion by colorectal 
cancer cells compared with wild-type animals (Viloria et al., 2009). This indicates that ADAMTS-15 
is a tumour suppressor gene. 
Epigenetic silencing of ADAMTS-9 (Lo et al., 2007) and ADAMTS-12 (Moncada-Pazos et 
al., 2009) has been reported in different types of carcinomas suggesting their role of tumour 
suppressors for these enzymes. ADAMTS-9 suppresses tumour formation in nude mice and inhibits 
angiogenesis in vivo by down-regulating  MMP-9 and VEGF (Lo et al., 2010). Lack of Adamts-12 
in mice results in increased angiogenesis and tumour progression (El Hour et al., 2010). 
Patients with advanced metastasis display lower ADAMTS-13 levels and it has been 
hypothesised that the consequent accumulation of highly polymeric vWF may facilitate adhesive 
interactions between circulating tumour cells and platelets (Oleksowicz et al., 1999; Koo et al., 
2002). 
ADAMTS-18 has been indicated as a tumour suppressor in esophageal and nasopharyngeal 
cancer (Jin et al., 2007). Moreover, mutations of ADAMTS-18 were reported in kidney and 
colorectal cancer (Sjöblom et al., 2006; Wood et al., 2007) and melanoma (Wei et al., 2010). In 
vitro, mutations of ADAMTS-18 were shown to promote growth factor-independent cell 
proliferation, reduce adhesion to laminin and increase migration of melanoma cells and injections of 
mutant forms of ADAMTS-18 in immunodeficient mice result in increased metastasis (Wei et al., 
2010). However, the underlying biochemical mechanism is not known. 
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Silencing of Adamts-20 in mice results in increased melanoblast apoptosis, decreased 
soluble Kit ligand-stimulation of the pro-survival pathway and decrease processing of versican, 
suggesting a role of this enzyme as oncogene (Silver et al., 2008). In fact, Adamts-20 is over-
expressed in brain, colon and breast cancer (Llamazares et al., 2003). 
 
1.3. AGGRECANASES 
 
1.3.1. Aggrecan cleavage sites 
Aggrecan is a multidomain glycoprotein whose 220 kDa protein core consists of two 
globular domains at the N-terminus, G1 and G2, separated by an interglobular domain (IGD) of 150 
amino acids, and a third globular domain, G3, at the C-terminus (Figure 1.3). The region between 
the G2 and G3 domains is heavily modified with chondroitin sulphate (CS) and keratan sulphate 
(KS) GAGs, which cluster into CS-1 and CS-2 domains and a KS-rich region (Doege et al., 1991; 
Kiani et al., 2002). Negatively-charged groups on the GAGs are responsible for high osmotic 
pressure in cartilage, thus allowing aggrecan to swell and hydrate the network of collagen fibrils.  
The aggrecan G1 domain interacts with link protein and HA to form large molecular weight 
aggregates containing up to approximately 100 proteoglycan molecules/HA (Hardingham et al., 
1992). Although the G2 domain shares structural similarities with the HA binding region of the G1 
domain, it lacks the ability to bind HA (Watanabe et al., 1997). The G3 domain, which is 
structurally distinct from the G1 and G2 domains, is involved in secretion, glycosylation and 
interaction of aggrecan with other ECM components (Aspberg et al., 1997; Chen et al., 2002). 
Two autosomal recessive chondrodysplasias, cartilage matrix deficiency (cmd) in mice 
(Kimata et al., 1981; Rittenhouse et al., 1978) and nanomelia in chicken (Argraves et al., 1981; Li et 
al., 1993) are both caused by aggrecan gene mutations. Nanomelia is due to a point mutation which 
results in premature termination and retention of the truncated aggrecan molecule in the 
endoplasmic reticulum (Vertel et al., 1994). Cartilage matrix deficiency is caused by a deletion in 
exon 5 within the region coding the G1 domain, which results in the appearance of a premature 
termination codon and, ultimately, in the synthesis of a truncated protein (Watanabe et al., 1994). 
Cmd homozygotes show an extensive reduction in ECM content of the cartilage and die shortly 
after birth, while the heterozygotes are born normal and later develop spinal disorder (Rittenhouse 
et al., 1978; Vertel et al., 1994). In other mutants, such as the chubby (cby) (Wikstrom et al., 1987) 
and brachymorphic (bm) (Wikstrom et al., 1985) mice and the tibial dyschondroplasia (TD) chicken 
(Tselepis et al., 2000), the structure of aggrecan GAG chains is abnormal and growth plate presents 
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major defects. In TD chicken, an increase in the number of KS chains of aggrecan has been 
observed (Tselepis et al., 2000). 
 
 
 
Figure 1.3: Domain structure of aggrecan proteoglycan. The boxes report the main cleavage sites by ADAMTSs 
(red), MMPs (blue), serine proteases (yellow), cysteine proteases (m calpain, cathepsins B and L) (green) and aspartic 
proteases (cathepsin D) (purple) for both human (bold) and bovine aggrecan sequences. Numbers in brackets indicate 
the preferred order for cleavage. 
 
The proteases that are responsible for aggrecan degradation in cartilage are ADAMTSs as 
well as MMPs and cysteine proteases. In ex vivo cartilage explants systems, the initial enzymes 
responsible for degrading aggrecan are aggrecanases, followed by MMPs at a later stage (Little et 
al., 2002b). As the disease progresses and pH falls, cysteine proteases such as cathepsin B, 
cathepsin L (Lang et al., 2000) and cathepsin K (Konttinen et al., 2002) from chondrocytes may 
participate in further cartilage destruction.  
In general, aggrecan cleavage sites are highly conserved in humans, bovines, mice and rats. 
In the following description of aggrecan cleavage sites I will follow the numbering of the full-
length human aggrecan sequence (NCBI accession number P1612). It is worth noting that the 
classic numbering actually subtracts 19 residues from the NCBI database numbering to 
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accommodate the finding that the natural N-terminal of porcine aggrecan is VEVS (Barry et al., 
1992) and this corresponds to 20VETS in human aggrecan (Doege et al., 1991). 
Aggrecanolysis is currently investigated by anti-neoepitope antibodies reacting with the new 
N- and C- termini of the cleavage products (Hughes et al., 1995). Cleavage sites which are most 
detrimental for cartilage integrity occur in IGD, since they lead to the release of the major portion of 
aggrecan core from the matrix meshwork (Sandy et al., 1991; Little et al., 2007). These sites 
comprise the NITEGE392↓393ARGSV, which is a signature of aggrecanase activity (Sandy et al., 
1991), the MMP cleavage site at VDIPEN360↓361FFGVGG (Flannery et al., 1992) and the cysteine 
proteinase m-calpain cleavage site at TVQTV375↓376TWPDM (Struglics and Hansson, 2010). 
In vitro, aggrecanases preferentially cleave aggrecan at FKEEE1733↓1734GLGSV in the CS-2 
domain, then in the order at ASELE1564↓1565GRGTI in the CS-2 domain, and 
NITEGE392↓393ARGSV in the IGD (Tortorella et al., 2000a; Tortorella et al., 2002) (Figure 1.3). 
Cleavages at PTAQE1838↓1839AGEGP and TISQE1938↓1939LGQRP in the CS-2 domain follow the 
primary cleavage at FKEEE1733↓1734GLGSV, contributing to further C-terminal processing 
(Tortorella et al., 2000a; Tortorella et al., 2002). These sites have a glutamic acid in the P1 position 
and a non-polar residue (Ala, Leu, Gly) in the P1’ position, and are highly conserved in aggrecan 
from various species (Figure 1.3). Aggrecanase cleavage in the CS-2 domain occurs preferentially 
relative to cleavage in the IGD in human (Struglics et al., 2006), bovine (Tortorella et al., 2001) and 
rat (Sandy et al., 2000) and C-terminal processing may be a pre-requisite for aggrecanase cleavage 
in the IGD (Ilic et al., 1998; Struglics et al., 2006). 
MMPs recognise 6 main cleavage sites in human aggrecan with the following preferential 
order (Struglics and Hansson, 2012) (Figure 1.3): 1) RPAE2116↓2117THLE at the border between the 
CS2 region and the G3 domain, 2) VDIPEN360↓361FFGV in the IGD and multiple sites 
GVED↓I(L)SGL in CS1; 3) GVGD952↓953LSGL and GVED1028↓1029ISGL in the CS1 domain; 4) an 
undefined site in the border between KS and CS1 regions; 5) GVEE698↓699WIVT in the KS region. 
MMP-1, -2, -3, -7, -8, -9, -12, -13, -14, -15 and -16 are able to cleave aggrecan at the MMP 
cleavage site (Malfait et al., 2002; Durigova et al., 2011a) with MMP-3 and -12 being the most 
efficient (Durigova et al., 2011a). MMP-14 (MT1-MMP) can cleave also at the aggrecanase site, 
although high concentrations and incubation times are required (Büttner et al., 1998). 
The cysteine protease m calpain cleaves human aggrecan first at multiple cleavage sites in 
the CS1 domain (GDLS1353↓1354GLPS, EDLS1411↓1412RLPS, GDLS1431↓1432GVPS, 
TDLS1452↓1453GLPS, EDLS1472↓1473GLPS), then in the order at PGVA709↓710AVPV in the KS 
region, FGVG365↓366GEED in the IGD, IGIS1572↓1573GAGE and GLPS1596↓1597GTEL in the CS2 
region and PDLS1681↓1682GQPS in the CS-2 region (Struglics and Hansson, 2010) (Figure 1.3). 
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Calpains are calcium-dependent neutral proteases which are located mainly inside the cells (Hood et 
al., 2004) but have also been found in SF (Suzuki et al., 1990; Yamamoto et al., 1992) and in the 
culture medium of cartilage explants and chondrocytes (Szomor et al., 1999; Fushimi et al., 2004), 
suggesting that they may play a role in the cartilage degradation. Indeed, G1-PGVA709 fragments 
produced by m-calpain have been detected in bovine (Oshita et al., 2004) and human cartilage 
(Maehara et al., 2007), although in human OA and normal cartilage they constitute a small 
proportion (0.5-2%) compared with aggrecanase-generated G1-TEGE (71-76%) and MMP-
generated G1-IPEN (23-29%) fragments (Struglics and Hansson, 2010). Abundance of m-calpain 
has been shown to correlate with the severity of arthritis in both animal models (Szomor et al., 
1995) and human disease (Yamamoto et al., 1992). 
The cysteine-proteases cathepsin B and L recognise the MMP cleavage site at 
VDIPEN360↓361FFGVGG (in the case of cathepsin B cleavage at the MMP site is secondary to 
cleavage at NFFG363↓364VGGE) (Fosang et al., 1992; Mort et al., 1998). Aspartic protease cathepsin 
D cleave at NFFG363↓364VGGE and PENF361↓362FGVG respectively (Handley et al., 2001), in the 
aggrecan IGD but no fragments derived from cathepsin cleavage sites have been detected in vivo. 
Cathepsin D cleaves bovine aggrecan also at TVSL1481↓1482VDTT between the CS-1 and CS-2 
domains, and DTSL1673↓1674VEVT, TVSF1773↓1774VDRT and EVTL1873↓1873ITSE within the CS-2 
domain (Handley et al., 2001). The ECM of cartilage is buffered at a pH of 7.4, so cathepsins may 
be active outside the cell just only when pH lowers upon cartilage degradation.  
Serine proteases plasmin, urokinase and leucocyte elastase cleave within the IGD of 
aggrecan (Fosang et al., 1993; Mok et al., 1992). Cleavage by leucocyte elastase occurs at 
RGSV397↓398ILTV (Mok et al., 1992). Recently, cleavage by the serine protease HtrA1 at 
VQTV356↓357TWPD in human aggrecan core protein has been reported, although this neoepitope 
was present at about 5% of the level of NITEGE373 neoepitope in human OA cartilage protein 
extracts (Chamberland et al., 2009). 
 
1.3.2. Physiological and pathological catabolism of aggrecan 
Both aggrecan and HA constantly undergo turnover in healthy cartilage. Studies of precursor 
radiolabelling established that both the biosynthetic and turnover rates for HA and aggrecan are 
similar (Morales and Hascall, 1988). 
Cleavage in the IGD of aggrecan is the most detrimental for cartilage integrity since it 
releases the bulk of aggrecan from its anchor to HA and releases the entire CS-rich region essential 
for the biomechanical properties of aggrecan (Little et al. 2007). This CS-2 region of aggrecan is 
lost from the cartilage by diffusion and found in the medium or SF (Sandy and Verscharen; 2001; 
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Fosang et al., 2000; Lohmander et al., 1993). Cartilage explant experiments have shown that C-
terminal aggrecanase-produced ARGSV fragments are released into the culture media, with only 
very low ARGSV neoepitope content in the tissue (Malfait et al., 2002). Other studies have shown 
that these fragments are only in SF but not in cartilage samples (Struglics and Larsson, 2010; 
Struglics et al., 2006). On the other hand, cartilage contains significant amounts of both the N-
terminal aggrecanase-generated G1-TEGE and MMP-generated G1-IPEN fragments (Lark et al, 
1997; Struglics et al., 2006; Struglics and Hansson, 2010). The ratio between G1-IPEN and G1-
TEGE fragments is approximately 1:3 in both OA and normal cartilage (Struglics and Hansson, 
2010). G1-TEGE fragments can be detected also in the SF (Struglics et al., 2006) and can be 
internalised by chondrocytes through a mechanism involving HA/CD44-mediated endocytosis 
(Fosang et al., 2000; Embry and Knudson, 2003). Intact aggrecan molecules are not internalised, 
suggesting that only partial degradation of aggrecan is a pre-requisite for turnover (Embry and 
Knudson, 2003).  
The G1-IPEN neoepitopes generated by MMPs are mostly abundant around the pericellular 
matrix, whereas G1-TEGE neoepitopes generated by aggrecanases are mostly abundant in the 
interterritorial matrix, thus indicating a spatial confinement for both MMP and aggrecanase 
activities (Lark et al, 1997; Struglics et al., 2006). Struglics et al. (2006) proposed a model where 
MMPs cleave full-length aggrecan in the IGD in the pericellular matrix, and secondarily 
aggrecanases process these fragments at the C-terminus in the interterritorial matrix; aggrecanases 
are also active against full-length aggrecan in the interterritorial matrix, cleaving first in the CS-2 
domain and in the IGD. In normal mature cartilage, two distinct pools of aggrecan are present, a 
pool with short-lived aggrecan surrounding the chondrocytes and another pool with long-lived 
aggrecan in the interterritorial matrix (Mok et al., 1994). 
SF of patients with various forms of arthritis, such as OA and RA, and joint injury, all show 
aggrecan products of cleavage at the aggrecanase site (Lohmander et al., 1993), and MMP-
generated VDIPEN360 neoepitopes have been detected in human cartilages from normal, OA and 
RA patients (Fosang et al., 1996; Lark et al., 1997). Aggrecanase cleavage in the IGD increases in 
the SF of OA patients and in the acute injury phase as compared with the SF from knees of healthy 
patients, which is opposite to what is found for cleavage by MMPs (Larsson et al., 2009; Struglics 
et al., 2011). The amount of ARGSV fragments detected in SF of human healthy cartilage is 
approximately 2-fold the level of MMP-generated FFGV fragments, whereas in SF from knee-
injured or OA patients, the levels of ARGSV fragments are 47- and 82-fold higher, respectively, 
than the levels of FFGV fragments (Struglics and Hansson, 2012). Moreover, the levels of SF 
ARGSV fragments increased 14-fold in the injury and OA samples compared with healthy samples, 
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whereas the levels of FFGV fragments slightly decreased (Struglics and Hansson, 2012). A marked 
increase in the ratio of G1-NITEGE to G1-VDIPEN has also been observed in human articular 
cartilage in the early post-injury period (Sandy and Verscharen, 2001). 
In mouse models of arthritis, aggrecanase-generated NITEGE neoepitopes appear before the 
MMP-generated VDIPEN neoepitopes, but they disappear with the progression of the cartilage 
damage (Van Meurs et al., 1999a). In porcine explants cultures, MMPs are involved in baseline 
turnover of mature articular aggrecan (Fosang et al., 2000). In mice there are no phenotypic 
consequences of replacing endogenous aggrecan with aggrecan that is resistant to MMP cleavage 
by mutating the MMP cleavage site, suggesting that MMP activity is not required for aggrecan 
turnover during development (Little et al., 2005b). However, resistance to MMP activity is partially 
compensated by aggrecanase cleavage in the IGD (Little et al., 2005b). The cartilage of these mice 
show only 45% aggrecan release comparing with wild-type cartilage (Little et al., 2005b). MMP 
activity correlates with collagen breakdown, and not with aggrecan breakdown in cartilage explants 
after prolonged incubation with IL-1, which induces synthesis of pro-MMPs (Kozaci et al., 1997) 
and aggrecan degradation in porcine articular cartilage explants stimulated with IL-1α is inhibited 
by TIMP-3, an inhibitor of aggrecanases, but not by TIMP-1 or TIMP-2, two inhibitors of MMPs 
(Gendron et al., 2003). These data suggest a role for MMPs in normal aggrecan catabolism, whereas 
stimulated aggrecan loss is mediated by aggrecanases (Fosang et al., 2000; Sandy and Verscharen, 
2001). Moreover, as it has been pointed out previously (See Section 1.1), MMP activity is involved 
with the final stages of cartilage degradation through cleavage of both aggrecan and collagen in vivo 
(van Meurs et al., 1999a,b) and in vitro (Madsen et al., 2010; Durigova et al., 2011a; Little et al., 
1999).  
Collectively, these studies suggest that aggrecanase cleavage in the IGD of aggrecan is 
responsible for a major contribution to aggrecan catabolism relatively to MMP activity in arthritis 
and injury and promotes cartilage degradation during the early stages of disease. As a result, 
aggrecan fragments produced generally by aggrecanase activity have been tested as sensitive 
biomarkers of OA joint disease (Larsson et al., 2009; Struglics et al., 2009; Dufield et al., 2010; 
Swearingen et al., 2010) and are likely to be used in clinics in the near future.  
Accumulation of aggrecanase-generated and MMP-generated neoepitopes in human 
articular and intervertebral cartilage has also been observed during ageing (Roughley et al., 1985; 
Sztrolovics et al., 1997; Lark et al., 1997). Cleavage by ADAMTS-4, but not ADAMTS-5, in the 
aggrecan IGD is affected by age in animal and human cartilage, with aggrecan from mature 
cartilage being cleaved more efficiently than aggrecan from young cartilage (Roughley et al., 2003, 
Pratta et al., 2000). A possible link between increase in aggrecan catabolism and ageing may be 
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represented by changes in GAG substitutions on the aggrecan molecule. A KS group near the 
aggrecanase site, which is associated with advanced age, has been thought to play a permissive role 
for aggrecanase digestion in mature bovines (Pratta et al., 2000). However, studies using 
recombinant IGD showed that cleavage by ADAMTS-4 can occur even in the absence of KS 
(Hughes et al., 1997; Mercuri et al., 1999; Miwa et al., 2006) and the absence of glycosylation has a 
lower impact on ADAMTS-5 than ADAMTS-4 (Roughley et al., 2003; Gendron et al., 2007). In 
vitro, deglycosylation of aggrecan with chondroitinase ABC and keratanase prior to digestion 
abolishes both aggrecanase (Pratta et al., 2000; Kashiwagi et al., 2004) and calpain activity 
(Struglics and Hansson, 2010), but has not effect on MMP activity. The presence of CS groups 
enhances ADAMTS-4 cleavage within the CS-2 domain and it has been proposed that the CS and 
KS groups may compete for binding to ADAMTS-4 (Miwa et al., 2006). 
 
1.3.3. Role of exosites in aggrecanase activity 
Exosites play important roles in the recognition and cleavage of aggrecan and in binding to 
ECM (Table 1.2). The function of non-catalytic domains in the recognition and cleavage of the 
substrate has been extensively investigated using C-terminal truncation forms of ADAMTS-1 
(Kuno et al., 1999; Rodriguez-Manzaneque et al., 2000), ADAMTS-4 (Tortorella et al., 2000b; Gao 
et al., 2002; Kashiwagi et al., 2004) and ADAMTS-5 (Gendron et al., 2007; Fushimi et al., 2008). 
Localisation at the cell surface has been shown for ADAMTS-1 (Rodriguez-Manzaneque et al., 
2000), -4 (Somerville et al., 2003a; Kashiwagi et al., 2004; Gao et al., 2004), -5 (Vankemmelbeke et 
al., 2001; Gendron et al., 2007), -7 (Somerville et al., 2004), and -9 (Somerville et al., 2003b) and 
likely occurs via ionic interactions with cell-surface or pericellular matrix molecules mediated by 
their ancillary domains. 
The Sp region and two of the C-terminal TS repeats in ADAMTS-1 interact with heparin 
(Kuno and Matsushima, 1998) and their removal increases the solubility of the enzyme in tissue 
culture conditions and decreases its catalytic activity (Kuno et al., 1999; Rodriguez-Manzaneque et 
al., 2000). Studies where the Sp domain of ADAMTS-4 was removed by processing (Gao et al., 
2002) or deletion (Kashiwagi et al., 2004; Gendron et al., 2007; Fushimi et al., 2008) highlight the 
role of this domain in binding to ECM, possibly through interaction with fibronectin (Hashimoto et 
al., 2004). 
For ADAMTS-5, the CysR domain is necessary for binding to ECM (Gendron et al., 2007) 
but a significant role is exerted also by the Sp domain. This domain contains 86 basic residues, as 
well as an XBBXBX motif (N739KKSKG744), which may constitute a GAG-binding site (Troeberg 
et al., 2012). Deletion of the Sp domain markedly reduces both direct binding of ADAMTS-5 to 
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pentosan polysulphate (PPS) and the effect of PPS in increasing the affinity between TIMP-3 and 
ADAMTS-5 (Troeberg et al., 2012). Another domain important in ADAMTS-5 pericellular 
localisation is the Dis domain, which contains a pair of contiguous HA-binding motifs (Plaas et al., 
2007). TS-1 domain mediates ADAMTS-5 endocytosis and this process is enhanced by the 
presence of the Sp domain (Yamamoto et al., 2013). 
 
Domain deletion ADAMTS-5 ADAMTS-4 
Full-length 100% IGD-activity1,2 
100% CS-2 activity1 
100% IGD-activity2 
100% CS-2 activity1,2,3 
ΔC-terminal TS Reduced IGD-activity 
(50% reduction)1 
100% CS-2 activity1 
N/A 
Δ-Sp domain Reduced IGD-activity 
(75% reduction)1 
Reduced CS-2 activity1 
(>99% reduction) 
Reduced IGD-activity2 
(95% reduction) 
Reduced CS-2 activity 
(96% reduction) 2 
Release into the medium 
Δ-CysR domain Reduced IGD-activity 
(99% reduction)1 
Reduced CS-2 activity1 
(>99% reduction) 
Release into the medium 
Reduced IGD-activity 
(>99% reduction)3 
Reduced CS-2 activity3 
(>99% reduction) 
 
Δ-TS No IGD or CS-2 activity1 No IGD or CS-2 activity1,3 
Δ-Dis No IGD or CS-2 activity1 No IGD or CS-2 activity1,3 
 
Table 1.2: Effects of C-terminal ancillary domain deletions on ADAMTS-5 and -4. 1(Gendron et al., 2007); 
2(Fushimi et al., 2008); 3(Kashiwagi et al., 2004) (CS-2 activity: cleavage at GELE1499↓1500GRGT in bovine aggrecan); 
N/A, not applicable, ND, not determined. 
 
Although it was reported that the Sp domain of ADAMTS-4 acts as an inhibitor since its 
removal increased the IGD-activity of ADAMTS-4 (Gao et al., 2002; Kashiwagi et al., 2004; 
Gendron et al., 2007), Fushimi et al. (2008) reported that full-length ADAMTS-4 is 20-times more 
active against aggrecan than its Sp domain deletion mutant. This was explained on the basis of 
inhibition of full-length ADAMTS-4 by heparin, particularly for cleavage at the Glu392↓393Ala bond 
of aggrecan (Fushimi et al., 2008) (Table 1.2). Deletion of the Sp domain decreases the IGD-
activity of ADAMTS-5 and -4 down to 25% and 5% of the full-length enzyme, respectively 
(Gendron et al., 2007). Moreover, removal of this region dramatically reduces the CS-2 activity of 
ADAMTS-4 (Fushimi et al., 2008) and ADAMTS-5 (Gendron et al., 2007). 
The TS-1 and Dis domains of ADAMTS-4 are also considered important for recognition of 
a triple-helical FRET substrate (Lauer-Fields et al., 2007). Deletion of the TS-1 domain and/or the 
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Dis domain in ADAMTS-4 and -5 leads to a complete absence of catalytic activity (Kashiwagi et 
al., 2004; Gendron et al., 2007): the “minimal” aggrecanase comprises the Cat domain, the Dis 
domain and the TS-1 domain. Also ADAMTS-9 Cat domain alone is not correctly localised on the 
cell surface nor is it proteolytically active (Somerville et al., 2003b). The same is observed for 
ADAMTS-13, where the minimal fragment possessing proteolytic activity consists of the Cat/Dis 
domain (Gao et al., 2006).  
In spite of these observations, the Cat domain seems to dictate a certain preference over 
macromolecular substrates. Combining ADAMTS-5 ancillary domains with ADAMTS-13 Cat 
domain does not produce chimeras able to cleave IGD or native aggrecan, reflecting the specificity 
of ADAMTS-13 Cat domain (Gao et al., 2012). When ADAMTS-5 ancillary domains (TS-
1/CysR/Sp) are replaced with those of ADAMTS-13, ADAMTS-5 Cat domain acquires the ability 
to cleave the Glu1615↓1616Ile bond of vWF domain A2 in peptide substrates or vWF multimers that 
had been sheared, but native (unsheared) vWF multimers are resistant (Gao et al., 2012). This 
chimera is also able to cleave aggrecan at the aggrecanase site in the IGD but not in the CS-2 
domain, thus underscoring the importance of ancillary domains in substrate recognition (Gao et al., 
2012). 
 
1.3.4. Other substrates of aggrecanases 
Because of their preference for cleaving at the C-terminus of glutamic acid, ADAMTS-4 
and ADAMTS-5 have been referred to as glutamyl endopeptidases. At least 32 residues at the N-
terminal of the cleavage site (P residues of the substrate) and 13 residues at the C-terminal side (P’ 
residues) are required for cleavage at the Glu392↓393Ala bond (Hörber et al., 2000). However, 
aggrecanases are not exclusively glutamyl endopeptidases. For example, ADAMTS-4 also cleaves 
aggrecan at Asn360↓361Phe bond (Westling et al., 2002) (Table 1.3). Both ADAMTS-4 and -5 cleave 
α2M at Met690↓691Gly and this cleavage results in their inactivation (Tortorella et al., 2004). 
ADAMTS-4 cleavage of carboxymethylated transferrin occurs at Met↓Tyr, Gly↓Tyr, Ser↓Leu, and 
Leu↓Phe (Kashiwagi et al., 2004).  
Biglycan, decorin, fibromodulin and keratocan belong to the family of small leucine-rich 
repeat proteoglycans (SLRPs), characterised by the presence of 6-10 adjacent leucine-rich repeats 
flanked by cysteine-rich domains (Iozzo, 1999). Biglycan interacts with type VI collagen and plays 
a role in establishing the type VI collagen network (Wiberg et al., 2001; Wiberg et al., 2002). 
Biglycan degradation products are present in the ECM of articular cartilage from OA and RA 
patients but not in normal adult human articular cartilage (Melching et al., 2006). Both ADAMTS-4 
and -5 cleave human biglycan at an asparagines-cysteine bond (Asn149↓150Cys) within the fifth 
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leucine-rich repeat (Rees et al., 2000; Melching et al., 2006; Gendron et al., 2007). This 
proteoglycan represents a substrate for ADAMTS-5 in cartilage (Zhen et al., 2008).  
 
Substrate Aggrecanase Sequence Reference 
ADAMTS-4 ADAMTS-4 GSFRKFRYGY 
GSALTFREEQ 
Flannery et al., 2002 
ADAMTS-5 ADAMTS-5 VRIPEGATHI Georgiadis et al., 2002 
Agg (Glu392) ADAMTS-4,5 RNITEGEARGSVI Tortorella et al., 2000a 
Agg (Glu1564) ADAMTS-4,5 STASELEGRGTIG Tortorella et al., 2000a 
Agg (Glu1733) ADAMTS-4,5 TTFKEEEGLGSVE Tortorella et al., 2000a 
Agg (Glu1838) ADAMTS-4,5 QAPTAQEAGEGPS Tortorella et al., 2000a 
Agg (Glu1938) ADAMTS-4,5 EPTISQELGQRPP Tortorella et al., 2000a 
Agg (Asn360) ADAMTS-4,5 FVDIPENFFGVGG Westling et al., 2002 
α2M (Met690) ADAMTS-4,5 FYESDVMGRGHAR Tortorella et al., 2004 
Biglycan ADAMTS-4,5 LRNMNCIEMG Melching et al., 2006 
Gendron et al., 2007 
Brev (Glu393) ADAMTS-4 QEAVESESRGAIS Matthews et al., 2000 
Cm-tf (L195) ADAMTS-4,5 FK*CLKD Gendron et al., 2007 
Cm-tf (L391) ADAMTS-4,5 AMSLDG Gendron et al., 2007 
Cm-tf (L525) ADAMTS-4,5 FR*CLVE Gendron et al., 2007 
COMP ADAMTS-4 - Dickinson et al., 2003 
Decorin ADAMTS-4,5 - Kashivagi et al., 2004 
Gendron et al., 2007 
Fibromodulin (Y44) ADAMTS-4,5 YAYGSP Kashiwagi et al 2004 
Fibronectin  - Gendron et al., 2007 
Keratocan ADAMTS-4,5 - Rees et al., 2009 
Matrilin-3  SATEEARRLV Hills et al., 2007 
Neurocan ADAMTS-4 - Tauchi et al., 2012 
Phosphacan ADAMTS-4 - Tauchi et al., 2012 
Reelin ADAMTS-4 
ADAMTS-5 
- Hisanaga et al., 2012 
Krstic et al., 2012 
Ver V1(Glu441) ADAMTS-4 KDPEAAEARRGQY Sandy et al., 2001 
 
Table 1.3: Alignment of the known aggrecanase cleavage sites for human aggrecan (Agg), brevican (Brev), 
versican (Ver), and secondary substrates. For reduced, carboxymethylated transferrin (Cm-tf) major cleavage sites by 
ADAMTS-5 are reported, whereas ADAMTS-4 presents multiple cleavage sites. In bold are reported P1’ residues. *C, 
S-carboxymethylated cysteine. 
 
ADAMTS-4 and -5 are also able to cleave in vitro decorin (Kashiwagi et al., 2004; Gendron 
et al., 2007) and keratocan (Rees et al., 2009). Bovine fibromodulin is cleaved at Tyr44↓45Ala by 
recombinant ADAMTS-4 and -5 (Kashiwagi et al., 2004; Gendron et al., 2007). The hyalectan 
subfamily of CS proteoglycans includes aggrecan, brevican, neurocan, phosphacan and versican. 
These proteoglycans are related by the presence of homologous N-terminal G1 and C-terminal G3 
globular domains, with a centrally located GAG attachment region. The G1 domain is highly 
homologous between the hyalectans and contains an immunoglobulin fold that mediates binding to 
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the family of small globular link proteins and two homologous proteoglycan tandem repeat (PTR) 
motifs responsible for binding to HA (Spicer et al., 2003). 
Brevican is the main proteoglycan in the central nervous system; its expression in the brain 
coincides with periods of glial cell motility, such as in the developing brain during gliogenesis 
(Viapiano and Matthews, 2006). ADAMTS-4 and ADAMTS-5, but not ADAMTS-1 cleave 
brevican at Glu395↓396Ser (Matthews et al., 2000). The 23 amino acids surrounding the cleavage site 
are 50% identical to the cleavage site in aggrecan (Yamada et al., 1995). ADAMTS-4 has been 
reported to cleave in vitro phosphacan and neurocan (Tauchi et al., 2012). 
Versican is found in ECM as four isoforms (V0, V1, V2, and V3) derived by alternative 
splicing. Each isoform is characterised by distinct structure, tissue localisation and signalling 
function. ADAMTS-1, -4, -5, -9, and -20 can cleave human versican V1 at the Glu441↓442Ala bond, 
within the sequence DPEAAEARRGQ (Sandy et al., 2001; Somerville et al., 2003b) (See Sections 
1.2.2 and 1.3.5 for the biological significance of versican cleavage by hyalectanases). The 
equivalent ADAMTS cleavage site in V0 is Glu1428↓1429Ala (Sandy et al., 2001). ADAMTS-4 
cleaves the versican V2 variant at Glu405↓406Gln (Westling et al., 2004). 
Matrilins are adaptor proteins which connect fibrillar and network-like components such as 
aggrecan, fibrillar collagens, COMP, decorin and biglycan in the cartilage ECM. Cleavage of 
matrilins makes these molecules less efficient in providing matrix cohesion. ADAMTS-4 (Hills et 
al., 2007) and ADAMTS-5 (Groma et al., 2011) but not ADAMTS-1 (Ehlen et al., 2009) cleave 
matrilin-3 and -4 at SATEE435↓436ARRLV. In mouse growth plate chondrocytes during 
endochondral ossification, ADAMTS-5, but not ADAMTS-4, colocalises with cleaved matrilin-4 in 
vesicles derived from the Golgi apparatus and cleaved matrilin-4 is absent in the growth plate of 
ADAMTS-5 knock-out mice (Groma et al., 2011).  
ADAMTS-4 cleaves COMP, a pentameric disulphide-bonded glycoprotein present in 
cartilage, which represents a main substrate for ADAMTS-7 (Dickinson et al., 2003). ADAMTS-5 
and -4 cleave Reelin, an important signalling glycoprotein in the nervous system (Hisanaga et al., 
2012; Krstic et al., 2012) (See Section 1.2.2). Cleavage of Reelin by ADAMTS-4 and -5 occurs 
both at the C- and N-terminal site, but ADAMTS-5 is also responsible for further N-terminal 
degradation (Krstic et al., 2012).  
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1.3.5. ADAMTS-5 (aggrecanase-2) as a target in OA 
Members of the aggrecanases/hyalectanases subgroup of ADAMTSs (comprising 
ADAMTS-1, -4, -5, -8, -9, -15, -16) share the ability to cleave aggrecan at the aggrecanase site 
Glu392↓393Ala and are therefore potentially involved in dysregulated aggrecan catabolism which 
occurs in OA (Tortorella et al., 1999; Abbaszade et al., 1999; Collins-Racie et al., 2004; Zeng et al., 
2006). However, if we look at different criteria such as specific activity, colocalisation with areas of 
aggrecan depletion in human OA cartilage, and correlation between loss of function and loss of 
aggrecan catabolism either in vitro, ex vivo and in vivo, ADAMTS-5 (aggrecanase-2) emerges as a 
major player in development of OA and as an attractive target for therapeutic intervention. 
Only ADAMTS-1, -4, and -5 have been shown to cleave human aggrecan at all five 
aggrecanase sites (Glu392↓393Ala, Glu1564↓1565Gly, Glu1733↓1734Gly, Glu1838↓1839Ala, Glu1938↓1939Leu) 
(Rodriguez-Manzaneque et al., 2002; Tortorella et al., 2004; Tortorella et al., 2002) (Figure 1.3), 
but, among these, ADAMTS-5 is the most active under physiological conditions (Gendron et al., 
2007, Fushimi et al., 2008). 
With the exception of ADAMTS-8, expression in human OA cartilage is widespread across 
all members of the hyalectanase subgroup (Kevorkian et al., 2004; Collins-Racie et al., 2004). In 
particular, ADAMTS-4 and ADAMTS-5 are expressed in cartilage and synovium from OA and RA 
patients (Vankemmelbeke et al, 2001; Yamanishi et al., 2002; Bau et al., 2002; Naito et al., 2007) 
and expression of ADAMTS-4 mRNA and protein levels correlate with the progression of OA in 
humans (Naito et al., 2007). However, the specific relevance of ADAMTS-5 and ADAMTS-4 in 
human cartilage is evident from in vitro knock-down experiments (Song et al., 2007). Only 
ADAMTS-4 or ADAMTS-5 short interfering RNAs (siRNAs), once transfected, individually or in 
combination, into cytokine-treated human normal cartilage explants and primary human 
chondrocytes significantly decrease aggrecan catabolism by decreasing the expression of the 
targeted gene (Song et al., 2007). The same effect is observed following siRNA-mediated knock-
down of either gene in human OA cartilage in the absence of cytokine stimulus, whereas 
transfection with ADAMTS-1 siRNA fails to inhibit aggrecan degradation in either normal or OA 
cartilage (Song et al., 2007).  
ADAMTS-5 is more highly expressed than ADAMTS-4 in both normal and OA cartilage at 
the mRNA level (Bau et al., 2002; Kevorkian et al., 2004). However, mRNA levels for ADAMTS-5 
in OA cartilage are not significantly elevated compared to that in normal cartilage (Naito et al., 
2007; Bau et al., 2002; Kevorkian et al., 2004). ADAMTS-5 activity is down-regulated by 
endocytosis LRP-1-mediated in the normal cartilage, but LRP-1 shows a ~ 90% reduction in protein 
level in OA cartilage (Yamamoto et al., 2013) (See Section 1.2.4.3). This suggests that ADAMTS-5 
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dysregulation in OA is principally due to impaired post-translational regulation. Interestingly, also 
TIMP-3 is endocytosed by an LRP-1-mediated pathway (Troeberg et al., 2008). 
The two aggrecanases have been detected also in synovium from RA patients. In RA 
synovium, staining for ADAMTS-4 and –5 is mainly observed in the sublining layer of synovial 
membrane and pannus (Mimata et al., 2012). In another report, in RA synovium ADAMTS-5 was 
immunolocalised around cells lining the pannus and in some areas of ECM (Vankemmelbeke et al., 
2001). 
The importance of ADAMTS-5 in aggrecan breakdown and in facilitating progression of 
cartilage loss has been outlined by in vivo models of OA. Adamts-4 and Adamts-1 -null mice do not 
exhibit any significant protective effect on cartilage aggrecan loss (Glasson et al., 2004; Little et al., 
2005a). These results suggest that neither ADAMTS-4 nor ADAMTS-1 is the major enzyme 
involved in cartilage aggrecan loss. On the other hand, studies with Adamts-5-null mice 
(catalytically inactivated homozygous allelic mice) showed that the lack of ADAMTS-5 protects 
against cartilage destruction when OA (Glasson et al., 2005) or inflammatory arthritis (Stanton et 
al., 2005) are induced. Adamts-5-null mice are resistant to OA development induced by the 
destabilisation of medial meniscus (DMM) surgery and to the associated mechanical allodynia 
(Malfait et al., 2010). Adamts-4-/-/Adamts-5-/- double knockout mice are physiologically normal and 
also protected from developing OA (Majumdar et al., 2007). Adamts-5-null mice show essentially 
no cartilage erosion and fibrous overgrowth in DMM and in the OA model induced by the 
combination of TGF-β1 injection and enforced uphill treadmill running (TTR) (Li et al., 2011). In 
TTR model, these mice still show aggrecanase activity in the IGD (aggrecanase activity is present 
also in Adamts-4-/-/Adamts-5-/- double knockout mice), but are protected from joint fibrosis and 
accumulate aggrecan in the articular cartilage (Li et al., 2011). In the TTR model, the deposition of 
versican was also observed (Li et al., 2011). These data indicate that the rate of aggrecan synthesis 
exceeds that of aggrecan degradation in Adamts-5 null mice.  
Collectively, these data point to a pivotal role exerted in vivo by ADAMTS-5, alone or in 
combination with ADAMTS-4, in mouse cartilage breakdown during the progression of OA, but 
other hyalectanases do not seem to be pathologically relevant. However, limitations of studies 
involving knock-out mice should be considered carefully before extrapolating to the human setting. 
First of all, ablating ADAMTS-5 function during development does not mimic clinical use of 
ADAMTS-5 inhibitors; in this case conditional knock-out mice involving specific ablation of 
ADAMTS-5 expression before or after onset of OA may represent a closer model of ADAMTS-5 
inhibition in OA setting. Moreover, given the larger number of proteases in the murine (641) 
compared with human (565) proteome (Puente et al., 2003), mouse models may show a higher 
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degree of redundancy in performing protease functions. In the following paragraphs, we will first 
look at embryonic expression of Adamts-5 and the effects of ADAMTS-5 ablation during 
development; successively, we will describe adult expression of Adamts-5 and try to extrapolate the 
phenotypes of Adamts-5-null mice to the effects of a potential ADAMTS-5 inhibition in human 
setting. 
Early reports showed that Adamts-5-null mice are viable, with a normal lifespan, and neither 
histological analysis of organs nor blood chemistry have identified any anomalies in the absence of 
challenge (Glasson et al., 2005; Stanton et al., 2005). However, recent studies have shown the 
presence of subtle phenotypes and these may be related to impaired cleavage of versican, rather 
than aggrecan.  
Embryonic expression of Adamts-5 is scarce prior to 11.5 days of gestation (E11.5) and 
limited to the floor plate of the developing brain at E9.5 (McCulloch et al., 2009c). After E11.5, 
continued expression in brain (choroid plexus, peripheral nerves, dorsal root ganglia, cranial nerve 
ganglia, spinal and cranial nerves and neural plexuses of the gut) is detected (McCulloch et al., 
2009c). Aggrecan turnover is very high during embryonic skeletogenesis but there is no expression 
of Adamts-5 in developing cartilage (McCulloch et al., 2009c). During chondrogenesis, Adamts-1 
and -5 expression is down-regulated, whereas the expression of Adamts-4, -9, and -16 is up-
regulated (Boeuf et al., 2012). Aggrecanase cleavage products (NITEGE fragments) are not 
detected in human mesenchymal stem cells during chondrogenesis but cleavage products of MMPs 
(VDIPEN fragments) are detected 14 days after the induction of chondrogenesis (Boeuf et al., 
2012). Expression of Adamts-1 and -5 can be up-regulated in these cells by IL-1β (Boeuf et al., 
2012). When chondrogenesis is induced with conditioned medium containing bone morphogenetic 
protein-2 (BMP-2), Adamts-4 is up-regulated after 2 days, thus this gene may be linked to early 
chondrogenesis (Djouad et al., 2007). In fact, Adamts-4 expression is widespread during mouse 
embryonic development (McCulloch et al., 2009c). The lack of ADAMTS-5 expression in 
embryonic cartilage is consistent with the normal skeletal development reported in Adamts-5-/- mice 
(Glasson et al., 2005; Stanton et al., 2005) and Adamts4-/-/Adamts5-/- double null mice (Majumdar et 
al., 2007).  
Adamts-5 is expressed and colocalises with myosin heavy chain in embryonic mouse limbs 
when myoblasts initiate fusion into multinucleated tubes (McCulloch et al., 2009c; Jungers et al., 
2005). Expression of Adamts-5 during neuromuscular development and in smooth muscle cells 
coincides with that of versican (McCulloch et al., 2009c). Adamts-5-/- mice (Stupka et al., 2013) as 
well as Adamts-5-/-/Adamts-4-/- double knock-out mice (Rogerson et al., 2008; McCulloch et al., 
2009c) do not present overt myopathy or deficit in gait and mobility, likely due to compensation by 
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other hyalectanases such as Adamts-15 during skeletal muscle development. However, higher levels 
of centrally positioned nuclei in myofibres during postnatal growth are observed, suggesting 
delayed maturation (Stupka et al., 2013).  
ADAMTS-5 is found marked reduced in aortas of apolipoprotein E-null mice, which 
spontaneously develop atherosclerotic lesions, resulting in accumulation of biglycan and versican 
(Didangelos et al., 2012) (See Section 1.2.2.). FGF-2, which suppresses Adamts-5 expression and 
activity in cartilage (Sawaji et al., 2008; Chia et al., 2009), is up-regulated in atherosclerosis (Raj et 
al., 2006; Hughes et al., 1993) and accumulates in aortas of apoE-null mice (Didangelos et al., 
2012). In the vasculature, the suppression of Adamts-5 expression by FGF-2 could be related to the 
ability of this growth factor to increase neointima formation following arterial injury (Agrotis et al., 
2004). Recombinant ADAMTS-5 reduces the LDL-binding ability of biglycan and releases LDL 
from human aortic lesions (Didangelos et al., 2012), thus suggesting a crucial role for this enzyme 
in mediating proteoglycan-mediated lipoprotein retention. These observations are supported by data 
from Adamts-5-null mice. In aortas of these mice, biglycan levels are increased, and no versican 
fragments are detectable (Didangelos et al., 2012). Moreover, Adamts-5-null mice display 
abnormally enlarged pulmonary valves in late foetal development and in the adult as a result of 
impaired cleavage of versican (Dupuis et al., 2011). Adamts-5 is expressed by valvular endocardium 
during cardiac valve maturation and its loss cannot be compensated by Adamts-1 or -9 (Dupuis et 
al., 2011). 
Recent data (Hattori et al., 2011; Velasco et al., 2011) suggest that ADAMTS-5 plays a 
critical role in dermal fibroblasts during dermal repair. Fibroblast to myofibroblast transition occurs 
physiologically during skin wound healing but may persist in pathologic situations such as 
hypertrophic scarring, contractures after burns, systemic and cutaneous scleroderma, and fibrosis of 
internal organs such as lung, kidney and liver (Abraham and Varga, 2005). 
Whereas Adamts-4-/- mice show essentially normal wound contracture and collagen 
fibrillogenesis, Adamts-5-/- mice exhibit impaired contraction and dermal collagen deposition in an 
excisional wound healing model (Velasco et al., 2001). This phenotype is associated with 
accumulation in the dermal layer of cell aggregates and fibroblastic cells surrounded by a 
pericellular matrix enriched in full-length aggrecan which resemble immature skin appendages such 
as hair follicles and sweat glands (Velasco et al., 2011). According to Velasco et al. (2011), the 
impaired repair response observed in dermal fibroblast from Adamts-5-/- mice is due to 
accumulation of complexes between aggrecan, HA and CD44 on the cell surface which ultimately 
results in an altered signalling of TGF-β1, a key regulator of multiple processes in wound healing. 
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Dermal fibroblasts from Adamts5-/- mice show reduced versican proteolysis, increased 
pericellular matrix volume due to accumulation of versican, altered cell shape, enhanced α-smooth 
muscle actin expression and increased contractility within 3D-collagen gels. This myofibroblast-
like phenotype is associated with activation of TGF-β signalling (Hattori et al., 2011). Since 
versican binds to fibrillin-1, which interacts with the large latent complex of TGF-β/TGF-β-binding 
proteins (Isogai et al., 2002), accumulation of versican in the pericellular matrix due to absence of 
ADAMTS-5 could affect sequestration and consequent activation of TGF-β (Hattori et al., 2011). 
Moreover, aggrecan, but not collagen (col2), is expressed during murine dermal wound healing and 
by newborn fibroblasts so aggrecan cleavage as well as versican cleavage may be important in 
dermal fibroblasts and can be impaired in Adamts-5-/- mice (Velasco et al., 2011). 
In mouse adult tissues, Adamts-5 is expressed in synovium, tenosynovium, bone marrow 
sinusoids, tendons, ligaments, ligament insertions, periosteal cells, and bone vasculature (Wylie et 
al., 2012), in arterial smooth muscle cells, mesothelium lining the peritoneal, pericardial and pleural 
cavities (endocardium, pericardium, pleural and peritoneal mesothelial cells), smooth muscle cells 
in bronchi and pancreatic ducts, glomerular mesangial cells in the kidney, dorsal root ganglia and in 
Schwann cells of the peripheral and autonomic nervous system (McCulloch et al., 2009c). Since 
ADAMTS-5 expression is not detected in human mesenchymal stem cells during chondrogenesis, 
therapeutic inhibition of ADAMTS-5 would not impair regenerative self-healing pathways based on 
chondrogenesis of local progenitor cells in the joint (Boeuf et al., 2012). Moreover, since lacking of 
ADAMTS-5 is followed by activation of Smad1, 5, 8, resulting in chondrogenic response and pro-
anabolic activity in chondrocytes (Velasco et al., 2011), inhibition of this enzyme can represent a 
dual strategy for both attenuation of cartilage degradation and induction of articular cartilage repair. 
However, given the importance of ADAMTS-5 as a versicanase and the co-expression of 
Adamts-5 with versican in arterial smooth muscle cells and pericardial cavities in adult mice 
(McCulloch et al., 2009c) a potential side effect of anti-ADAMTS-5 therapy may be related to 
accumulation of versican in these tissues (Dupuis et al., 2011) and development of aortic lesions 
(Didangelos et al., 2012). ADAMTS-5 also plays a role in myoblast fusion (Stupka et al., 2013). 
Skeletal muscle regeneration occurs after mechanical stress such as intense physical activity or 
trauma, thus, inhibiting ADAMTS-5 could be potentially detrimental in patients with compromised 
skeletal muscle due to immobilisation. ADAMTS-5 inhibition could also potential impair wound 
healing (Hattori et al., 2011; Velasco et al., 2011). The degree of these side effects mostly depend 
on the contribution of ADAMTS-5 to versican cleavage relative to that of other hyalectanases such 
as ADAMTS-9 and -20 with whom it has been shown to cooperate (McCulloch et al., 2009a).  
 
Chapter 1  Introduction 
53 
1.4. Strategies to develop disease-modifying osteoarthritic drugs  
There are currently no cures for OA, and no effective pharmacological treatments exist that 
slow or halt its progression (Sun, 2010). OA treatment is currently limited to steroidal and non-
steroidal anti-inflammatory drugs, which provide symptomatic relief for pain and inflammation 
(Fajardo and Di Cesare, 2005). However, analgesic agents are only slightly superior to placebo in 
controlling OA-related pain (Zhang et al., 2008) and physical activity is one of the most widely 
prescribed non-pharmacological therapies for OA management (Fransen et al., 2002; Roddy et al., 
2005). So there is strong urgency for a drug able to halt disease progression and improve the quality 
of life of OA patients. Recently, considerable effort has been put on the discovery and development 
of drugs able to slow down or halt the progression of OA, i.e. disease modifying osteoarthritic 
drugs. 
 
1.4.1. Small molecule inhibitors of metalloproteinases 
Inhibition of members of both MMP and ADAM families has a long and well-established 
tradition. Nevertheless, most synthetic inhibitors against MMPs such as Batimastat or Ilomastat 
(GM6001) failed in clinical trials. The primary cause of the high rate of failure is the 
musculoskeletal syndrome (MSS), a side-effect associated with the clinical administration of broad-
spectrum MMP inhibitors and involving arthralgia, myalgia, joint stiffness and tendonitis. These 
symptoms are predominantly in the upper limbs, do not respond to analgesics and non-steroidal 
anti-inflammatory agents, and are to large extent reversible following the discontinuation of the 
drug (Tierney et al., 1999; Wojtowicz-Praga et al., 1998). 
Most of the compounds which reached phase I and II in clinical trials have common 
structural features: they contain a zinc-chelating group, such as hydroxamate, and a peptidic or 
peptidomimetic backbone that lies in the side of the active site cleft, and side chains binding to the 
different enzyme pockets. Since members of the metzincin clan of metallopeptidases show a high 
similarity of their catalytic site structure and they all bind to the catalytic zinc with similar 
geometry, it is very likely that MSS is due to lack of selectivity by synthetic MMP inhibitors. 
However, the identity of the metalloproteinase(s) involved in MSS is not known. An early 
hypothesis was that inhibition of MMP-1 (collagenase-1) activity induced MSS but this syndrome 
was observed following treatment with MMP-1 sparing inhibitors, indicating that inhibition of this 
enzyme is not essential for this side effect (Whittaker et al., 1999). 
Over-expression of TIMP-1 and TIMP-3 is protective in mouse models of RA (Schett et al., 
2001; van der Laan et al., 2003), thus some MMPs represent a real target of arthritis therapy. 
However, it is evident that cross-inhibition of certain MMPs is detrimental. For example, based on 
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studies in mice lacking MMP-2 (Itoh et al, 2002), MMP-3 (Clements et al., 2003) or MMP-14 
(Holmbeck et al., 1999), inhibition of MMP-2, -3, and -14 appears to facilitate aggrecan 
degradation.  
It has been proposed that inhibition of ADAMs by broad-spectrum MMP inhibitor is 
responsible for MSS (Bird et al., 1999). An alternative hypothesis is that MSS is not due to MMP 
inhibition. For example, GM6001 is also a potent inhibitor of neprilysin, leucine aminopeptidase 
and dipeptidylpeptidase III, three metallopeptidases lacking any sequence homology with MMPs 
(Saghatelian et al., 2004). However, none of these enzymes has been associated with MSS. 
Because of chronic administration in an old population with multiple co-morbidities, 
candidates for OA therapy must demonstrate utmost safety. To circumvent cross-inhibition-related 
issue, an approach is to engineer TIMPs to obtain inhibitors directed only against one or few 
enzymes. Following this strategy, a mutant N-terminal domain of TIMP-3 that selectively inhibits 
only aggrecanases has been developed (Lim et al., 2010). An alternative approach is using 
monoclonal antibodies (mAbs) directed against a target enzyme. 
 
1.4.2. Monoclonal antibodies (mAbs) 
mAbs were proved potent and selective binders of many biologically relevant targets and are 
well established as therapeutic agents for several diseases including cancer, autoimmune disorders, 
and infectious diseases (Weisser and Hall, 2009). Antibodies now represent one third of the total 
number of recombinant proteins used for therapy in developed countries (Hagemeyer et al., 2009). 
In 2011, there were 34 US Food and Drug Administration-approved mAbs in the market (Aggarwal, 
2011). 
In 1975, Köhler and Milstein described hybridoma technology, a method to generate 
monoclonal antibodies based on the fusion of B-lymphocytes from an immunised animal with 
immortal myeloma cells (Köhler and Milstein, 1975). Soon this method became popular for 
generation of antibodies for a variety of applications. This technology was subsequently used by 
many labs to generate metzincin inhibitors with a focus on the Cat domain. For example, REGA-
3G12 mAb is a selective inhibitor of MMP-9 which does not inhibit MMP-2 (Paemen et al., 1995). 
This antibody recognises the amino terminal part of the catalytic domain of MMP-9 but not the zinc 
-binding region (Martens et al., 2007). More unusually, in order to produce MMP-blocking 
antibodies, Sela-Passwell et al. (2011) immunised mice with a synthetic molecule (a tris-imidazole-
zinc complex) that mimics the conserved structure of the metalloenzyme catalytic zinc-histidine 
complex and isolated monoclonal antibodies by hybridoma technology. The resulting blocking 
antibodies were directed against the catalytic zinc-protein complex and enzyme surface 
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conformational epitopes of endogenous MMP-2 and MMP-9 (Sela-Passwell et al., 2011). These 
antibodies did not show cross-reactivity with free zinc ions or analogous metal-protein motifs 
present in carbonic anhydrase, alcohol dehydrogenase and myoglobin as well as a plethora of 
MMPs (Sela Passwell et al., 2011). Atapattu et al. (2012) reported the generation by hybridoma 
technology of mAbs which specifically bound to a distal substrate binding pocket in the CysR 
domain of ADAM-10 and inhibited ephrin cleavage, thus acting as exosite inhibitors. 
An alternative way to generate mAbs is phage display, which has superseded hybridoma 
technology through the creation of large natural and synthetic in vitro repertoires of antibody 
fragments. The display of antibody fragments on filamentous phage was first described in 1990 
(McCafferty et al., 1990). Phage display exploits a vast number of possibilities from a 
combinatorial biology approach and the linkage between genotype and phenotype to isolate 
antibodies against a desired antigen. The genotype-phenotype linkage permits the rapid 
determination of the amino acid sequence of the specific binding molecule by DNA sequencing of 
the specific insert in the phage genome. Phage display allows to manipulate in vitro conditions 
during selections and screening to tailor the properties of the antibodies isolated. For example, 
antibodies may be selected for features like affinity to the antigen, stability or yield. 
The most popular vectors for display are phagemids, which are hybrid of phage genome and 
plasmid vectors. Phagemids are designed to contain the origin of replications for both the M13 
phage and E. coli in addition to gene III (which codes for a protein necessary for infection of male 
E. coli or competent E. coli strains like TG1), appropriate multiple cloning sites, and an antibiotic-
resistance gene (Mead and Kemper, 1988). However, phagemids lack all other structural and non-
structural gene products required for phage biology (phage genome consists of 11 genes). 
Phagemids can be grown as plasmids, or, alternatively, packaged as recombinant M13 phages with 
the aid of a helper phage that contains a defective origin of replication (such as M13KO7 or 
VCSM13) and supplies, in trans, all the structural proteins required for generating a complete 
phage. The latter process is named “phage rescue” (See Section 2.2.3). The resulting phage 
particles may thus incorporate either pIII derived from the helper phage (wild-type pIII) or the pIII-
antibody fragment from the phagemid.  
To construct an antibody library, genes of variable heavy (VH) and variable light (VL) chains 
of antibodies are prepared by reverse transcription of mRNA obtained from B-lymphocytes. The VH 
and VL gene products are then amplified by polymerase chain reaction (PCR) and assembled into a 
single gene using a DNA linker. The assembled scFv DNA insert is then cloned into a phagemid 
vector which is transformed into competent E. coli cells (Schofield et al., 2007). 
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Phage display libraries can be classified as antigen-biased (immune) or antigen unbiased 
(non-immune). Immune libraries are created by using V genes derived from the immunoglobulin G 
(IgG) mRNA of B-cells from immunised animal or naturally immunised/infected patients. 
Humanised immune repertoires can also be prepared using immunised transgenic mice (xenomice) 
thus combining immunisation and phage display (Yang et al., 1999). Xenomice harbour most of the 
human immune system V genes in the germline (instead of the native murine immune repertoire) 
(Yang et al., 1999). In this case the immune library will be enriched in antigen-specific antibodies 
which, potentially, have already undergone affinity maturation (Clackson et al., 1991). 
Non-immune libraries comprise naïve, synthetic and semi-synthetic libraries and show 
several advantages over other techniques such as hybridoma technologies or immune libraries. A 
first, plain, advantage is the ability to isolate human antibodies against human (self) antigens with 
no need of animal immunisation. Since phage display does not depend on an animal immune 
system, antibodies against antigens which are particular problematic (non-immunogenic, cell-
surface, toxic antigens, etc) can be generated. Cross-reactive antibodies are often difficult to obtain 
by hybridoma technology owing to tolerance by immune system but are commonly isolated by 
phage-display. Naïve libraries are derived from natural, non-immunised, rearranged V genes, which 
are amplified using family-based oligonucleotides. Heavy and light chains are then randomly 
combined and cloned. Synthetic libraries introduce wholly novel sequences into an antibody 
framework. Semi-synthetic libraries are created by engineering the non-immune repertoire to 
increase natural diversity, for example by randomisation of complementarity determining region-3 
(CDR-3), which has an estimated potential diversity of 1023 sequences (Sanz, 1991). 
Antibody fragments such as scFv (single-chain variable fragment) and Fab (antigen- binding 
fragment) had been displayed on filamentous phages. scFvs comprise the variable regions of the VH 
and VL of immunoglobulins connected with a short glycine-rich linker. This fusion protein retains 
the specificity of the immunoglobulin, thus it constitutes a minimal paratope. Fabs are composed of 
one constant and one variable domain from the heavy and light chains of the antibody. Since the 
heavy and light chains in the Fab molecule are connected by a disulphide bond, folding and 
assembly of Fab fragments in the periplasm of E. coli is less efficient than for scFvs (Skerra et al., 
1991). A further disadvantage of Fabs is the tendency of light chains to form homo-dimers, which 
are known as Bence-Jones proteins (Kirsch et al., 2005). 
Phage display can be used for mapping epitopes of monoclonal and polyclonal antibodies, 
identifying peptide ligands, and to define substrates for different enzymes (Matthews and Wells, 
1993). Antibodies isolated by phage display have been shown to act as agonists and antagonists of 
receptors (Cortese et al., 1994; Doorbar and Winter, 1994). Catalytic antibodies (i.e. mAbs with 
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catalytic activity) are generated by immunisation with haptens that are analogous of rate-
determining state structures in a particular chemical reaction (Lerner et al., 1991). Phage display has 
been proved successful in providing both selective and potent inhibitors of MMPs (Koivunen et al., 
1999; Björklund et al., 2004; Devy et al., 2009; Bahudhanapati et al., 2011), human neutrophil 
elastase (Roberts et al., 1992) and ADAM-17 (Tape et al., 2011). DX-2400 is a highly selective 
human MMP-14-blocking antibody selected from a human Fab phage display library that reduces 
angiogenesis, tumour growth and metastasis of MMP-14-expressing tumours in mice (Devy et al., 
2009). 
 
1.5. Aim of the thesis 
On the basis of the in vitro and in vivo data accumulated so far, ADAMTS-5 plays a major 
role in cartilage degradation. Thus it is appealing to inhibit this enzyme for therapeutic purposes. In 
particular, I hypothesised that exosite inhibitors of ADAMTS-5 would suffer from less side effects 
than active-site inhibitors due to specific targeting of enzyme regions involved in substrate 
recognition and binding. 
The aim of this thesis is the isolation and characterisation of selective ADAMTS-5 
inhibitors. Owing to the high selectivity shown by mAbs, we chose to select by phage display mAbs 
able to block aggrecanase activity of ADAMTS-5. 
My specific objectives were:  
(i) Isolation of antibodies against ADAMTS-5 by selection from a human antibody phage 
display library. 
(ii) Characterisation of ADAMTS-5 binding antibodies as inhibitors: investigation of their 
mechanism of action (active site-directed versus exosite inhibition) and assessment of 
their selectivity against other members of metalloproteinase family, in particular 
MMPs and ADAMTSs families.  
(iii) Assessment of inhibitory efficacy in in vitro systems. 
Selective inhibition of ADAMTS-5 could pave the way for the therapeutic blocking of 
cartilage breakdown in OA and could help to further investigate the functional role of this enzyme 
in OA pathology. 
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2.1.  REAGENTS 
 
2.1.1.  Tissue and cell culture reagents  
Human embryonic kidney-Epstein Barr nuclear antigen (HEK293-EBNA) and FreeStyleTM 
HEK293-F cell lines were from Invitrogen (Paisley, UK); human chondrosarcoma cells (HTB-94) 
were from American Culture Type Collection (Manassas, VA, USA). HEK293-EBNA cells 
transfected with pCEP4 vector expressing different deletion mutants of ADAMTS-5, ADAMTS-4 
or TIMP-3, and HTB-94 cells expressing mouse ADAMTS-5 were obtained from frozen stocks 
prepared in this lab. Porcine joints were supplied by Fresh Tissue (London, UK) and dissected on 
site within 24 h of slaughter.	  
Cell and tissue culture reagents were from the following sources: heparin, pluronic F68, 
sodium chlorate, polyethyleneimine (PEI), trypan blue, oncostatin-M (OSM), Dimethylmethylene 
Blue (DMMB) and shark chondroitin sulphate from Sigma-Aldrich (Dorset, UK); Falcon plates 
from Beckton-Dickinson (Oxford, UK); Dulbecco’s modified Eagle’s medium (DMEM), 
penicillin/streptomycin from Biowhittaker (Berkshire, UK); fetal calf serum (FCS), trypsin-EDTA 
and hygromycin B from PAA Laboratories (Pashing, Austria), FreeStyle™ 293 Expression Medium 
from Invitrogen (Paisley, UK); vented polycarbonate Erlenmeyer flasks and HYPERflaskTM cell 
culture vessels from Corning (Corning, NY); Deep-well 24 well block from Qiagen (Manchester, 
UK).  
Purified IL-1α was a gift from Professor J. Saklatvala (Kennedy Institute of Rheumatology, 
University of Oxford). Human articular cartilage was obtained from patients after they provided 
informed consent and following approval by the Riverside Research Ethics Committee (Riverside 
Health Authority, London, UK). Non-OA cartilage was obtained from the knee following 
amputation due to soft tissue sarcoma and osteosarcoma with no involvement of the cartilage. 
Tissues were obtained from 3 patients. Anti-desmin scFv-Fc antibody was kindly provided by Dr 
Mike Dyson, Iontas, Ltd. 
 
2.1.2. Sodium dodecyl sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and 
Western blot reagents 
Materials were from the following sources: 30 % (w/v) acrylamide/bis-acrylamide from 
Severn Biotech (Worcestershire, UK); 2-amino-2-methyl-1,3-propanediol (amediol), Bovine Serum 
Albumin (BSA), Tween®20 and mouse monoclonal anti-FLAG M2-antibody from Sigma-Aldrich 
(Dorset, UK); pre-stained and unstained Precision Protein Standards, Trans-Blot® TurboTM 
Transfer System, Trans-Blot® TurboTM polyvinylidene difluoride (PVDF) transfer packs and 
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BioRad GS-710 densitometer from Bio-Rad (Hemel Hempstead, UK); the rabbit anti-ADAMTS-5 
Cat domain antibody, the rabbit anti-AGEG antibody (which recognises the N-terminal AGEG 
fragment generated by aggrecanase cleavage of bovine aggrecan at Glu1790↓1791Ala) and the rabbit 
anti-GELE antibody (which recognises the C-terminal GELE fragment generated by aggrecanase 
cleavage of bovine aggrecan at Glu1499↓1500Gly) were prepared by Masahide Kashiwagi in this 
laboratory; antibody 2-B-6 (raised against the aggrecan CS stubs that remain after deglycosylation 
with chondroitinase ABC and keratanase) was a kind gift from Dr. Clare Hughes and Professor 
Bruce Caterson (University of Wales, Cardiff, UK); mouse monoclonal BC-3 antibody (which 
recognises the N-terminal ARGSV fragment generated by aggrecanase cleavage of bovine aggrecan 
at Glu392↓393Ala) and anti-TIMP-3 antibody were from Abcam (Cambridge, UK); rabbit polyclonal 
anti-G3 was from Pierce Biotechnology (Rockford, USA); mouse monoclonal anti-NITEGE 
antibody (BC-13) was from MD Bioproducts (Zürich, Switzerland); Western Blue® stabilised 
substrate (5-bromo-4-chloro-3-indolyl-1-phosphate and nitroblue tetrazolium) for alkaline 
phosphatase (AP), streptavidin AP-linked, anti-mouse AP-linked antibody, anti-human IgG AP-
linked and anti-rabbit AP-linked antibodies from Promega (Southampton, UK).  
 
2.1.3. Protein chemistry reagents 
 
2.1.3.1.   Proteins and protein purification 
Materials were from the following sources: anti-FLAG M2-agarose, Brij®35 solution 30% 
(w/v), trichloroacetic acid (TCA) and imidazole were from Sigma-Aldrich Ltd (Dorset, UK); FLAG 
peptide (D-K-Y-D-D-D-D-K) from Advanced Biotechnology Centre (Imperial College, London, 
UK); Vivacell 250 filters (MWCO 5000) from Sartorius Ltd (Epsom, UK); PD-10 Desalting 
Columns from GE Healthcare (Buckinghamshire, UK); bacterial recombinant N-TIMP-3 from Dr 
Ngee Han Lim and Dr. Linda Troeberg in this laboratory; MMP-1 Cat domain, MT-1 MMP and 
MMP-13 from Dr Rob Visse in this laboratory. 
 
2.1.3.2.   Biotinylation 
Materials were from the following sources: Zeba Spin Desalting columns (7 kDa cut-off) 
and EZ-link Sulpho-N-Hydroxysuccinimide (NHS)-biotin containing a 19 atoms spacer (Sulpho-
NHS-LC) were from Pierce Biotechnology; Fluoreporter Biotin Quantitation Assay Kit was from 
Invitrogen; CHES was from Sigma.  
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2.1.3.3.   Quenched-Fluorescent (QF) peptide cleavage assay and aggrecan cleavage assay 
QF peptide substrates ortho-aminobenzoyl-Thr-Glu-Ser-Glu~Ser-Arg-Gly-Ala-Ile-Tyr-(N-
3-[2,4-dinitrophenyl]-L-2,3-diamino-propionyl)-Lys-Lys-NH2 [Abz-TESE↓SRGAIY-Dpa-KK, “↓” 
indicates the cleavage site] and carboxyfluorescein-Ala-Glu↓Leu-Asn-Gly-Arg-Pro-Ile-Ser-Ile-Ala-
Lys-N,N,N’,N’-tetramethyl-6-carboxyrhodamine [Fam-AE↓LQGRPISIAK-Tamra] were custom-
synthesised by Bachem. QF peptide substrate (7-methoxycoumarin-4-yl) acetyl-Lys-Pro-Leu-
Gly↓Leu-(N-3-[2,4-dinitrophenyl]-L-2,3-diaminopropionyl)-Ala-Arg-NH2 (Mca-KPLG↓L-Dpa-
AR) (FS-6) was from Sigma. Chondroitinase ABC and keratanase were from Seikagaku (Tokyo, 
Japan). Bovine nasal aggrecan was prepared in this lab according to the method of Hascall and 
Sajdera (1969). 
 
2.1.4. Phage display and molecular biology reagents 
Phage display library was provided by Dr John McCafferty (Department of Biochemistry, 
Cambridge University). TG1 electrocompetent cells were from Lucigen; streptavidin-coated 
paramagnetic beads (Dynabeads M-280) were from Invitrogen; skimmed milk powder from 
Marvel; TPCK-Trypsin, ampicillin, kanamycin, streptavidin from Streptomyces avidinii were from 
Sigma; GM6001 was from Elastin Products Co. (Owensville, MO); 96 Deep-well plates and 
polystyrene tubes from Nunc (Roskilde, DK); Qiagen Plasmid Miniprep Kit from Qiagen (Qiagen, 
Valencia, CA); T4 DNA Ligase, NcoI, NotI and BstnI restriction enzymes were from New England 
Biolabs. ZymoCleanTM Gel DNA recovery was from ZymoResearch (Orange, CA). pSANG-10 and 
pBIOCAM-5 expression vectors was kindly provided by Dr John McCafferty. 
 
2.1.5. Primary screening  
Materials were from the following sources: Black Nunc MaxiSorp plates and Abgene 800 µl 96-
well block from Fisher Scientific (Loughborough, UK); BL21(DE3) cells from Merck; isopropyl β-
D-1 thiogalactopyranoside (IPTG), kanamycin, ampicillin, Greiner 96 well polypropylene plates, 
anti-M13 antibody were from Sigma; anti-6x His tag antibody from R&D; CircleGrow ® broth 
from Krackeler Scientific; Whatman	  MBPP 25 micron filter plate from GE Healthcare;	  Nucleobond 
Anion II anion exchange resin was custom-produced by Machery-Nagel (Fisher Scientific); Quant-
IT double strand DNA assay Kit from Invitrogen; Nickel-nitrilotriacetic (Ni-NTA) resin was from 
Qiagen; Generon Proteus 1-step batch midi-spin columns from Generon (Maidenhead, UK); 
imidazole and anti-FLAG antibody F3165 was from Sigma; europium-labelled anti-mouse and anti-
human IgG antibodies, europium-labelled streptavidin and dissociation-enhanced lanthanide 
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fluorescence immunoassay (DELFIA enhancement solution were from Perkin Elmer (Beaconsfield, 
UK).	  	  
	  
2.1.6. scFv-Fc characterisation 
CM5 biosensor chip and anti-human IgG were from GE Healthcare; gelatin from Sigma; 
heparin-binding plates from Beckton Dickinson Life Science; anti-mouse antibody coupled with 
horseradish peroxidase (HRP) from Dako (Ely, UK); anti-human HRP from Promega; 
tetramethylbenzidine substrate from KPL (Wembley Middlesex, UK), Dynabeads Protein G from 
Invitrogen. 
	  
2.2. METHODS 
 
2.2.1. SDS-PAGE and Western Blot 
 
2.2.1.1.SDS-PAGE 
Proteins were resolved by SDS-PAGE using either a modification of the 
ammediol/glycine/HCl buffer system of Wyckoff et al. (1977) or the Tris-glycine buffer system 
according to Laemmli (1970). Polyacrylamide gels were made with 6-12 % total acrylamide, 
depending on the size of the proteins to be separated. Samples were diluted with an equal volume of 
double strength sample buffer [42 mM ammediol, 0.01% (w/v) sodium azide, 2 % SDS, 0.1% (w/v) 
bromophenol blue, 50% (w/v) glycerol] and loaded into the wells of the upper gel (4% total 
acrylamide). Unless otherwise specified, sample buffer contained 1% β-mercaptoethanol. Typically, 
ammediol gels were run at 200 V for 45-60 min and Tris-glycine gels were run at 70 V for 120 min. 
 
2.2.1.2.   Gel staining 
 
2.2.1.2.1. Coomassie Brilliant Blue (CBB) R-250 staining 
SDS-PAGE gels were stained with Coomassie Brilliant Blue R-250 stain [0.1 % (w/v) CBB, 
50 % (v/v) methanol and 20 % (v/v) acetic acid] for 30 min before several 30 min-washes with 
destaining solution [30 % (v/v) methanol and 1 % (v/v) formic acid]. Gels were then scanned with a 
BioRad GS710 calibrated imaging densitometer and dried. 
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2.2.1.2.2. Silver staining 
SDS-PAGE gels were stained using silver stain (Shevchenko et al., 1996). Gels were 
incubated with fixing solution [50 % (v/v) methanol and 5 % (v/v) acetic acid] for 20 min and 
washed for 10 min with 50 % (v/v) methanol. Next, gels were washed with distilled water (dH2O) 
and then incubated with sensitizer [0.02 % (w/v) sodium thiosulphate] for 1 min. After washing two 
times with dH2O, gels were incubated with cold silver reagent [0.1 % (w/v) silver nitrate] for 1 h at 
4ºC. Following this incubation, gels were washed twice with dH2O and protein bands were detected 
by addition of developer [0.04 % (v/v) formalin and 2 % (w/v) sodium carbonate]. The developer 
was discarded and replaced as soon as it turned yellow so that protein bands were developed in an 
absolutely transparent solution. Once protein bands could be detected, the developing reaction was 
stopped using 5 % (v/v) acetic acid. Gels were then scanned with a BioRad GS710 calibrated 
imaging densitometer and dried.  
 
2.2.1.3.   Western blot analysis 
Proteins separated by SDS-PAGE were analysed by Western blotting using Trans-Blot® 
TurboTM Transfer System according to the manufacturer’s instructions (BioRad). Proteins were 
transferred onto PVDF at 1.3 A for 7 min (Mixed Molecular Weight Protocol, 5-150 kDa proteins) 
or for 10 min (High Molecular Weight Protocol, >150 kDa proteins) Following transfer, the 
membranes were blocked with 5% BSA in Tris-Buffered saline (TBS, 50 mM Tris, 200 mM NaCl, 
pH 7.5) for 1 h at room temperature (RT). In general, membranes were incubated overnight with 
primary antibodies in 1 % BSA/TBS at 4 ºC. Antibody dilutions were as follows: anti-FLAG M2 
1:1000, anti-ADAMTS-5 Cat domain 1:500; anti-NITEGE 1:100; anti-AGEG 1:500; anti-GELE, 
anti-ARGSV 1:200; anti-G3 1: 500, anti-TIMP-3 1:1000. Membranes were then washed three times 
with TBS containing 0.1% Tween 20 and incubated with AP-linked secondary antibody (1:5000). 
Membranes were subsequently washed three times with TBS containing 0.1% Tween 20 before 
development. AP Western blots were developed with Western Blue AP substrate until bands 
appeared. The AP reaction was then stopped with AP stop solution [20 mM Tris-HCl pH 7.5, 10 
mM EDTA]. Membranes were then scanned with a BioRad GS710 calibrated imaging densitometer 
and dried. 
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2.2.2. Antigen preparation and characterisation 
 
2.2.2.1.  Expression and purification of recombinant proteins 
Recombinant human ADAMTS-4 and ADAMTS-5 deletion mutants and mouse ADAMTS-
5 containing a FLAG tag (N- D-K-Y-D-D-D-D-K C) at the C-terminus were expressed and purified 
from stably transfected cell lines following the procedure established in our laboratory (Gendron et 
al., 2007). The vector used for expression of human ADAMTS-4 (Kashiwagi et al., 2004) and -5 
(Gendron et al., 2007), as well as mouse ADAMTS-5, was pCEP4. 
Stably transfected HEK293-EBNA cells were selected for hygromycin B resistance (100 
µg/ml) in DMEM containing 10% FCS, 100 units/ml penicillin and 100 units/ml streptomycin. 
HTB94 cells stably expressing mouse ADAMTS-5 were selected with 300 µg/ml hygromycin and 
maintained in Corning HYPERflask cell culture vessels. The culture medium was replaced to 
serum-free DMEM containing penicillin, streptomycin, and 100 µg/ml heparin. After 3 days, the 
conditioned media were harvested, centrifuged for 20 min, at 3,000 rpm to remove cells, filtered 
through a 0.2 µm filter to eliminate any cell debris, supplemented with 0.02% sodium azide and 
stored at -20° C until purification. The collected conditioned media (0.5 L) were passed over a 3-ml 
anti-FLAG M2 agarose column at 4°C, which was previously equilibrated with TNC buffer (50 mM 
Tris-HCl pH 7.5, 100 mM NaCl, 10 mM CaCl2, 0.02% NaN3 and 0.05% Briji). After loading the 
media, the column was washed with 1 M NaCl to remove heparin (Kuno & Matsushima, 1998), and 
the bound protein was eluted with 200 µg/ml FLAG peptide. All the fractions were checked by 
Western blot analysis with anti-FLAG M2 and anti-ADAMTS-5 Cat domain antibodies and purity 
was assessed by silver stain. All stocks were passed through PD-10 pre-calibrated gel-filtration 
column in TNC buffer to remove excess of FLAG peptide and stored at -80°C before use.  
Recombinant C-terminally FLAG-tagged TIMP-3 was purified following the procedure 
described by Troeberg et al. (2009). HEK293-EBNA cells stably transfected with pCEP4-TIMP-3 
construct were initially selected for hygromycin resistance (800 µg/ml) in DMEM containing 10% 
FCS, penicillin and streptomycin, then switched to serum-free DMEM containing 30 mM sodium 
chlorate (NaClO3) for protein expression.  
Active concentrations of all enzymes were determined by titration against known 
concentrations of N-TIMP-3 in the QF peptide cleavage assay (see Section 2.2.2.2). Active 
concentrations of TIMP-3 were determined by titration against known concentrations of MMP-1 
Cat domain. 
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2.2.2.2.   QF peptide cleavage assay 
All enzyme assays were conducted in TNC buffer at 37°C, using a Gemini microplate 
spectrofluorometer (Molecular Devices, Sunnyvale, CA, USA). The activity of ADAMTS-5 was 
monitored using the QF peptide substrate Abz-TESE↓SRGAIY-Dpa-KK. This peptide is based on 
the ADAMTS-4 cleavage site in rat brevican (Matthews et al., 2000) and recombinant ADAMTS-5 
cleaves this substrate more readily than ADAMTS-4 in vitro (Troeberg et al., 2009). The substrate 
was used at a final concentration of 20 µM with an excitation wavelength of 300 nm and an 
emission wavelength of 430 nm (420 nm cut-off). The activity of ADAMTS-4 was monitored using 
the QF peptide substrate Fam-AE↓LQGRPISIAK-Tamra at a final concentration of 0.5 µM with an 
excitation wavelength of 485 nm and an emission wavelength of 538 nm (495 nm cut-off) (Wayne 
et al., 2007). The activity of MMP-1 Cat domain, MT1-MMP, and MMP-13 was measured using 
the QF peptide substrate Mca-KPLG↓L-Dpa-AR at 2 µM final concentration (Knight et al., 1992). 
Enzymatic rates were corrected for spontaneous hydrolysis of the substrate. 
  
2.2.2.3.   Aggrecan digestion assay 
Bovine nasal aggrecan (50 µg, 670 nM, MW=1500 kDa) was incubated with ADAMTS-5 in 
50 µl TNC at 37°C for 2 h. The reaction was stopped by adding 2 volumes of sodium acetate buffer 
(200 mM sodium acetate, 250 mM Tris HCl pH 8.0 and 100 mM EDTA). Aggrecan was then 
deglycosylated by incubating with 0.1 mU/µl of chondroitinase ABC and 0.1 mU/µl of keratanase 
overnight at 37°C. The samples were precipitated by adding 5 volumes of cold acetone, incubated at 
-20°C for 4 h, and then centrifuged at 13,000 x g for 30 min. The dried pellet was dissolved in 50 µl 
of reducing sample buffer, run on SDS-PAGE (6% total acrylamide), and subjected to Western blot 
analysis as described in Section 2.2.1.3.  
 
2.2.2.4.   Biotinylation of ADAMTS-5 and ADAMTS-4 
ADAMTS-5 and ADAMTS-4 were biotinylated with EZ-link Sulpho-NHS-LC biotin. This 
biotinylation reagent contains a long alkyl spacer arm which guarantees that the interaction between 
biotin and avidin/streptavidin occurs far away (22 angströms) from the biotinylated protein. The 
NHS ester present on the biotinylation reagent reacts with primary amines in alkaline conditions 
such as the side chains of lysines or the N-termini of proteins to yield stable amide bonds. Protein 
samples were passed through Zebaspin gel filtration columns (7 kDa cut off), recovered in CHES 
buffer (20 mM CHES pH 8.8, 200 mM NaCl, 10 mM CaCl2) and incubated with Sulpho-NHS-LC-
biotin for 30 min RT. Reaction was stopped with an equal volume of TNC buffer (final [Tris]=25 
mM) and excess of biotin was removed by gel filtration. Biotinylated enzyme was finally recovered 
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in TNC buffer and stored at -80°C before use. ADAMTS-5 was titrated before and after 
biotinylation and the estimated recovery was ~90%. 
The level of biotinylation was first assessed by anti-biotin Western blot using AP-
conjugated streptavidin A (1:1000). Next, FluoReporter ® Biotin Quantitation Assay Kit was used 
following the manufacturer’s protocol. This Kit provided a fluorescence displacement assay for 
accurately determining the degree of labelling (DOL) of protein samples. The assay is based on a 
modified form of avidin which has been labelled both with a fluorescent donor group and a 
quenching acceptor. Both chromophores occupy the biotin binding sites on the avidin molecule, at a 
distance which allows for highly efficient Förster resonance energy transfer (FRET). Since the 
interaction between biotin and avidin is characterised by high affinity (dissociation constant, KD, 
around 10-15 M) (Green, 1963), biotin molecules covalently attached to the protein sample are able 
to displace the quencher groups from avidin. The separation of donor and quencher chromophores 
abolishes the FRET and leads to an increase in fluorescence which is proportional to the number of 
biotin molecules in the sample. In order to expose any biotin group which could be sterically 
inaccessible to the avidin, biotinylated ADAMTS-5 was digested overnight at 37°C with 2 U/ml of 
protease type XIV from Streptomyces griseus. Each reaction was performed in phosphate buffered 
saline (PBS) in a total volume of 100 µl (all samples in triplicate). After 5 minute incubation at 
room temperature with fluorescently-labelled avidin, fluorescence was measured at excitation 
wavelength of 495 nm and emission wavelength of 519 nm. Background represented by 
unbiotinylated protein was subtracted and the fluorescence detected was compared to that of a 
standard curve of 1.5-200 pmoles of biocytin (biotinylated lysine), which represents the form of 
biotin upon proteolytic cleavage of a biotinylated protein sample. 
 
2.2.3. Phage display selections 
Solution phase scFv phage display selection was performed using protocols and library 
provided by Dr John McCafferty (Department of Biochemistry, University of Cambridge). 
McCafferty’s library (with a diversity of 1.1 x 1010 clones) was created by sequentially cloning an 
antibody repertoire of light chain variable domains (VL) followed by cloning of an antibody 
repertoire of heavy chain variable domains (VH) (Schofield et al., 2007). The VH and VL repertoires 
were created by PCR amplification from human lymphocytes from 43 non-immunised donors 
(Schofield et al., 2007). This results in a “naïve” or non-immunised antibody library that can be 
used to isolate antibodies to any given antigen including antibodies recognising “self” proteins. The 
format is an scFv fragment (the fragment antibody containing the antigen binding domain) (scFv), 
with VH and VL fragments joined by a flexible linker (Gly4 Ser Gly4 Ser Gly3 Ala Ser) and fused to 
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the minor coat protein pIII of filamentous phage M13 (5 copies per virion). The cloning vector is 
the pSANG4 phagemid, which carries an ampicillin resistance marker, bacterial and phage origins 
of replication, and a phage-packaging signal (Figure 2.1). Moreover, it contains the signal sequence 
from M13 gene III, restriction sites for NcoI and NotI, a myc tag and the pIII gene under the control 
of lac promoter.  
 
Figure 2.1: Schematic representation of pSANG4 vector and scFv insert. 
 
The pIII protein begins phage infection when it attaches to the F pilus of a susceptible E. coli strain 
and assists in the release of phage from the bacterial cell (Rakonjac and Model, 1998). The scFv 
insert is cloned via NcoI and NotI so that the recombinant protein is expressed at the N-terminus of 
pIII, which extends into solution, without interfering with pIII functions. The following protocol 
uses a KingFisher 96 Well System (Thermoscientific) and is schematically reported in Figure 2.2. 
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Figure 2.2: Solution-phase scFv Phage Display. 1) ADAMTS-5 is expressed, purified, and 2) biotinylated with 
Sulpho-NHS-LC-biotin. 3) A naïve human scFv phage display library (McCafferty’s library) is exposed to unwanted 
binding partners such as streptavidin (here represented by beads coated with streptavidin) and FLAG peptide. 4) The 
de-selected library is then exposed to biotinylated ADAMTS-5 and 5) the phage-antigen complex is captured by 
streptavidin-coated paramagnetic beads. 6) The bead-antigen-phage complex is washed several times to remove weak-
binding or aspecific phages. 7) The specifically-bound phages are eluted from the antigen-bead complex using trypsin-
mediated proteolytic digestion of pIII. 8) Specifically-eluted phages are used to infect TG1 E. coli. The bacteria are 
plated out and selected for ampicillin resistance (only TG1 cells containing an ampicillin-resistant phagemid are able to 
grow). After overnight growth, the cells are used to prepare glycerol stocks. 9) For the second round of selection, 
bacteria are harvested, grown in liquid phase and super-infected with helper-phage, which confers kanamycin 
resistance. Double-infected cells are lysed in solution to release a polyclonal (and amplified) mixture of selected phages 
(phage rescue). The polyclonal phage population can be tested in ELISA to check antigen-binding activity (polyclonal 
phage ELISA). Glycerol stocks from step 8 can be used to grow and rescue phages for additional rounds of selection or, 
as an alternative, as a source of DNA for subcloning the scFv inserts into an expression vector. 
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2.2.3.1.  Solution-phase phage-display selection 
 
2.2.3.1.1. Preparation of host TG1. A 100 ml culture of 2x TY (Trypton yeast extract) was 
inoculated from a single colony of E. coli TG1 cells (taken from a freshly grown minimal media 
plate). The monoculture was grown at 37°C/250 rpm and placed on ice when optical density at 600 
nm (OD600) was around 0.5-0.8 (i.e. logarithmic growth phase). 
2.2.3.1.2. Blocking of streptavidin magnetic beads. Pre-washed streptavidin-coated 
magnetic beads (1 mg, 100 µl) were pelleted using a Dynal Magnetic separator, re-suspended in 1 
ml 3% Marvel/TNC in a deep-well plate and mixed on a microtitre plate mixer for 15 min at RT. 
2.2.3.1.3. Library De-Selection. The selection of binders to the fusion partner (FLAG) or 
streptavidin beads can be reduced by de-selection in the presence of an excess of the unwanted 
partner. McCafferty library (50 µl, 1012 phages) was blocked with 900 µl of 3% milk/TNC and used 
to re-suspend streptavidin-coated magnetic beads (1 mg). FLAG peptide was added to the mixture 
of phages and beads at a final concentration of 5 µM. The phage-bead solution was mixed and then 
resolved by magnetic separation on the KingFisher 96. The supernatant (preliminary de-selection 
phage library) was transferred to a separate plate. 
2.2.3.1.4. Exposure to antigen. Biotinylated ADAMTS-5 (10 or 100 nM) was added to the 
de-selected library in the presence and absence of a 100-fold excess of GM6001. The mixture was 
incubate at RT for 1 h in a microtitre plate mixer. 
2.2.3.1.5. Capture and pull-down of phage-antigen complex. Following incubation, the 
phage-antigen solution described in Section 2.2.3.1.4 was used to re-suspend the blocked 
streptavidin coated magnetic beads described in Section 2.2.3.1.2. The bead-antigen phage solution 
was mixed at RT for 10 minutes, then resolved using paramagnetic separation. The supernatant 
containing non-bound phage was discarded. 
2.2.3.1.6. Washing. The bead-antigen-phage complexes were washed 5 times with 3% 
marvel/TNC. All wash steps were performed in solution and magnetic separation was used to re-
isolate the bead-antigen-phage complexes. 
2.2.3.1.7. Elution. The plate was then taken out from KingFisher and 10 µl of 1.25 mg/ml 
L-1-tosylamide-2-phenylethyl chloromethyl ketone (TPCK)-Trypsin in trypsin buffer (50 mM Tris-
HCl pH 8.0, 20 mM CaCl2) to the bead-antigen-phage complexes. Trypsin cleaves the scFv 
antibody from the gene III fusion protein, releasing the bound phage. The gene III protein is still 
functional after removal of the scFv molecule, thus allowing the phage to infect TG1 host cells. The 
solution was incubated at RT for 15 min, then the elution mixture was returned to the KingFisher 
and resolved for the final time by magnetic separation. 
Chapter 2   Material and Methods 
70 
2.2.3.1.8. Infection. Supernatant from step 2.2.3.1.7 (120 µl) containing eluted phage was 
transferred to a new deep-well plate and combined with 800 µl mid log phase TG1 (OD600=0.3-0.5) 
from step 2.2.3.1.1 and incubated at 37°C, 150 rpm for 60 min. 
2.2.3.1.9. Selection for phage-infected TG1. A small aliquot of infected TG1 cells was 
diluted (1:10, 1:100, 1:1000) and plated out on 2xTYAG (containing ampicillin as a resistance 
marker and glucose to suppress expression of scFv antibodies) agar plates to titrate the number of 
selected clones. The rest of the infected cells was pelleted at 3000 x g for 10 min at 20°C, re-
suspended in 500 µl 2xTYAG, plated on 2xTYAG agar plates and incubated overnight at 30°C 
(only TG1 cells containing an ampicillin-resistant phagemid were able to grow). An aliquot of 
uninfected TG1 cells was also plated on 2xTYAG to assess eventual phagemid contamination. 
2.2.3.1.10. Phage rescue. Positively-infected TG1 cells were re-suspended in 2 ml 2xTYAG 
and either stored as glycerol stocks at -80°C or used to inoculate a poly-culture in 1 ml 2xTYAG. 
The culture was grown at 37°C, 600 rpm till mid-log phase (OD600= 0.3-0.5) was achieved, then 
exposed to 1010 M13K07 helper phage at a multiplicity of infection of ~ 10 (approximately 10 
helper phages per infected TG1 cell) and incubated at 37°C, 150 rpm, for 1 h. This helper phage 
brings a gene which confers kanamycin-resistance and will preferentially package phagemid DNA 
rather than its own helper phage DNA. Moreover, it encodes a modified pIII with an additional 
trypsin-sensitive site between domains D2 and D3, which are essential for phage infectivity. Thus 
‘bald’ phage with no scFv molecule which were bound non-specifically to the antigen or have not 
been removed by the wash step are inactivated, giving a more efficient selection process. All cells 
were centrifuged at 3,200 rpm for 10 min at 20°C and re-suspended in 10 ml 2xTYAK (only TG1 
cells which bring both the ampicillin-resistance carried by the phage display phagemid and the 
kanamycin-resistance by the helper phage can survive). Dual-infected cells were incubated 
overnight at 30°C, 600 rpm. During this period the combined burden of phage infection and 
aggressive agitation results in TG1 cells lysis and release of packaged phages into the growth 
medium.  
2.2.3.1.11. Polyethylene-glycol (PEG) precipitation. The 10 ml culture described in 
Section 2.2.3.1.10 was centrifuged at 8000 rpm for 10 min. The supernatant was transferred to a 
new tube, supplemented with 3 ml 20% PEG/2.5 M NaCl and incubated on ice for 1 h. Precipitated 
phages were pelleted at 10,000 rpm for 10 min and re-suspended in 0.5 ml PBS. In order to remove 
any bacterial debris, re-suspended phages were centrifuged at 10,000 rpm for 20 min at 4°C and the 
supernatant containing purified selected phages was stored as a glycerol stock at -80°C and/or used 
in the second round of phage display (thus replacing the de-selected phage library described in 
Section 2.2.3.1.3). 
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2.2.3.2.   Solid-phase phage display selection (biopanning) 
The antigen was immobilised by passive adsorption on Nunc Maxisorp polystyrene tubes 
and all the phage display steps (selection, washing, elutions, etc.) described in Section 2.2.3.1 were 
performed manually. 
 
2.2.3.3.   Polyclonal Phage Enzyme-Linked Immunosorbent Assay (ELISA) 
Black Nunc MaxiSorp plates were coated overnight at 4°C with streptavidin (50 µl/well, 10 
µg/ml), blocked for 1 h at RT with 5% BSA/TNC and incubated for 30 min with biotinylated 
ADAMTS-5 (50 µl/well of 50 nM dilution in 1% BSA/TNC). After three washes with TNC buffer, 
a dilution in PBS of rescued phages was added for 1 h at RT. Plates were washed 3-times with 
TNC/0.1% Tween and 3-times with TNC before incubation with anti-M13 antibody (50 µl/well, 
1:500 dilution in 1% BSA/TNC) for 1 h at RT. After washing, bound phages were detected by time-
resolved fluorescence using europium-labelled anti-mouse-antibody (50 µl/well, 1:1500 dilution in 
1% BSA/TNC) and DELFIA enhancement solution (50 µl/well for 3-5 min on a shaker) followed 
by europium signal acquisition (330 nm excitation, 620 nm emission) on a plate reader. 
 
2.2.4. Primary Screening 
 
2.2.4.1.   Subcloning selected populations into pSANG10-3F and pBIOCAM5 expression 
vectors 
After phage display selection, the selected antibody population exists as a polyclonal 
phagemid mixture in E. coli. The glycerol stocks described in Section 2.2.3.1.10 (containing 
bacteria which were selected for the presence of a phagemid by ampicillin resistance) can be used 
directly as a source of DNA in a PCR reaction to amplify scFv sequences. The scFv inserts can then 
be subcloned into a vector suitable for soluble expression of antibody fragments (glycerol stocks 
can also be used to grow and rescue phage for additional rounds of selection if necessary). Plasmid 
DNA of selected clones from the second round of each selection was extracted following the 
Qiagen Plasmid Miniprep Kit and amplified by PCR using M13 LeadSeq and NotMycSeq primers. 
The amplified DNA was run on a 1% agarose gel and the insert excised and purified using 
ZymocleanTM Gel DNA recovery Kit. Purified PCR products were digested with NcoI and NotI 
restriction enzymes and then ligated into the NcoI/NotI digested p-SANG10 or p-BIOCAM5 
expression vectors using T4 DNA ligase. The ligation product was used to transform BL21 (DE3) 
(pSANG-10) or DH5α (pBIOCAM5) chemically competent cells by thermic shock. Transformed 
cells are then plated out and individual colonies are picked and transferred to separate wells in 
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microtitre plates. After overnight growth, glycerol is then added to the plates to a final 
concentration of 16-17% and the plates are stored at -70°C. These archive plates are then be used to 
inoculate replica plates for primary screening. 
A schematic representation of pSANG-10 and pBIOCAM-5 vectors is shown in Figure 2.3. 
Both vectors contain 6 His and triple FLAG tags for antibody detection and purification. pSANG10 
vector contains a leader for expression in the bacterial periplasm. The insert is under the control of 
the T7 promoter. pBIOCAM-5 vector contains a signal peptide for secretion of protein under the 
control of an enhanced cytomegalovirus promoter (CMV). In this case scFv are expressed in 
mammalian cells as fusion proteins with the Fc of a human IgG1 (scFv-CH2-CH3 dimers). 
 
 
Figure 2.3: Schematic representation of pSANG10 and pBIOCAM5 expression vectors. CMV, cytomegalovirus 
promoter. 
 
2.2.4.2. Bacterial Screening 
 
2.2.4.2.1. Expression of scFv in E. coli 
The strain BL21 (DE3) carries a chromosomal copy of T7 RNA polymerase, under the 
control of the lacUV5 promoter. Expression is controlled by the lac promoter driving expression of 
T7 RNA polymerase which in turn acts on the T7 promoter of pSANG-10 vector to induce scFv 
expression. The lac promoter can be induced using isopropyl β-D-1 thiogalactopyranoside (IPTG) 
in mid-log phase growth or auto-induction (Studier, 2005).  
2.2.4.2.1.1. Isolation of individual clones. Transformed BL21 (DE3) cells described in Section 
2.2.4.1 were plated and selected on 2x TY, containing 50 µg/ml kanamycin and 2% glucose (2x 
TYKG). One-hundred ninety colonies were picked and used to inoculate 100 µl 2x TYKG in 96-
well polypropylene plates. Isolated cultures were incubated at 37°C, 150 rpm for 4-5 h. Cultures 
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were replicated in 2x TYKG and 2% glucose and, following overnight incubation, stored as 10% 
glycerol stocks. 
2.2.4.2.1.2. Induction. Cultures were centrifuged at 2,000 rpm for 5 min. All supernatant was 
removed and each pellet was re-suspended in 200 µl of 2x TY containing 0.02 mM IPTG and 50 
µg/ml kanamycin. Induced cultures were incubated overnight at 30°C, 200 rpm. 
2.2.4.2.1.3.  Isolation of scFv from E. coli periplasm. Inoculated cultures were centrifuged at 
4,000 rpm for 10 min and cell pellets were re-suspended in 150 µl TES (50 mM Tris-HCl pH 8.0, 
0.5 mM EDTA and 0.5 M sucrose). After 10 min, as osmotic shock was initiated by supplementing 
each re-suspended culture with 150 µl of 20% TES and incubating on ice for 30 min. All cultures 
were then centrifuged at 4,000 rpm for 10 min and 180 µl of each supernatant (containing soluble 
scFv) was transferred to a 96 well polypropylene plate. In alternative, after centrifugation of 
bacterial cultures, supernatant was directly tested on ELISA (See Section 2.2.4.2.2). 
 
2.2.4.2.2. scFv-ELISA 
Black Nunc MaxiSorpTM plates were coated overnight at 4°C with streptavidin (50 µl/well, 
10 µg/ml), blocked for 1 h at RT with 5% BSA/TNC and incubated for 30 min with biotinylated 
ADAMTS-5 (50 µl/well of 50 nM dilution in 1% BSA/TNC). After three washes with TNC buffer, 
bacterial supernatant or periplasm extract was added (50 µl/well, final 1% BSA/TNC) for 1 h at RT. 
Plates were then washed 3-times with TNC/Tween and 3-times with TNC before incubating with 
anti-6x his-tag antibody (50 µl/well, 1:500 dilution in 1% BSA/TNC). After washing, bound 
antibodies were detected by time-resolved fluorescence using europium-labelled anti-mouse 
antibody (50 µl/well, 1:500 dilution in 1% BSA/TNC) and DELFIA enhancement solution (50 
µl/well for 3-5 min on a shaker) followed by europium signal acquisition (330 nm excitation, 620 
nm emission) on a plate reader. 
 
2.2.4.3.   Mammalian Screening	  
	  
2.2.4.3.1. High-throughput DNA purification 
DH5α glycerol stocks described in Section 2.2.4.1 were used to inoculate 1.5 ml of 
CircleGrow ® broth, containing 100 µg/ml ampicillin in 96 deep-well blocks, at 37°C, 800 rpm for 
20-24 h (OD600>2). Blocks were spinned for 5 min at 5300 x g on a Sorvall RC12 centrifuge and 
cultures were re-suspended in TE Re-suspension Buffer (50 mM Tris pH 8.0, 10 mM EDTA, 0.1 
mg/ml RNAse) and lysed with 0.2 M NaOH, 1% SDS. Suspensions were neutralised with 2.8 M 
potassium acetate pH 5.1 and centrifuged for 30 minutes at 5300 x g to pellet the lysate. To clear 
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the lysate, supernatant was transferred to a Turbofilter 96 well plate placed over a 96-deep-well 
plate and centrifuged at 750 x g for 5 minutes. The clear lysate was then transferred to a 25 µm 
Whatman MBPP filter plate containing Nucleobond Anion II anion exchange resin previously 
equilibrated with Equilibration buffer (100 mM Tris-phosphoric acid pH 6.3, 15% ethanol, 900 mM 
KCl, 0.15% Triton-X-100) and centrifuged for 10 minutes at 300 x g to bind DNA. DNA was 
washed 3-times with Wash Buffer (100 mM Tris-phosphoric acid pH 6.3, 15% ethanol, 1.15 M 
KCl) and eluted with Elution Buffer (100 mM tris-phosphoric acid pH 8.5, 15% ethanol, 1M KCl). 
DNA was then precipitated in isopropanol, washed with 70% ethanol, re-suspended in 10 mM Tris-
HCl pH 8.0 and finally quantified by OD260 or Quant-IT double strand DNA assay Kit.  
 
2.2.4.3.2. Transient transfection of HEK293-F cells 
HEK293-F cells were maintained in serum-free FreeStyle™ 293 Expression Medium in 
agitated vented polycarbonate Erlenmeyer flasks at 120 rpm (orbital throw 25 mm), 37°C, 5 % CO2 
and 40 % humidity. Cells were routinely maintained at > 95 % viability and passaged when cell 
density reached 1–4 ×106 cells/ml. Cell number and viability was determined using trypan blue 
exclusion staining and manual cell counts on haemocytometer. For screening, HEK293-F cells (2 
ml) were seeded at 1 x 106 cells/ml and transfected with 2.4 µg DNA in 24 well blocks containing 
0.1% pluronic F68 (Chapple et al., 2006). Linear PEI was used as a transfection reagent (Boussif et 
al., 1995; Durocher et al., 2002). Blocks were sealed with an air-pore membrane and incubated in 
an Infors Multitron II incubator (37°C, 5 % CO2, 75 % humidity, 400 rpm). After 5 days 
supernatant was collected by centrifugation at 4000 rpm, 5 min, supplemented with sodium azide 
and stored at 4°C before analysis by ELISA. 
 
2.2.4.3.3. scFv-Fc-ELISA 
Black Nunc MaxiSorpTM plates were coated overnight at 4°C with streptavidin (50 µl/well, 
10 µg/ml), blocked for 1 h at RT with 5% BSA/TNC and incubated for 30 min with biotinylated 
ADAMTS-5 (50 µl/well of 50 nM dilution in 1% BSA/TNC). After three washes with TNC buffer, 
supernatant from transfected HEK cultures was added (50 µl/well, final 1% BSA/TNC) for 1 h at 
RT. After washing, bound antibodies were detected by time-resolved fluorescence using europium- 
labelled anti-human antibody (50 µl/well, 1:500 dilution in 1% BSA/TNC) and DELFIA 
enhancement solution (50 µl/well for 3-5 min on a shaker) followed by europium signal acquisition 
(330 nm excitation, 620 nm emission) on a plate reader. 
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2.2.5. Secondary Screening 
 
2.2.5.1.   Sequence analysis 
Clones were sequenced using primers 2151 (5’-TTAGGAGGGAA CAGGAACACGGAG-
3’) and 2152 (5’-TTTCTCTCCACAGGTGTCCACTCC-3’) for DH5α. Sequences were analysed 
using FinchTV (GeospizaTM, Seattle, USA) and aligned by BLAST. Following alignment, 
different clones were identified while duplicate clones were discarded. The consensus DNA 
sequence was subjected to 3 frame translations and scFv linker (Gly4 Ser Gly4 Ser Gly3 Ala Ser), 6-
His tag and triple FLAG tag sequences were identified. Subsequently, the framework regions and 
CDRs were identified. 
 
2.2.5.2.   Determination of scFv-Fc concentration in cell supernatant by sandwich ELISA 
Black Nunc MaxiSorpTM plates were coated overnight at 4°C with anti-FLAG antibody (50 
µl/well, 5 µg/ml) and blocked for 1 h at RT with 5% BSA/PBS. After three washes with PBS, 
supernatant from transfected HEK cultures was added (50 µl/well of a 1:50 dilution in PBS) for 1 at 
RT. After washing, bound antibodies were detected by time-resolved fluorescence using europium-
labelled anti human antibody (50 µl/well, 1:500 dilution in 1% BSA/TNC) and DELFIA 
enhancement solution (50 µl/well for 3-5 min on a shaker) followed by europium signal acquisition 
(330 nm excitation, 620 nm emission) on a plate reader. Purified scFv-Fc antibodies were used as a 
standard. 
 
2.2.5.3.   Purification of scFv and scFv-Fc antibodies 
Antibodies were purified by one-step immobilised metal chromatography (IMAC). For 
scFv-Fc expression, HEK293-F cells (25 ml) were transfected as described in Section 2.2.4.3.2 and 
medium was harvested by centrifugation for 30 min at 2000 x g and stored at 4°C. For scFv 
expression, bacterial periplasm from 50 ml-induced culture was harvested as described in Section 
2.2.4.2.1. Conditioned medium (supplemented with 10 x Binding buffer: 10x PBS + 100 mM 
imidazole, pH 8.0) or bacterial periplasm (dialysed in 10 x Binding Buffer) were incubated Ni-NTA 
slurry for 2 h at 4°C on a rotating wheel. After this binding step, the mixture was centrifuged at 
4000 rpm for 5 minutes to collect beads; the resin was re-suspended in 1 ml supernatant, loaded 
onto a Generon Proteus spin column and centrifuged at 50 x g for 1 min at 4°C. Resin was washed 
twice with 10 ml Washing Buffer (PBS, 300 mM NaCl, 25 mM imidazole, pH 8.0) and bound 
antibodies were eluted in Elution buffer (PBS, 300 mM NaCl, 300 mM imidazole, pH 8.0). Eluted 
fractions were analysed by SDS-PAGE and Coomassie Blue staining. Antibodies were dialysed 3 
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times in TN buffer (50 mM Tris HCl, 400 mM NaCl, pH 7.5) and once in TNC buffer. The final 
yield was determined from the UV absorption at 280 nm and the theoretical extinction coefficient 
was calculated from its amino acid composition. Antibody stocks were stored at 4°C. 
 
2.2.6. scFv-Fc characterisation 
 
2.2.6.1.   Surface Plasmon Resonance (SPR) 
SPR measurements were carried out on a BIAcore-T100 instrument (GE Healthcare). Anti-
human IgG was chemically immobilised on CM5 biosensor chips, and the anti-ADAMTS-5 
antibodies were captured to give ~300 response units (RU). For kinetics measurements, 3-fold serial 
dilutions of ADAMTS-5 (1-100 nM) were injected in TNC buffer containing 0.05% Tween-20 at 
25°C with a flow rate of 30 µl/min. The surface of the chip was regenerated after each injection of 
sample with 3M MgCl2. Binding was corrected for background binding to a non-coated control 
channel. The binding kinetics were derived from the SPR sensorgrams after subtraction of baseline 
responses. Association rate constants (kon) and dissociation rate constants (koff) were obtained by 
using a simple one-to-one binding model (BIACore Evaluation Software). 
 
2.2.6.2.   Investigation of inhibition mechanism 
To characterise the inhibition mechanism of scFv-Fc antibodies, their inhibitory effect on 
ADAMTS-5 was measured at different concentrations of the QF substrate Abz-TESE~SRGAIY-
Dpa-KK (10, 20, 40 and 80 µM). Data for the reciprocal of the rate of peptide hydrolysis (1/v) 
versus antibody concentration (Dixon Plot) were fitted to a linear polynomial equation using Prism 
software version 5.0 (GraphPad Software, Inc., La Jolla, CA) (Dixon et al., 1979).  
 
2.2.6.3.   Dual inhibition studies 
Double-inhibitor experiments were conducted as described by Yonetani and Theorell 
(1964). Inhibition by two inhibitors is examined by varying the concentration of one inhibitor, i, 
over a range of concentrations in the absence or in the presence of a second inhibitor, j, held at a 
constant concentration (generally corresponding to its apparent inhibition constant, Ki app). A plot of 
the reciprocal of the rate of peptide hydrolysis in the presence of both inhibitors (1/vij) versus the 
concentration of inhibitor i will yield: a) two parallel lines if the two inhibitors compete for the 
same site; b) two lines intersecting the abscissa if the inhibitors bind at two independent sites. 
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2.2.6.4.   Solid-phase binding assay for ADAMTS-5 binding to heparin 
Heparin (10 µg/ml TBS) was coated overnight at 25°C on to heparin-binding plates 
(Mahoney et al., 2004). Wells were washed in TNC buffer containing 0.1%Tween 20 between each 
subsequent incubation. Wells were blocked with 0.2% gelatin in TNC buffer and then incubated 
with recombinant ADAMTS-5 in blocking solution for 3 h at 37°C. Bound proteins were detected 
using either an M2 anti-FLAG antibody followed by anti-mouse antibody coupled to horseradish 
peroxidase (HRP) or anti-human HRP antibody for 1 h at 37°C. Hydrolysis of tetramethylbenzidine 
(TMB) substrate was measured at 450 nm using a BioTek EL-808 absorbance microplate reader. 
 
2.2.6.5.   Immunoprecipitation of ADAMTS-5 with scFv-Fc antibodies 
Purified scFv-Fc antibodies (5 µg) were incubated with Protein G paramagnetic beads (0.6 
mg) for 30 min at RT. The mixture was resolved using magnetic separation and the beads 
containing bound scFv-Fc were incubated with purified ADAMTS5-2 (100 nM, 100 µl), TIMP-3 
(100 nM) or both for 1 h at RT. The beads were washed 3 times with TNC buffer containing 0.02 % 
Tween, re-suspended in 100 µl reducing sample buffer and heated at 90°C for 10 minutes. The 
mixture was resolved by magnetic separation and the supernatant was collected for Western blot 
analysis. 
 
2.2.7. Cartilage explant degradation studies 
 
2.2.7.1.   Cartilage explant culture 
Porcine articular cartilage from the joints of 3-9 month old pigs was dissected into small 
pieces approximately 3 mm long and 3-4 mm wide. Each piece weighed roughly 10 mg. Human 
articular cartilage was dissected into small pieces approximately 1-2 mm thick, 2 mm long, and 2 
mm wide. Each piece weighed roughly 20 mg. After dissection, the cartilage was allowed to 
acclimatise for 24 h at 37°C under 5% CO2 in DMEM containing 100 U/ml penicillin, 100 µg/ml 
streptomycin, 10 % FCS.  
 
2.2.7.2.   Cartilage explant culture conditions for aggrecan degradation 
Each cartilage piece placed in one well of a round bottom 96-well plate was incubated in 
200 µl of serum-free DMEM (Dulbecco’s modified Eagle’s medium) with or without IL-1α (10 
ng/ml) and OSM (50 ng/ml) to stimulate aggrecan degradation. To test the ability of anti-
ADAMTS-5 scFv-Fc antibodies to block aggrecan degradation, each scFv-Fc was added at a 
concentration of 1 µM. N-TIMP-3 (0.1 µM) was used as a positive control. Three pieces of cartilage 
Chapter 2   Material and Methods 
78 
were subjected to each treatment. After 24 h incubation, the conditioned media were harvested and 
stored at -20°C. 
 
2.2.7.3.   Dimethylmethylene blue (DMMB) assay 
GAG-released into the conditioned medium was measured in duplicate using a modification 
of the DMMB assay as described by Farndale et al. (1986). A 200 µl portion of the DMMB assay 
reagent (16 mg/L DMMB dye, 41 mM sodium chloride, 40 mM glycine, 9.5 mM HCl) was added 
to 2 µl sample and the absorbance was read at 540 nm. Shark chondroitin sulphate was used as a 
standard. All data were analysed by unpaired one-tail t-test with Welch’s correction using the 
software package GraphPad Prism. 
 
2.2.7.4.   Analysis of aggrecan fragments in the conditioned medium 
Conditioned medium from cartilage explant culture was mixed with an equal volume of 
double strength GAG buffer. Aggrecan fragments released into the conditioned medium were 
deglycosylated using chondroitinase ABC and keratanase, acetone-precipitated and subjected to 
SDS-PAGE as described in Section 2.2.1.3. Membranes were probed with BC3 anti-ARGSV 
antibody and scanned with a BioRad GS710 calibrated imaging densitometer. Densitometric data 
were analysed by unpaired one-tail t-test with Welch’s correction using the software package 
GraphPad Prism. 
 
2.2.8. Phylogram 
A computer sequence analysis of the 19 known ADAMTS family members plus 7 
ADAMTS-like (ADAMTSL) proteins was performed. Using the full-length protein sequence for 
each of the family members, a multiple sequence alignment was generated using CLUSTAL W. 
CLUSTAL W was run under the default settings. The “.dnd” tree file created was then used as input 
to TREEVIEW (Page, 1996; http://taxonomy.zoology.gla.ac.uk/rod/treeview.html) for the 
generation of a phylogram. ADAM-10 was chosen as outgroup. The following human 
ADAMTS/ADAMTSL family member proteins (UniProt identifiers given in parenthesis) were 
collected for the generation of the phylogram: ADAMTS-1 (Q9UHI8 ), ADAMTS-2 (O95450), 
ADAMTS-3 (O15072), ADAMTS-4 (O75173), ADAMTS-5 (Q9UNA0), ADAMTS-6 (Q9UKP5), 
ADAMTS-7 (Q9UKP4), ADAMTS-8 (Q9UP79), ADAMTS-9 (Q9P2N4), ADAMTS-10 
(Q9H324), ADAMTS-12 (P58397), ADAMTS-13 (Q76LX8), ADAMTS-14 (Q8WXS8), 
ADAMTS-15 (Q8TE58), ADAMTS-16 (Q8TE57), ADAMTS-17 (Q8TE56), ADAMTS-18 
(Q8TE60), ADAMTS-19 (Q8TE59), ADAMTS-20 (P59510), ADAMTSL-1 (A2A344), 
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ADAMTSL-2 (Q86TH1), ADAMTSL-3 (P82987), ADAMTSL-4 (Q6UY14), ADAMTSL-5 
(Q6ZMM2), ADAMTSL-6 (Q6ZMP0), papilin (O95428), ADAM-10 (O14672). 
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3.1. Introduction 
This chapter focuses on purification and characterisation of ADAMTS-5 which was used as 
an antigen in phage display selections with the ultimate aim of isolating anti-ADAMTS-5 mAbs. 
The quality of the antigen is one of the most important factors that affect the success of a phage 
display selection. Both the purity and the biological activity of a protein antigen are crucial. If the 
antigen is denatured or incorrectly folded or in an aggregate form, or if it tends to auto-degrade 
during the selection conditions, the antibodies isolated from primary screening may not have the 
desired properties. These antibodies may score as positive in ELISA settings but result ineffective 
in functional assays (for example they would not be able to block catalytic activity of their target 
enzyme or receptor signalling). This is particularly important when selecting antibodies for 
therapeutic use. The biological activity of the antigen can be measured in the same assay that will 
be used later during secondary screening.  
Our phage-display protocol uses streptavidin beads to pull down biotinylated antigen/phage 
complexes during selection (See Section 2.2.3), so biological activity of biotinylated antigens must 
be assessed and this must be theoretically as similar as possible to that of the native (unbiotinylated) 
protein. Source of antigen may be also relevant. Antigens expressed in bacteria can be incorrectly 
folded. Moreover, glycosylation patterns may be significant for biological activity of a mammalian 
antigen and these are completely absent in a bacterial-expressed antigen or very different in yeast 
(Powers et al., 2001) and insect cells (Kost and Condreay, 1999). Glycosylation sites on the antigen 
may also affect antibody binding. The formulation of the antigen is also important. For example, it 
should not contain carrier protein. As the carrier (usually BSA) is generally at much higher 
concentration than the antigen, the majority of phage display antibody will bind only to the carrier. 
Minor contaminants can also cause serious problems. For example, FLAG peptide used to elute 
FLAG-tagged antigens from anti-FLAG-resin if not removed can be biotinylated and outnumber the 
antigen during liquid-phase selections. Another factor which plainly influences the choice of an 
antigen is the expression level. For example, point or deletion mutants of enzymes may be 
expressed at higher levels than the wild type/full-length enzyme. Since high amounts of purified 
antigen are needed for selection and primary screening, the final yield should be reasonably high.  
Taking in account all these factors, we chose to use ADAMTS5-2 as an antigen for phage 
display selection (Fig 3.1). This form of ADAMTS-5 lacks the C-terminal TS domain (TS-2); 
deletion of this domain has no detectable effect on matrix binding or general aggrecanolytic activity 
of ADAMTS-5, but produces a 2-fold decrease in IGD aggrecanolysis (Gendron et al., 2007) (See 
Section 1.3.3). However, expression of full-length ADAMTS-5 (ADAMTS5-1) is approximately 
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10% the expression of ADAMTS5-2 (only 2 µg from 1 L conditioned medium). For this reason, we 
chose ADAMTS5-2 as an antigen. 
 
3.2. ADAMTS-5 purification 
The ADAMTS5-2 construct consists of a signal peptide necessary for extracellular 
secretion, a prodomain, a Cat domain, a Dis domain, a TS domain, a Sp domain and a FLAG tag at 
the C-terminus (Fig 3.1). This enzyme was expressed in stably-transfected HEK293-EBNA cells 
and purified from the conditioned media in the presence of heparin using anti-FLAG affinity 
chromatography as described in Section 2.2.2.1. Heparin was added to enhance the release of the 
mature enzyme in the conditioned medium owing to its ability to compete with ECM for binding to 
ADAMTS exosites (Kuno & Matsushima, 1998; Gendron et al., 2007). Since heparin also inhibits 
aggrecanase activity (Fushimi et al., 2008), high concentrations of salt (1 M) were used to remove 
heparin from anti-FLAG resin. A typical Western blot from affinity step is shown in Figure 3.2.  
 
 
Figure 3.1: Schematic representation of ADAMTS-5 construct. S, signal peptide; Pro, prodomain; Cat, catalytic 
domain; Dis, disintegrin domain; TS, thrombospondin domain; CR, cysteine-rich domain; Sp, spacer domain; F, FLAG 
tag. 
 
 
Figure 3.2: SDS-PAGE and Western blot analysis of samples collected from anti-FLAG M2 affinity 
chromatography. Lanes: 1) Conditioned medium. 2) Unbound. Medium was harvested after 3 days of culture and 1 ml 
was precipitated with 5% TCA. Unbound was precipitated in the same way. 3), 6) and 10) wash. 4) and 5) wash with 1 
M NaCl; 7), 8) and 9) FLAG peptide-eluted fractions. The membrane was probed with anti-FLAG antibody. MW, 
Molecular weight (kDa). 
 
The eluted fractions were concentrated and applied to a PD-10 gel filtration column to 
remove excess of FLAG peptide. The purified protein was analysed by Western Blot analysis using 
both the anti-ADAMTS-5 Cat domain and the anti-FLAG antibodies, and purity was assessed by 
silver stain (Figure 3.3). The enzyme ran at a molecular weight that was higher than that predicted 
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for the active form: 75-80 kDa versus the predicted 68 kDa, as previously shown in our lab 
(Gendron et al., 2007). This may be due to glycosylation of the protein. 
 
 
Figure 3.3: SDS-PAGE and Western blot analysis of ADAMTS-5. Purified ADAMTS5-2 was concentrated, passed 
through a PD-10 column and then subjected to SDS-PAGE (10% total acrylamide) and Western blot analysis using 
either the anti-FLAG M2 or the anti-ADAMTS-5 Cat domain antibodies. Proteins were stained with silver. Lanes: 1) 
Pool of eluted fractions from affinity chromatography; 2) 6-folds concentrated pool; 3) flow-through from concentration 
cell; 4) TNC-buffer; 5) Flow-through; 6), 7) and 8) TNC-eluted fractions. Red stars indicate mature ADAMTS5-2, blue 
stars C-terminally truncated products. Mw, molecular weight (kDa). 
 
ADAMTS-5 is predicted to undergo N-glycosylation (where the glycan is attached to an 
asparagine residue present in the tripeptide consensus sequence Asn-X-Ser/Thr, with X being any 
amino acid except proline), O-glycosylation (in which the glycan is attached to a serine or threonine 
residue) and C-mannosylation (where a mannose sugar is added to the first tryptophan residue in the 
sequence Trp-X-X-Trp) and these modifications are linked to protein secretion (Wang et al., 2009; 
Ricketts et al., 2007). In particular, four N-glycosylation sites (one in the Dis domain, one in the 
CysR domain and two in the Sp domain), one O-glycosylation site (in the Sp domain) and five C-
mannosylation sites (one in the Cat domain, three in the TS-1 domain and one in the TS-2 domain) 
are predicted in mature ADAMTS-5. Glycosylation sites for human and mouse sequences are 
reported in Table 3.1. A change in electrophoretic mobility of recombinant ADAMTS-5 after 
digestion with N-glycosidase F confirmed N-linked glycosylation in ADAMTS-5 Sp (Zeng et al., 
2006) and Dis (Gendron et al., 2007) domain. Moreover, also two C-mannosylation modifications 
of tryptophan and a glucose-fucose disaccharide on the TS-1 domain of recombinant ADAMTS-5 
were experimentally confirmed (Wang et al., 2009). 
The protein was mainly present in its processed, active form, as a result of intracellular 
processing by furin (Gendron et al., 2007). A minor band of approximately 20 kDa was detected 
with anti-FLAG M2 antibody (Figure 3.3); Western blot using the anti-ADAMTS-5 Cat domain 
antibody also showed a ~60 kDa band which was absent in the anti-FLAG Western Blot. The 
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combined molecular weights of the 20-kDa band detected in anti-FLAG Western blot and the 60- 
kDa band detected in the anti-ADAMTS-5 Cat domain Western blot gave the original molecular 
weight of the enzyme.  
 
Post-translational Modification Aa residue Human Mouse Domain 
N-glycosylation* 498 + + Dis 
N-glycosylation 728 + + CysR 
N-glycosylation 802 + + Sp 
N-glycosylation 807 + + Sp 
O-glycosylation 25 + - Propeptide 
O-glycosylation 211 + + Propeptide 
O-glycosylation 215 + - Propeptide 
O- glycosylation** 582 + - TS-1 
O-glycosylation 840 + - Sp 
C-mannosylation 255 + - Propeptide 
C-mannosylation 452 + + Cat 
C-mannosylation** 570 + + TS-1 
C-mannosylation** 573 + + TS-1 
C-mannosylation 576 + + TS-1 
C-mannosylation 884 + + TS -2 
 
Table 3.1: Post-translational modifications of ADAMTS-5. Positions were predicted by NetNGlyc 1.0, NetOGlyc 
3.1 and NetCGly1.0 (Julenius et al., 2005; Julenius, 2007) softwares. *Gendron et al., 2007, ** Wang et al., 2009. 
 
The final concentration of ADAMTS-5 was determined by active-site titration with N-
terminal domain of TIMP-3 (N-TIMP-3). Approximately 150 µg of ADAMTS-5 was routinely 
obtained from 1 L of conditioned medium. 
 
3.3. Characterisation of aggrecanase activity of ADAMTS5-2 
The enzyme concentration-dependence of aggrecan cleavage was characterised by 
incubating purified bovine aggrecan (670 nM) with different amounts of purified ADAMTS5-2 for 
2 h. The products were deglycosylated and subjected to SDS-PAGE and Western blot analysis with 
the anti-AGEG, anti-GELE, anti-ARGSV (BC3), anti-NITEGE, 2-B-6 (which recognises the 
chondroitinase-resistant chondroitin 4-sulphate stubs), and anti-G3 antibodies (Fig. 3.4). 
ADAMTS5-2 showed a general preference for cleavage in the CS-2 domain relative to cleavage in 
the IGD of aggrecan. Both the 130-kDa AGEG- and 250-kDa GELE- reactive fragments were 
generated with as low as 1 pM enzyme (Fig. 3.4 A, B); generation of these species peaked at around 
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5 and 50 pM, respectively, and then declined (Fig 3.4 G), suggesting further C-terminal cleavage. 
The anti-GELE antibody detected also a second band at around 370 kDa at high (10-100) pM 
concentrations of enzyme. This fragment was not observed at around 0.5 nM of enzyme (Fig. 3.4 
B). Interestingly, at this concentration, 250-kDa ARGSV-reactive fragments start to be detected 
(Fig 3.4 C), thus it is likely that the 370-kDa band represents a product of cleavage at both the 
GELE1499↓1500GRGT and NITEGE392↓393ARGSV sites (bovine aggrecan numbering). 
The 250-kDa ARGSV-reactive fragments peaked at 1 nM ADAMTS5-2 and showed little or 
no signal at picomolar concentration of enzyme (Figure 3.4 C). As it has previously been shown 
(Tortorella et al., 2002), the anti-NITEGE neoepitope antibody detected two bands at around 80-70 
kDa, which for sake of clarity we define here as “70-kDa band”’. As expected, the 70-kDa 
NITEGE391-reactive fragments showed a similar pattern with a peak around 1-5 nM, 
notwithstanding the differences in the relative sensitivities of the two antibodies (Figure 3.4 G).  
In the absence of ADAMTS5-2, both the anti-CS stubs antibody and the anti-G3 antibody 
detected a 500-kDa band representing intact aggrecan. With increasing concentration of enzyme (1-
100 pM) 4 different species appeared: 1) a ~250-kDa band which reacted with both the anti-
ARGSV antibody (Fig 3.4 C) and the anti-GELE antibody (Fig 3.4 B), indicating that this fragment 
was generated by cleavage at the  NITEGE392↓393ARGSV and GELE1499↓1500GRGT sites; 2) a 140-
kDa band, which cross-reacted with both the anti-CS stub and the anti-G3 antibodies and was likely 
to be generated by cleavage at KEE1685↓1686GLGS within the CS-2 domain; 3) a 130-kDa band, 
which reacted with anti-CS stub, anti-G3 antibody and anti-AGEG antibody, was generated by 
cleavage at PTAQE1790↓1791AGEG in the CS-2 domain; 4) a 98-kDa band, which cross-reacted with 
both the anti-CS stub and the anti-G3 antibodies, was likely generated by cleavage at 
TVSQE1890↓1891LGQR in the CS-2 domain. 
In summary, cleavage in the CS-2 domain is favoured over cleavage in the IGD; in 
particular, cleavage at GELE1499↓1500GRGT, PTAQE1790↓1791AGEG and TVSQE1890↓1891LGQR is 
preferred over cleavage at NITEGE392↓393ARGSV. These preferences are inferred from comparison 
between neoepitope antibody Western blots and anti-CS stubs/anti-G3 Western blots, thus 
overcoming difficulties related with different antibody sensitivities.  
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Figure 3.4: Enzymatic characterisation of ADAMTS5-2. ADAMTS5-2 was incubated with aggrecan (670 nM) for 2 
h at 37°C. The reaction was stopped with 50 mM EDTA and the samples were deglycosylated. After acetone 
precipitation, the protein pellets were re-suspended in reducing sample buffer, run on SDS-PAGE (6% total 
acrylamide), and subjected to Western Blot analysis. Membranes were probed with anti-AGEG (A), anti-GELE (B), 
anti-ARGSV (C), anti-NITEGE (D), anti-CS stub (E) or anti-G3 (F) antibodies. Detected molecular species are reported 
on the left side of each blot. G) Plot of ADAMTS-5 generated neoepitopes over the concentration of enzyme 
(continued). Blots were quantified by scanning densitometry and the intensity of the bands was plotted as a percent 
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(continued) maximum of reactivity against enzyme concentration. For GELE, only the 250 kDA band is plotted; GLGS 
indicates the intensity of the band corresponding to 140 kDa-1686GLGS fragment as detected by anti-CS stub or anti-G3 
antibodies. 
Fragments that react with both the anti-ARGSV and the anti-AGEG antibodies were not 
detected; instead, only fragments cross-reacting with both the anti-ARGSV and the anti-GELE 
neoepitope antibodies were observed, thus it may be concluded that cleavage at 
GELE1499↓1500GRGT is favoured over cleavage at PTAQE1790↓1791AGEG. Bands with size 
corresponding with cleavage at KEE1685↓1686GLGS are also readily detected with the 2B-6 and anti-
G3 antibodies, with intensities peaking at around 2 pM and then declining (Fig.3.4 G). Taken 
altogether, the data suggest the following order of cleavage (minimum amount necessary to 
generate maximum cleavage product): 1) cleavage at KEE1685↓1686GLGS; 2) cleavage at 
GELE1499↓1500GRGT; 3) cleavage at NITEGE392↓393ARGSV in the IGD and at 
PTAQE1790↓1791AGEG of 1500GRGT-G3 fragments.  
 
3.4. ADAMTS-5 biotinylation 
In order to perform solution-phase phage display selections, purified ADAMTS5-2 was 
biotinylated with EZ-link Sulpho-NHS-LC biotin. This biotin-derivative contains a 19-atom spacer 
which guarantees that streptavidin binding will not interfere with any local scFv-antigen binding. In 
fact, the high-affinity (KD ~ 10-5 M, Green, 1963) biotin-streptavidin interaction occurs significantly 
far away from ADAMTS-5 during antigen pull-down.  
Owing to the relatively low enzyme stock concentration (200-300 nM, 15-23 µg/ml) to 
enhance the efficiency of biotinylation protein/biotin ratios higher than unity (1:4.5; 1:13.5; 1:27; 
1:46; 1:90) were explored. Biotinylation was confirmed by anti-biotin Western blot and the degree 
of labelling (DOL, number of molecules of biotin per molecule of enzyme) was determined by 
florescence displacement assay (See section 2.2.2.4) (Figure 3.5. and Table 3.2). Enzyme/biotin 
ratios up to 1:90 resulted in incorporation of up to 12.5 molecules of biotin per molecule of enzyme. 
At 1:13.5 and 1:4.5 enzyme/biotin ratios the fluorescence detected was the same of the background 
and the DOL was calculated as  ≤ 1.  
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Figure 3.5: Assessment of biotinylation level for ADAMTS-5. A) Standard curve of biocytin (range: 6-100 pmoles 
biocytin). B) Western blot with streptavidin A conjugated with AP. 0.9 pmoles of samples were loaded in each lane. 
Positive control for Western blot is represented by biotinylated IgG provided by the manufacturer.  
	  
Enzyme/Biotin ratio Degree of labelling (DOL) 
1:4.5 <1 
1:13.5 <1 
1:27 2 
1:45 2.7 
1:90 12.5 
 
Table 3.2: Determination of biotinylation level (DOL) for different enzyme/biotin ratios by fluorescence 
displacement assay. 
 
Activity of ADAMTS-5 labelled with different numbers of molecules of biotin was tested 
both in a QF peptide cleavage assay and in the aggrecan digestion assay to ensure that biotinylated 
antigen retained the activity of the native one. No significant difference in activity was detected 
between unbiotinylated and biotinylated ADAMTS-5 in the QF peptide cleavage assay even at the 
highest level of biotinylation (Figure 3.6 A). However, the aggrecan digestion assay revealed a 
marked decrease in anti-AGEG and anti-ARGSV neoepitope detection for ADAMTS-5 with DOL 
of 12.5 and 2.7 (Figure 3.6 B, C).  
Taken altogether DOL and activity of biotinylated samples, a 1:20 enzyme/biotin ratio was 
chosen for antigen labelling. This ratio resulted in an average DOL of 1.5 (on average each 
molecule of enzyme is labelled with 1.5 molecules of biotin). A DOL less than unity would produce 
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non-biotinylated molecules which will not be pulled down during phage display-selection, thus 
leading to loss of binders. 
 
 
Figure 3.6: Enzymatic activity of biotinylated ADAMTS-5. A) QF-peptide cleavage by biotinylated ADAMTS-5. 
Enzyme (5 nM) was pre-incubated for 10 min at 37°C before adding 20 µM of QF-peptide substrate ortho-
aminobenzoyl-Thr-Glu-Ser-Glu~Ser-Arg-Gly-Ala-Ile-Tyr-(N-3-[2,4-dinitrophenyl]-L-2,3-diamino-propionyl)-Lys-
Lys-NH2. The assay was performed in triplicate in a total volume of 200 µl per well in 96-well microtitre plates. For 
each DOL mean and standard deviation are reported. B, C) Aggrecanase activity by biotinylated ADAMTS-5. Bovine 
aggrecan (50 µg) was digested for 2 h at 37°C with 1 and 2.5 pM (B) or 1 nM (C) unlabelled ADAMTS-5 or with 
ADAMTS-5 labelled with increasing number of molecules of biotin. The reactions were stopped with 50 mM EDTA 
and the products were deglycosylated overnight with chondroitinase ABC and keratanase and analysed by Western 
blotting for ARGSV-containing fragments using anti-AGEG (B) and anti-ARGSV (C) neoepitope antibodies. For all 
these assays, activity of unlabelled ADAMTS-5 is reported for comparison.  
 
3.5. Discussion 
In this chapter we presented a detailed characterisation of ADAMTS-5 which was 
preliminary to phage display selection and following screening. A deletion form lacking the C-
terminal TS (TS-2) domain (ADAMTS5-2) was expressed in HEK293 cells and purified from the 
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conditioned medium in the presence of heparin, which enhances release of aggrecanases from ECM 
(Gendron et al., 2007). The preparation contained mainly the desired enzyme form, although a 
proportion of the purified protein was C-terminally cleaved, as evidenced by Western blot analysis 
and silver stain (Figure 3.3). On the basis of the observed molecular weight and Western blot data 
it is very likely that the cleavage sites for autocatalytic processing lie in the Sp and CysR domain. A 
cleavage site in the Sp domain at Glu753↓754Gly has been reported by Georgiadis et al. (2002) and 
Zeng et al. (2006). This cleavage generated a 60-kDa band on SDS PAGE (Zeng et al., 2006). 
However, identification of the cleavage sites may require N-terminal amino acid analysis. 
The aggrecanase activity of the antigen was then characterised. ADAMTS5-2 cleaves 
preferentially in the CS-2 domain of aggrecan with the following order of cleavage 1) cleavage at 
KEE1685↓1686GLGS; 2) cleavage at GELE1499↓1500GRGT; 3) cleavage at NITEGE392↓393ARGSV in 
the IGD and at PTAQE1790↓1791AGEG of 1500GRGT-G3 fragments. The observed order is in 
agreement with previous studies reporting time-dependent aggrecanase cleavage of bovine aggrecan 
(Tortorella et al., 2000a; Tortorella et al., 2002).  
The antigen was biotinylated and both peptidolytic and aggrecanolytic activity were 
checked. High biotinylation levels resulted in a substantial decrease in aggrecanase activity as 
evaluated by detection of AGEG- and ARGSV-fragments with no effect on cleavage of a QF-
peptide. ADAMTS5-2 displays 51 sites for biotinylation, comprising 48 lysine residues (10 in the 
Cat domain), the N-terminus and 2 lysine residues in the FLAG tag. Therefore, it is statistically 
more likely that biotinylation reaction involves residues in the ancillary domains rather than in the 
Cat domain. Since these domains are important in cleavage of macromolecular substrates such as 
aggrecan (See section 1.3.3) but may not be necessary in cleavage of small peptides, the 
discrepancy in activity between the two assays observed at high biotinylation levels may be 
explained on the basis of biotinylation of critical lysine residues in the ancillary domains. For 
example, ADAMTS-5 presents a lysine-rich sequence (739NKKSKG744) in the Sp which represents 
a consensus motif for interaction with GAGs (Troeberg et al., 2012; Cardin and Weintraub, 1989) 
thus over-biotinylation may impair binding to macromolecular substrates/ECM. 
A 1:20 enzyme/biotin ratio resulted in a reasonable labelling (1.5 molecules of 
biotin/molecule of enzyme) without any effect on aggrecanolytic activity and was chosen for 
biotinylation of ADAMTS5-2 in preparation for liquid-phase phage display selections. 
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4.1.   Introduction 
Phage display provides a powerful tool to isolate antibodies against a desired antigen. The 
possibility to manipulate conditions during selection and screening allows to target or, alternatively, 
exclude specific epitopes on the target antigen. This is particularly important if the isolated 
antibodies are required for therapeutic use. 
The aim of the selection process is to isolate a small subset of phages that recognise the 
target antigen from a large and diverse library. One main parameter which modulates the size and 
diversity of the selected population is the stringency. Stringency is defined as “the degree to which 
peptides with higher fitness are favoured over peptide with lower fitness”, the fitness itself being 
defined in its Darwinian terms as the contribution to the gene pool of the next generation by an 
individual with a specific genotype and phenotype (Smith and Petrenko, 1997). Stringency is 
inversely proportional to the yield (or output), i.e. “the fraction of particles with a given fitness that 
survive selection” (Smith and Petrenko, 1997). Most common parameters affecting stringency are 
the duration of incubation of library with the target, conditions of washing steps (e.g. detergent 
concentration, pH value of washing buffer) (D’Mello and Howard, 2001; Lunder et al., 2005; Yu et 
al., 2004) and target concentration/density (Kretzschmar et al., 1995). Antibodies can also be 
selected on the basis of kinetic parameters (“off-rate selection”) by incubating the library with the 
biotinylated antigen in the presence of an excess of unlabelled antigen (Vaughan et al., 1996). The 
same principle can be exploited to direct the selection towards particular epitopes by adding an 
excess of a ligand (small molecule or protein) during incubation of the library with the antigen, thus 
actually negatively selecting antibodies sharing an epitope with the ligand. Finally, screening of the 
selected phage population can be tailored to enhance the chance to identify antibodies with desired 
properties. Primary screening usually involves isolation of antibodies for antigen-binding activity 
by ELISA. This allows for screening of large numbers of clones in parallel. Eventually, secondary 
screening can be performed to further identify antibodies on the basis of their ability to interfere 
with the biological activity of the antigen. 
In pursuing our aim to isolate ADAMTS-5-blocking antibodies, we exploited the versatility 
of phage display selection by varying parameters such as antigen concentration and presence of 
ligand. Moreover, after primary screening by ELISA, ADAMTS-5-binding antibodies were tested 
for their ability to inhibit peptidolytic and aggrecanolytic activity of the enzyme. Screening for 
inhibition of a QF peptide cleavage identifies antibodies able to inhibit ADAMTS-5 activity by 
interacting with Cat/Dis domain; on the other hand, screening for inhibition of aggrecan cleavage 
not only allows to assess the inhibitory potency of antibodies against an endogen (native) substrate 
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but may also identify antibodies able to inhibit specifically cleavage of macromolecular substrates 
by interaction with enzyme ancillary domains. 
 
4.2.   Phage display selections 
Different approaches for panning of phage display libraries are available. For example, 
antigen columns can be used where the library is passed through a column with immobilised 
antigen; selections can also be performed on antigen adsorbed on plastic surface (solid-phase 
selection) or using biotinylated antigen which can be captured by streptavidin-coated magnetic 
beads (liquid-phase selection). Alternatively, libraries can be incubated with monolayers of cells or 
on cells in suspension which express the antigen and then target cells are sorted by Fluorescence-
Activated Cell Sorting (FACS) using antibodies against an irrelevant antigen (de Kruif et al., 1995). 
Finally, in in vivo selections phage libraries are directly injected into animals and then tissues are 
collected and examined for phage bound to tissue-specific markers (Pasqualini and Ruoslahti, 
1996). 
I chose to perform phage display selection against ADAMTS-5 in liquid phase. Biotinylated 
human recombinant ADAMTS5-2 was exposed to a naïve scFv antibody phage-display library for 
two rounds of solution-phase phage display selections. Owing to the presence of a FLAG tag at the 
C-terminus of the antigen, the library was previously deselected against 5 µM FLAG peptide.  
Two antigen concentrations (10 and 100 nM) were explored and for each condition exposure 
to the library was carried out both in the presence and in the absence of a 100-fold excess of the 
broad-spectrum metalloprotease inhibitor GM6001 (Grobelny et al., 1992). GM6001 is a zinc-
chelating hydroxamate-based compound which inhibits ADAMTS-5 with a Ki app of 600 nM in QF 
peptide cleavage assay (Figure 4.1). Notably, no differences in GM6001 inhibition between 
unbiotinylated and biotinylated form of ADAMTS-5 are detected (Ki app 630 ± 50 and 590 ± 80, 
respectively), thus confirming that under these biotinylation conditions ADAMTS-5 is fully active. 
The use of a large excess of a small molecule inhibitor has two possible effects: 1) to redistribute 
the conformational distribution of the antigen towards a closed, stable form, preventing potential 
auto-catalysis; 2) competition with scFv-antibodies with epitopes localised in the proximity of the 
active site zinc. 
A solid phase selection (biopanning), using passive adsorption to polystyrene tubes for 
antigen immobilisation, was performed using 50 nM ADAMTS5-2. Although this method can 
induce conformational changes in the structure of native antigens, it generally provides a robust 
alternative for generate a large number of binders. 
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Figure 4.1: Inhibition of ADAMTS-5 by broad-spectrum MMP inhibitor GM6001. A) Structure of GM6001; B) 
Dose-response inhibition of biotinylated and unbiotinylated ADAMTS5-2. Enzyme (5 nM) was pre-incubated for 2 h at 
37°C with different concentrations of inhibitor before adding 20 µM of QF peptide substrate ortho-aminobenzoyl-Thr-
Glu-Ser-Glu~Ser-Arg-Gly-Ala-Ile-Tyr-(N-3-[2,4-dinitrophenyl]-L-2,3-diamino-propionyl)-Lys-Lys-NH2.  
 
As a positive control for phage display selections, a well-characterised antigen (kindly 
provided by Dr John McCafferty, University of Cambridge), SHC-transforming protein 1 (Shc1) 
was biotinylated and used as an antigen (100 nM concentration) for solution-phase phage display 
selections. 
Following two rounds of phage display selection, the estimated enrichment ratio (calculated 
by the number of colony-forming units, cfu, eluted in the second round of selection versus the 
number of cfu present in the first round) was between 5- and 13.5-folds for the selections performed 
in the absence of the inhibitor and between 22.5- and 29-folds in the presence of inhibitor (Table 
4.1). The solid-phase selection gave 4.5-folds of enrichment, comparable with liquid-phase 
selections performed in the absence of GM6001. For comparison, the positive control (Shc1) gave 
about 4000-fold enrichment. The enrichment after round II is explained by a selective increase in 
targeted-eluted phage pool and the degree of this enrichment depends on the nature of the antigen.  
Further rounds of selection may provide a greater enrichment ratio but at the same time may 
decrease final phage diversity. In fact, since phage selection is a function of display level (i.e. 
expression) as well as binding affinity, excessive rounds of selection can lead to artefacts such as 
the biased production of better expressing clones or “monster” phage clones lacking any displayed 
ligand (Jackson et al., 1995). 
 
 
Chapter 4   Phage display selection and screening 
95 
Selection [Ag] 
nM 
Inhibitor* 
 
Output  
Round I 
Output  
Round II 
Enrichment 
(Round II/ 
Round I) 
ADAMTS-5 
solid-phase 
50 - 2.2 x104 1x105 4.5 
ADAMTS-5 
liquid-phase 
10 - 5.7 x 104 7.7x105 13.5 
ADAMTS-5 
 liquid-phase 
10 + 6.5 x 104 1.9x106 29 
ADAMTS-5 
liquid-phase 
100 - 3.5 x 105 2x106 6 
ADAMTS-5 
liquid-phase 
100 + 4 x 105 9x106 22.5 
Shc1  
liquid-phase 
100 - 3. 9x 103 15x106 4000 
 
Table 4.1: Number of phages (cfu) present in pools from the selection experiments. Success rate is defined as the 
number of ELISA-positive clones over the total number of screened clones and the values reported are for mammalian 
expression system (See section 4.3.4). *100-fold excess of GM6001. 
 
The trypsin-based phage elution specifically targets only phages bound via scFv by cleaving 
the scFv and the D1 domain of pIII (Figure 4.2). This results in a low phage background when 
compared with other elution methods, such as pH shift, which also removes phages which bind to 
the antigen through aspecific interactions (i.e. non-scFv-mediated). The pIII protein is still 
functional after removal of the scFv molecule, thus allowing the phage to infect TG1 host cells.  
Another advantage of trypsin elution is the specific removal of so-called “bald” phages 
lacking an scFv molecule derived by the helper phage. When the phagemid is rescued by infection 
with helper phage, the cell contains pIII protein from the helper and pIII-scFv fusion protein from 
the phagemid. Approximately 90% of all phage particles produced have only pIII protein from the 
helper phage and do not carry an scFv molecule. During packaging and rescue of the library, the 
pIII protein from the helper phage competes with the scFv-pIII fusion protein for incorporation into 
the phage particles. The helper phage KM13, however, encodes a modified pIII with an additional 
trypsin-sensitive sequence between domains N1 and N2. Thus, whereas the wild-type pIII protein of 
the phagemid is resistant to trypsin treatment and retains the infectivity, the modified pIII from the 
helper phage loses infectivity after trypsin treatment. The net result is the inactivation of phages not 
carrying an scFv molecule.  
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Figure 4.2: Principle of trypsin-based elution. 
 
To check the quality of selections, polyclonal phage ELISA was performed (Figure 4.3). 
Figure 4.3 A shows the results for the 10 nM antigen selections (liquid-phase), the control selection 
using biotinylated Shc1 as an antigen (liquid-phase) and a standard biopanning selection in 
immunotubes using 45 nM ADAMTS-5 as an antigen (solid-phase). The solid-phase selection 
produced a low cognate versus non-cognate (ADAMTS-5/streptavidin) signal ratio. This is may be 
due to the general lower efficiency in the selection procedures in immunotubes coated with 
streptavidin compared with the pull down mediated by streptavidin-coated paramagnetic beads. We 
therefore chose to focus our efforts on solution-phase selections. Figure 4.3 B reports the results 
after two rounds of selection for liquid-phase selections using 100 nM ADAMTS-5 as an antigen. 
In this case the antigen-specific binding after round II increased by around 100 folds with respect to 
round I. As a negative control, phages from liquid-phase selection against an unrelated antigen 
(lysozyme) were rescued and incubated with biotinylated ADAMTS-5 to check aspecific binding. 
These phages gave a signal about 1000 RFU, comparable with the signal from ADAMTS-5 
selections after round I, whereas the specific signal from ADAMTS-5 selections after round II 
increased to around 100,000 RFU. Thus, the signal detected after round I, in the absence of any 
amplification, is undistinguishable from background signal coming from a phage population 
selected against a non-cognate antigen. 
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Figure 4.3: Polyclonal Phage ELISA. A) After two rounds of selection, polyclonal ELISA was performed by 
incubating the polyclonal phage population (5-fold dilution in TNC) from each selection after round II with biotinylated 
ADAMTS-5 (50 nM) coated on streptavidin plates (black bars) or  with streptavidin alone control (white bars). As a 
comparison, phage population from a selection against Shc1 was incubated with biotinylated Shc1 coated on 
streptavidin plates or with streptavidin alone. B) Enrichment in antigen-specific phages after round II. To check 
aspecific binding to ADAMTS-5, phages rescued from a selection against lysozyme were incubated with biotinylated 
ADAMTS-5 coated on streptavidin plates. Phage binding was detected by a M13 europium-conjugated secondary 
antibody. The ELISA signal is represented as raw fluorescent units (RFU) on the y-axis. LP, liquid-phase selection; SP, 
solid-phase selection. 
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4.3.   Primary screening 
The vector used for phage display selection (pSANG4) is not designed for expression of 
soluble antibody fragments since scFvs are expressed at the N-terminus of pIII of filamentous 
phage. Moreover, although trypsin-based elution is highly efficient in removing bald phages, still 
some phagemids may not contain a complete scFv sequence. Therefore, an additional cloning step 
is required. 
For primary screening, selected libraries are usually subcloned into a vector suitable for 
soluble expression of scFvs by bacterial cells. Although bacterial expression is sufficient for most 
purposes, some sensitive biological assays and lead validation protocols prefer a mammalian 
expression system which can provide an antibody format whose features (stability, glycosylation, 
pharmacokinetics, etc) closely mimic those expected to occur with therapeutic agents. We therefore 
subcloned selected libraries in pBIOCAM5 vector for screening in HEK293-F suspension cells 
where antibodies were expressed as fusion proteins with the crystallizable fragment of human IgG1 
(scFv-CH2-CH3 dimers or scFv-Fc) (Chapple et al, 2006) (Figure 4.4). In parallel, the same eluted 
polyclonal scFv populations were subcloned into pSANG10-3F for expression of soluble scFv 
(Martin et al., 2006) to compare success rates (i.e. the number of positive clones over the total 
number of screened clones) and general performances between the two formats.  
 
 
Figure 4.4: Schematic representation of different antibody formats, showing intact IgG molecules alongside scFv 
and scFv-Fc antibody fragments. Approximate size in kDa is reported. Yellow bars indicate interchain disulphide 
bonds (intrachain disulphide bonds are omitted). 
 
In both cases, the primary screening was performed in an ELISA setting in the absence of GM6001, 
using as an antigen biotinylated ADAMTS-5 coated on streptavidin plates or streptavidin alone. 
Binding specificity was estimated as the ratio between the signal from the antigen plates over the 
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signal from streptavidin plates. The general strategy for isolation of ADAMTS-5 inhibitory 
antibodies is depicted in Figure 4.5.  
 
Figure 4.5: Strategy for isolation of ADAMTS-5-inhibitory antibodies. Libraries selected against ADAMTS-5 in the 
presence and absence of small molecule inhibitor GM6001 were subcloned into both bacteria and mammalian 
expression vectors. Individual clones were then isolated. Antibodies were first screened for binding to ADAMTS-5 in 
ELISA (primary screening) in the absence of GM6001. For bacterial screening, BL21 colonies expressing scFvs were 
directly screened after IPTG induction. For mammalian screening, DH5α colonies were used as a source of DNA which 
was successively transfected in HEK293-F cells for expression of scFv-Fc antibodies. After DNA sequencing, non- 
redundant clones were expressed in high amounts and tested in functional assays (secondary screening). 
 
4.3.1. Bacterial screening 
The scFv DNA sequences from the final round of selection pools were amplified by colony 
PCR, isolated by agarose gel extraction and re-cloned into the pSANG10-3F expression vector 
(Martin et al., 2006) for bacterial expression via NcoI/NotI. After transformation in BL21, colonies 
were picked and transferred to 96-well plates (masterplates). Ninety-five clones from the second 
round of the 100 nM antigen selections (total 190 clones, x 2 96-well plates) were isolated and used 
to express recombinant scFv antibodies (Figure 4.6). The capacity of each clone to bind to 
biotinylated recombinant human ADAMTS-5 was investigated by ELISA using anti6x His-tag-
antibody/europium-labelled anti-mouse-antibody as a detection system. Supernatant from a 
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bacterial clone specific for Shc1 and a purified anti-Shc1 scFv were used as positive controls for 
expression and ELISA, respectively.  
 
  
Figure 4.6: Isolation of anti-ADAMTS-5 antibodies expressed in E. coli. Following two rounds of solution-phase 
phage display selections against biotinylated ADAMTS-5 (in the presence and in the absence of a 100-fold excess of 
zinc-chelating inhibitor GM6001), the eluted phagemid populations were transferred into pSANG10-3F vector and 
antibodies were expressed as soluble scFvs in E. coli. Each clone was ELISA-screened against biotinylated ADAMTS-5 
(in the absence of GM6001) on streptavidin plate or streptavidin alone. Results are expressed as (A) binding specificity 
(fold of difference between ADAMTS-5 and streptavidin: RFUADAMTS-5/RFUstreptavidin) or, alternatively (B), as ΔRFU 
(difference in signal between antigen and streptavidin: ΔRFU = RFUADAMTS-5 – RFUstreptavidin). Red line indicates the 
arbitrary threshold for signal (~ 5000 RFU, 300 folds of difference). 
 
 
Both gave a signal of 10,000 RFU after binding biotinylated Sch1, showing saturation of the signal 
for this antigen (Figure 4.7). A threshold of 5000 RFU was chosen and gave a total success rate of 
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about 13% (19% for selection with 100 nM antigen without inhibitor and 7% for selection in the 
presence of inhibitor). In all cases, bacterial supernatant gave a signal of about 50-100 RFU when 
incubated with streptavidin alone controls. This proves the efficiency of the deselection strategy 
adopted before the actual phage display selection. 
 
Figure 4.7: Positive controls for bacterial screening. Culture supernatant from a bacterial clone positive for Shc1 
binding and purified anti-Shc1 scFvs from the same clone were incubated with biotinylated Shc1 on streptavidin wells 
as positive controls for induction and ELISA, respectively. Results are expressed as binding specificity (fold of 
difference between ADAMTS-5 and streptavidin: RFUSch1/ RFUstreptavidin) (A), or, alternatively, as ΔRFU (difference in 
signal between antigen and streptavidin: ΔRFU = RFUSch1 – RFUstreptavidin (B). Error bars indicate standard deviation 
(n=3). 
 
To check expression levels, scFvs were purified from bacterial periplasm after auto-
induction using immobilised metal affinity chromatography (IMAC) (Figure 4.8). Purified scFvs 
run as a single band of around 30 kDa on 12% SDS-PAGE. In this case, scFv expression was 
controlled by growth in a chemically-defined auto-induction medium, which removes the necessity 
to monitor bacterial growth by optical density and switches on recombinant protein expression 
(Studier, 2005). The growth medium contains a controlled amount of carbon sources and the 
expression is tightly controlled by catabolite repression. As the bacterial culture density increases, 
the catabolite repression is released by loss of carbon sources and expression from the lac promoter 
is turned on due the presence of lactose in the induction medium. The Studier-defined auto-
induction media greatly reduces unintended induction of cultures. In our case, we found that scFv 
expression induced by auto-induction medium is equivalent to IPTG-induction, as previously 
reported (Martin et al., 2006). scFvs are mainly present in the periplasmic fraction, although some 
expression “leaks” into the medium (Figure 4.8). However, although recovery of scFv from culture 
medium is achievable, it is not a straightforward one-step Ni-NTA purification procedure 
(Bannister et al., 2006). Thus we chose to work with the periplasmic fraction to facilitate 
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purification of resulting antibodies. Yields between 30-100 µg from 50 ml-scale cultures were 
routinely obtained for different antibodies (Table 4.2). 
 
Figure 4.8: scFv purification from bacterial periplasm. A typical purification of clone C2 is compared with that of a 
positive control (E6) for expression and purification. The first lane from left reports a positive control of E6 clone for 
SDS-PAGE. S, supernatant; P, periplasmic fraction; D, periplasmic fraction after dialysis in binding buffer; FT, flow-
through from Ni-NTA column; W 20 mM imidazole wash; E, 300 mM imidazole-eluted fraction. The red arrows 
indicate the scFv band at around 30 kDa. Samples were run on a 12% SDS-PAGE under reducing conditions and 
stained with CBB.  
 
Antibody Purified 
scFv 
(µg, total) 
1 120 
2 47 
3 36 
4 106 
5 68 
6 50 
7 91 
 
Table 4.2: Yields of purified scFvs from 50-ml auto-induction cultures. Antibodies were purified by IMAC 
and concentrations were determined by OD reading at 280 nm. 
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4.3.2. Mammalian Screening 
Phagemid populations were subcloned in pBIOCAM5 vector for expression in HEK293-F 
suspension cells. For transient expression, the recombinant expression vector was propagated in the 
E. coli strain DH5α. Colonies were picked and transferred to 96-well plates (masterplates). Each 
bacterial clone from master plates was used to inoculate a replica clone in 96 deep-well blocks for 
high-throughput plasmid DNA purification (See Section 2.2.4.3.1). On average, DNA yield for 1.5 
ml culture was ~ 25 µg, with OD260/OD280 ~ 1.9 and OD260/OD230 > 2. DNA was then used to 
transfect HEK293-F cells (2 ml) and 5 days after transfection supernatant was harvested and 
assayed directly by ELISA against biotinylated ADAMTS-5 coated on streptavidin plates. Antibody 
binding was detected by europium-labelled anti-human antibody (Figure 4.9). Ninety-five clones 
from the second round of the 100 nM antigen selections (total 190 clones, x 2 96 well plates) were 
tested. A threshold of 5000 RFU gave a total success rate of about 24% (29% for selection with 100 
nM antigen without GM6001 and 19% for selection in the presence of GM6001). In all cases, 
supernatant gave a signal of about 10-20 RFU when incubated with streptavidin alone controls. A 
similar signal was detected when supernatant from mock-transfected cells was incubated with 
biotinylated ADAMTS-5 or streptavidin (Figure 4.10). 
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Figure 4.9: Isolation of anti-ADAMTS-5 antibodies expressed in HEK293-F. Following two rounds of solution-
phase phage-display selections against biotinylated ADAMTS-5 (in the presence and in the absence of a 100-fold 
excess of the zinc-chelating inhibitor GM6001), the eluted phagemid populations were transferred into pBIOCAM5 
vector and antibodies were expressed as soluble scFv-Fc in HEK293-F cells. Each clone was ELISA-screened against 
biotinylated ADAMTS-5 (in the absence of GM6001) on streptavidin plate or streptavidin alone. Results are expressed 
as binding specificity (fold of difference between ADAMTS-5 and streptavidin: RFUADAMTS-5/RFUstreptavidin) (A) or, 
alternatively as ΔRFU (difference in signal between antigen and streptavidin: ΔRFU = RFUADAMTS-5 – RFUstreptavidin) 
(B). Red line indicates the arbitrary threshold for signal (~ 5000 RFU, 300 folds of difference).  
 
Supernatant from a clone specific for Shc1 was incubated with biotinylated Shc1 as a 
positive control for transfection and ELISA, giving a signal of about 10,000 RFU (Figure 4.10). 
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Figure 4.10: Positive controls for mammalian screening. HEK293-F cells were transfected with an anti-Shc1 
antibody and after 5 days supernatant was harvested and incubated with biotinylated Shc1 on streptavidin wells as 
positive controls for transfection and ELISA. As a negative control, HEK293-F cells were mock-transfected and 
supernatant was incubated with biotinylated ADAMTS-5. Results are expressed as binding specificity (fold of 
difference between ADAMTS-5 and streptavidin: RFUantigen/RFUstreptavidin) (A), or, alternatively, as ΔRFU (difference in 
signal between antigen and streptavidin ΔRFU = RFUantigen – RFUstreptavidin). Error bars indicate standard deviation 
(n=3). 
 
To estimate the concentration of scFv-Fc antibodies in the conditioned medium, a sandwich 
ELISA was developed. scFv-Fc antibodies were captured with anti-FLAG antibody and detected by 
an anti-human-europium labelled secondary antibody. A purified scFv-Fc, whose concentration was 
previously determined by OD reading, was diluted to give a standard curve with linearity in the 
range of 5-100 ng/ml (r2=0.98) (Figure 4.11). The lower detection limit was 0.5 ng/ml. Conditioned 
medium was diluted (10-, 50- and 100-folds in PBS) and concentration values were interpolated 
from the standard curve under conditions where the anti-human signals were proportional to bound 
scFv-Fc.  
 
Figure 4.11: Representative standard curve of scFv-Fc antibodies (range 5-100 ng/ml). 
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Concentrations in the conditioned medium from 2 ml-scale transfections ranged between 0.5 and 20 
µg/ml (Table 4.3). The average concentration was around 1 µg/ml, corresponding to 9 nM. 
 
Antibody [scFv] 
µg/ml 
[scFv] 
nM 
Purified 
scFv-Fc 
(µg, total) 
1 (1D) 2.2 20 4.4 
2 (1F) 0.95 9 1.9 
3 (5A) 0.55 5 1.1 
4 (2B) 1.85 17 3.7 
5 (2F) 1.55 14 3.1 
6 (5C) 0.8 7 1.6 
7 (2A) 20 180 40 
 
Table 4.3: Concentrations of scFv-Fc antibodies in conditioned medium from 2-ml cultures as 
determined by sandwich-ELISA. 
 
Differences in expression up to an order of magnitude were observed among different 
antibodies. It has been reported that even a single amino acid difference at the sequence level may 
affect the expression of antibodies in mammalian cells, possibly influencing folding, glycosylation, 
chaperone association and retention in the endoplasmic reticulum (Bentley et al., 1998; Swaroop et 
al., 1997).  
A limitation of the sandwich ELISA described here is the potential loss of C-terminal FLAG 
tag from the antibody molecule, which may result in an underestimation of antibody concentration 
in conditioned medium. To directly compare antibody yields between bacterial and mammalian 
expression systems, scFv-Fc were expressed in 25 ml-scale transfection and purified by IMAC 
(Figure 4.12). Purified scFv-Fc run as a single band (monomer) of around 60 kDa on a 12% SDS 
PAGE under reducing conditions. The observed size was in general slightly higher than the 
expected 55 kDa, probably due to post-translational modifications. 
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Figure 4.12: scFv-Fc purification from HEK293-F conditioned medium. Representative purifications for two clones 
are reported. The last lane on the right reports a positive control (purified scFv-Fc) for SDS-PAGE. S, supernatant; FT, 
flow-through from Ni-NTA column; W, 20 mM imidazole wash; E, 300 mM imidazole-eluted fraction. The red arrows 
indicate the scFv-Fc band at around 60 kDa. Samples were run on a 12% SDS-PAGE under reducing conditions and 
stained with CBB. 
 
Yields between 140-300 µg were obtained for different antibodies (Table 4.4). These correspond to 
concentrations of 5-12 µg/ml in the conditioned medium, with an average concentration of 6 µg/ml 
(50 nM). One reason for the discrepancy between the average yields determined by sandwich 
ELISA and the actual yields obtained after IMAC may be the loss of the FLAG peptide (the FLAG 
peptide is located C-terminal to the 6-His tag); another possibility is that the scale up from 2 ml 
cultures in 24 well blocks to 25 ml cultures in vented caps may lead to a more robust expression of 
scFv-Fc antibodies by HEK293-F cells. 
 
Antibody Purified 
scFv-Fc 
(µg, total) 
1 (1D) 245 
2 (1F) 140 
3 (5A) 150 
4 (2B) 220 
5 (2F) 290 
6 (5C) 180 
7 (2A) 260 
 
Table 4.4: Yields of purified scFv-Fc antibodies from 25-ml cultures. Antibodies were purified by IMAC and 
concentrations were determined by OD reading at 280 nm. 
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It is noteworthy that for screening, supernatant from HEK293-F conditioned medium was 
used as a source of scFv-Fc antibodies directly without further purification. Thus, scFv 
concentration was not assessed and the bias represented by different expression levels of different 
clones could potentially affect the binding of one clone relative to the other, meaning that it is not 
possible to compare directly antibody signal and affinity. We can assume on the basis of the 
sandwich ELISA and purification data reported here that the scFv-Fc concentration in the 
conditioned medium ranged between 10-50 nM. If we compare these values with the concentration 
of antigen coated on ELISA plates (50 nM), a large excess of antigen was not provided in ELISA. 
However, it was not possible to increase further the antigen concentration on the plate due to the 
limited ADAMTS5-2 purification yield. 
 
4.3.3. Comparison between bacterial and mammalian screening 
Traditionally in phage display, antibody populations are selected as scFv or Fab fragments 
fused to coat proteins on the phage surface. For primary screening, these antibodies are then 
subcloned in E. coli for expression of soluble antibody fragments. Within two days, cultures can be 
transformed, propagated and induced, and periplasm or bacterial supernatant can be tested for 
binding to the target antigen by ELISA. However, there are some drawbacks related to the use of 
scFvs during the screening procedure. First, the expression level of human antibody fragments in 
bacteria is relatively low; secondly, scFvs suffer from a lack of stability. As a result, unless a low 
molecular weight is desired for specific applications (like in vivo imaging), these antibodies need to 
be reformatted as Fabs or IgGs and, consequently, subcloned in a mammalian expression vector for 
functional characterisation.  
On the other hand, mammalian cells such as HEK or Chinese hamster ovary (CHO) cells 
can express whole IgGs in a fully glycosylated form although the complete procedure takes 7-10 
days to get the purified protein from DNA purification and transfection to antibody purification. A 
list of factors affecting bacteria and mammalian screening of antibody fragments is reported in 
Table 4.5. Here we were able to compare performances of these two systems by subcloning the 
same phagemid populations in two vectors optimised for expression of soluble antibody fragments 
in bacteria and mammalia, respectively. Although the detection system used was different (anti6x-
tag followed by europium-labelled anti-mouse antibody in the case of E. coli-expressed scFv versus 
europium-labelled anti-human antibody in the case of mammalian-expressed scFv-Fc antibdies), it 
is evident that the mammalian system presented a superior performance in terms of success rate 
(~30% versus ~15%, threshold: 5000 RFU or 300 folds of difference with respect streptavidin) 
(compare Figures 4.9 with Figure 4.6 and Figure 4.10 with Figure 4.7). This may be mainly due 
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to a combination of higher expression and an avidity effect due to the presence of two antigen-
binding sites on an scFv-Fc molecule. The yield of purified antibody was in the range of 30-200 µg 
scFvs from a 50 ml-induced E. coli culture and 100-500 µg scFv-Fc antibodies from 25 ml-
transfected HEK293-F culture. Moreover, in the case of scFvs, precipitation was observed after 
short storage at 4°C. Precipitation and inactivation of scFvs are a well documented phenomenon 
(Marks et al., 1992) and they may be due to the exposure and subsequent aggregation of 
hydrophobic patches that are in contact with the CH1 and CL domains in natural antibodies (Nieba et 
al., 1997, Reiter et al., 1996). In the case of scFv-Fc antibodies, little or no precipitation was 
observed after prolonged storage at 4°C, thus it is likely that the fusion of Fcγ1 to the scFv through 
the hinge region and the consequent dimerisation resulted in stabilisation of the antibody fragment.  
 
 Bacteria 
scFv 
Mammalia 
scFv-Fc 
Success rate 15% 30% 
Expression      ++* +++** 
Stability + +++ 
Glycosylation Absent Present 
Time consuming + 
(2 days) 
+++ 
(7-8 days) 
 
Table 4.5: Comparison between bacteria and mammalian systems for expression of antibody fragments. *30-200 
µg from 50-ml culture; **100-500 µg from 25-ml culture. 
 
Taken altogether data from ELISA and purification, we chose scFv-Fc expression by HEK293-F 
cells as a system to screen ADAMTS-5-binding antibodies. 
 
4.3.4. Primary screening of anti-ADAMTS-5 antibodies 
Three hundred-three (303) clones from different selections were ELISA-screened in HEK293-F 
cells (Figure 4.13). To check selectivity, 72 clones were randomly chosen and screened again by 
ELISA against ADAMTS-5 and its most similar ADAMTS member, ADAMTS-4 (Figure 4.14). 
Both recombinant human proteases are FLAG-tagged at the C-terminus (domain structure of the 
recombinant human proteins is reported in Figure 4.14 B). Biotinylated ADAMTS-4 gave 
approximately the same signal of ADAMTS-5 on two different types of ELISA (Figure 4.14 C). 
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Figure 4.13: Isolation of anti-ADAMTS-5 human antibodies expressed in HEK293-F cells. After high-throughput 
DNA plasmid purification and transfection in HEK293-F cells, individual clones were ELISA-screened against 
biotinylated ADAMTS-5 (in the absence of GM6001) on streptavidin plates or streptavidin alone. Results are expressed 
as binding specificity (fold of difference between ADAMTS-5 and streptavidin: RFUADAMTS-5/RFUstreptavidin) (A) or, 
alternatively as ΔRFU (difference in signal between antigen and streptavidin: ΔRFU = RFUADAMTS-5 – RFUstreptavidin) 
(B). Red line indicates the arbitrary threshold for signal (~ 5000 RFU, 300 folds of difference). 
 
First, biotinylated ADAMTS-5 and -4 were captured on streptavidin plates and binding was 
detected by europium-labelled anti-FLAG antibody; in the second ELISA setting, both enzymes 
were captured by anti-FLAG M2 antibody and the binding was detected by europium-labelled 
streptavidin. All 72 clones bound only to ADAMTS-5 but not to ADAMTS-4 or streptavidin. Since 
both enzyme forms used in this experiment are FLAG-tagged, we can exclude that these antibodies 
are directed against this tag. Moreover, since the scFv-Fc antibodies also contain a triple-FLAG tag, 
anti-FLAG tag scFv-Fc antibodies would compete each other for the binding or aggregate. 
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Out of 303 clones, 116 clones were sequenced and 72 different antibodies were identified. 
Table 4.6 reports the success rate (number of hits/total number of clones screened), the final 
diversity (number of different sequences/total number of clones sequenced) and the number of 
different sequences which have been identified for each selection. The total diversity of the selected 
phagemid populations was around 62%. 
 
 
Figure 4.14: Specificity of anti-ADAMTS-5 antibodies. A) Supernatant from HEK293-F cells containing scFv-Fc 
antibodies was incubated with biotinylated ADAMTS5-2 and ADAMTS4-2 on streptavidin plates or with streptavidin 
alone, and binding was detected by anti-human europium-labelled IgG (note logarithmic scale); B) Domain structure of 
ADAMTS antigens; F, FLAG tag; C) To check that equal levels of biotinylated antigens were coated on streptavidin 
plates, binding was detected by anti-FLAG europium-labelled IgG; alternatively, 50 nM of each antigen were captured 
on anti-FLAG wells and binding was detected by europium-labelled streptavidin. 
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Selection [Ag] 
nM 
Inhibitor* 
 
Success rate 
(total clones) 
Final 
diversity 
(total 
sequences) 
Number  
of different 
clones 
ADAMTS-5 
liquid-phase 
10 - 39%  
(64) 
69% 
(32) 
22 
ADAMTS-5 
 liquid-phase 
10 + 34% 
(45) 
94% 
(16) 
14 
ADAMTS-5 
liquid-phase 
100 - 29% 
(106) 
66% 
(44) 
28 
ADAMTS-5 
liquid-phase 
100 + 19% 
(88) 
100% 
(12) 
14 
 
Table 4.6: Success rate and final diversity for ADAMTS-5 phage display selections. Sequencing was used to 
determine final diversity. Numbers in brackets indicate the number of clones which were screened and sequenced, 
respectively. *100-fold excess of GM6001. Note: the number of different clones is higher than 72 owing to clones being 
shared between different selections. 
 
Three antibodies were identified both in the 10 and in the 100 nM selection in the absence of 
GM6001, whereas just one antibody out of 72 was isolated irrespective of the selection conditions. 
For each clone, the variable heavy and light chain subclasses as well as the 3 CDRs (CDR-1, -2, and 
-3) of each chain were identified (Table 4.7). CDRs represent a set of structural elements which 
determine the specificity of an antibody to the target (Jones & Thornton, 1996), namely the residues 
on the antibody that contact the epitopes (paratopes). The third CDR of the heavy chain (CDR-H3) 
is the most diverse and most important for antigen recognition (Xu and Davis, 2000; Zemlin et al., 
2003) and, in naturally occurring human antibodies, its size varies from 4 to >35 residues (Johnson 
and Wu, 2000). An analysis of the germ line contribution to CDR-H3 diversity points out that naïve 
loops are dominated by tyrosine and small residues (glycine, serine, alanine and threonine) (Zemlin 
et al., 2003). Tryptophan residues are not particularly abundant, and arginine residues are rare but 
become more abundant in antibodies that have undergone affinity maturation (Zemlin et al., 2003). 
The sequences of anti-ADAMTS-5 antibodies show an over-representation of a few amino acids 
(tyrosine, serine, asparagine and tryptophan), as previously reported (Ofran et al., 2008). Tyrosine 
residues mediate about 25% of the antigen contacts in functional antibodies (Mian et al., 1991). 
Aspartate and glycine are over-represented in the CDRs of the heavy chain. High abundance of 
tyrosine, serine and glycine has been correlated with increased antibody specificity (Birtalan et al., 
2008).  
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Clone Variable Heavy Variable Light 
CDR-1 CDR-2 CDR-3 Subclass CDR-1 CDR-2 CDR-3 Subclass 
MP2 A1 GFTFSSYGMH VISYDGSNKYYADSVKG LFYNNYYYVMDV III QGDSLRSYYAS GKNNRPS NSRDSSGNHVV Lambda IV 
MP2 A3 GFTFSSYGMH VISYDGSNKYYADSVKG DRDSSGYWYGMDV III RASQSISSYLN DASNLET QQSHSTPYT Kappa I 
MP2 A7 GFPFSSYGMH VISYDGSNKYYADSVKG DSGSSWHRYMDV II RASQSISSYLN AASSLQS QQSYSTPPT Lambda I 
MP2 
A11 
GYSFTSYWIS RIDPSDSYTNYSPSFQG GGDSSSLYDAFDI I TGTSSDVGGYNYVS EGSKRPS SSYTSTNSVV Lambda II 
MP2 B1 GYTLTELSMH GFDPEDGETIYAQKFQG FGRGY I TGSNGTIDSNFVQ EDNQRPS QSYDSTTVI Lambda VI 
MP2 B3 GFTFDDYAMH SISWNSGSIGYADSVKG DAVDGYYHYVDV III RASQSISSYLN AASSLQS QQSYSTPSRT Kappa I 
MP2 B8 GYSFTSYWIG IIYPGDSDTRYSPSFQG GTGTTIADAFDI I RASQSISSYLN AASSLQS QQTYKTPQT Kappa I 
MP2 B9 GFTFSSYAMS AISGSGGSTYYADSVKG DQTPLGGFYFDY III RASQSISSYLN AASSLQS QQSYSTPGT Kappa I 
MP2 C1 GGTFSSYAIS GIIPIFGTANYAQKFQG VLQGYSYGYWVFDY I TRSSGSIASNYVQ EDNQRPS QSYDSNNVV Lambda VI 
MP2 C7 GYTLTELSMH GFDPEDGETIYAQKFQG SGLLDY I TGSSGSIASNYVQ EDNQRPS QSYDSSNHCWV Lambda VI 
MP2 C9 GYTFTSYGIS GIIPIFGTANYAQKFQG DLYQLLYPGGAFDI I TGSGGSIASNDVQ EDDQRPS QSYDSVNRGI Lambda VI 
MP2 D3 GGTFSSYAIS GIIPIFGTANYAQKFQG EGRLVVGATTDYYYYYGMDV I RASQNINTYLN KASSLES QQYDNLPIT Kappa I 
MP2 D5 GFTFDDYAMH GISWNSGSIGYADSVKG ESSSWYLRYFDY III RASQSISSYLN AASSLQS QQSYSTPFT Kappa I 
MP2 D9 GGTFSSYAIS GIIPIFGTANYAQKFQG ALTVRYSSGWYIPPFNYYYYGMDV I GGNNIGSKNVH DDTDRPS QVWDSSTEEVV Lambda 
III 
MP2 
D11 
GFTFTDYYMS YIDTGSGGTYTKYADSVKG LWTLGGWYFDL III QASQDISNYLN DASNLET QQYDNLRLT Kappa I 
MP2 E2 GGIFSSYVIS GIIPIFGTANYAQKFQG LPTYGPSY I TGSSGSIASNYVQ EDNQRPS QSYDSSNVV Lambda VI 
MP2 E4 GYTLTELSIH GFDPEDGETIYAQKFQG DLVRGYDFWSGYTPPRDY I TGTGGNIADNFVQ EDDLRPS QSYDSSSWV Lambda VI 
MP2 E6 GFTFDDYAMH GISWNSGSIGYADSVKG TAGGLSAADNPYYYYGMDV III KSSQSVLYSSNNKNSLA WASTRES HQYYNAPLT Kappa IV 
MP2 E7 GYSFTSYWIS RIDPSDSYTNYSPSFQG GGDSSSLHDAFDI I SGRSANIGSNYVS RNNQRPS ASWDDLLSGWV Lambda I 
MP2 
E10 
GFTFDDYAMH GISWSSGSIGYADSVKG DRVAISGLLYAFDI III TRSSGSIASNYVQ EDNQRPS QSYDSSNVV Lambda VI 
MP2 F5 GFTLSDYYMDW RTRNKANGYTTEYAASVKG DFWSGYYDSGLGSGYFQH III GGENIGAKPVH YDSDRPS QVWDSSTVV Lambda 
III 
MP2 G7 GYTLTELSMH GFDPEDGETIYAQKFQG DYY I TGTSGSIASNYVQ EDDKRPS QSYDSSNHRWV Lambda VI 
MP2 G9 GGTFSSYAIS GIIPIFSTANYAQKFQG GDLRRDAFDI I SGSSSNIEFNTVN SNNQRPS AAWDDSLNGYV Lambda I 
MP2 H2 GGTFSSYAIS GIIPIFGTANYAQKFQG APSHGSGDY I TRSSGSIASNYVQ EDNQRPS QSYDSNNRV Lambda VI 
MP2 H5 GYTFTDYYMH LVDPEDGETIYAEKFQG DLLTTGDYGMDV I RASQGISNYLN DASNLET QQFDNLPIT Kappa I 
MP2 H9 GFTFSSYAMH LISYDGSNKYYADSVKG VSRFQLSLPFDY III RARQSIRDYLN GASSLQS QQSYSLPLT Kappa I 
MP1 A3 GYSLTQLAMH GFDPERGETIYAQQIQG HPRH I TGSSGSIASNFVQ EDKKRPS QSFDTSNWV Lambda VI 
MP1 A4 GFTFSSYGMH VISYDGSNKYYADSVKG DSGSSWHRYMDV III RASQSISSYLN AASSLQS QQSYSTPYT 
 
Lambda I 
MP1 A5 GYSFTSYWIG IIYPGDSDTRYSPSFQG LINGWYFDY I TRSGGDIANNFVQ EDNQRPS QSYDSTNHWV Lambda VI 
MP1 A6 GYTLTELSMH GFDPEDGETIYAQKFQG DTYYGVDY I TGSSGSIASNFVQ EDSQRPS QSYDSSNWV Lambda VI 
MP1 A7 GFTFSSYWS NIKQDGSEKYYVDSVKG DWNGDV III RASQSVTTYLA SASARAT QQYNSWPLT Kappa III 
MP1 A8 GYSFTSYWIG IIYPGDSDTRYSPSFQGQ GMVRGVISSAFDI I TRSSGSIASNYVQ EDNQRPS QSSDSIIVV Lambda VI 
MP1 A9 GYTFTSYGIS WISAYNGNTNYAQKLQG AAFGWFDP I SGDRLGDKYAY QDSKRPS QAWDSSTAV Lambda 
III 
MP1 
A11 
GFTFSSSDMH AIGTGGDSYYSDSVKG EGYSYNWNDWYFDL III QARQDISNYLN AASSLQS QQYNSYPYT Lambda I 
MP1 
A12 
GHTFTGYYMH RINPNSGGTNYAQKFQG QGYGVFYYYYGMDV I TGSSGSIASNYVQ EDNQRPS QSYDSSNHVV Lambda VI 
MP1 B1 GYTFTGYYMH WINPNSGGTNYAQKFQG DGGYCSSTSCHDAFDI I TRSSGSIARNYVQ GDNQRPS QSYDSNNHVV Lambda VI 
MP1 B3 GYTLTELSMH GFDPEDGETIYAQKFQG FASLLPGLNWFDP I GGNNIGSKSVH YDRDRPS QVWDSSSDHPG Lambda 
III 
MP1 B2 GFTFSSYAMH VISYDGSNKYYADSVKG DVGSNWHHWFDP III RASQSISSYLN AASSLQS QQSYSTPPSIT Kappa I 
MP1 B4 GGTFSSYTIS RIIPILGIANYAQKFQG VTGTVKGAFDI I RGDNIGHKLVH YDNDRPS QAWDSSHVVF Lambda 
III 
MP1 B6 GYSFTSYWIG IIYPGDSDTRYSPSFQG PILALGAFDI I GGNNIGSKSVH YDSDRPS QVWDSSSDHPGYV Lambda 
III 
 
Table 4.7: Paratope sequences and immunoglobulin subclasses of anti-ADAMTS-5 antibodies. 
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Clone Variable Heavy Variable Light 
CDR-1 CDR-2 CDR-3 Subclass CDR-1 CDR-2 CDR-3 Subclass 
MP1 B7 GGTFSSYAIS RIIPILGIANYAQKFQG PGYSGYDAVTTDYYYYYGMDV I SGSSSNIGSHTVD SDYHRPS AAWDDSLNGYV Lambda I 
MP1 B9 GFTFSNFGMS SISGHGYDKFYADSVKG DSSSNWWGLTRHFDN III TRSSGNIASNSVH EDNQRPS QSYDSSNLWV Lambda VI 
MP1 
B11 
GFTFSSYAMH VISYDGSNKYYADSVKG DLGSGWWVFDY III GGNNIGSKSVH YDSDRPS QVWDSSSDHPNVV Lambda 
III 
MP1 C1 GFTFDDYAMH GISWNSGSIGYADSVKG VSSSSWYHWFDP III RASQSISSYLN AASSLQS QQSYSTPYT Kappa I 
MP1 C8 GYTLTELSMH GFDPEDGETIYAQKFQG DYY I TGTSGSIASNYVQ EDDKRPS QSYDSSNHHWV Lambda VI 
MP1 D1 GFTFSSYAMS AISGSGGSTYYADSVKG DQTPLGGFYFDY III RASQSISSYLN AASSLQS QQSYSTPQT 
 
Kappa I 
MP1 D6 GGTFSSYTIS RIIPILGIANYAQKFQG GGVVPDTQGQGDDAFDI I RSSHSLLYTDGNTYLN KVSNRDS MQGRHWSTT Kappa II 
MP1 D9 GFTFSSYSMN AIFGSGGSTYYADSVKG DFGYYYGMDV III TRSSGSIASNYVQ EDDQRPS QSYDSGIVV Lambda VI 
MP1 
D10 
GYTFTDYGIT RIIPILGIANYAQKFQG HGGPRTFDI I TRTSGDIANNYVQ EDSQRPS QSYDSSNIWV Lambda VI 
MP1 
D11 
GGTFSSYAIS GIIPIFGTANYAQKFQG NSSSWYWPWADAFDI I RASQSISRYLN AASSLQS QQTYTTPWT Kappa I 
MP1 
D12 
GFTVSSNYMS VIYSGGSTYYADSVKG DSYQATYDFWSGYFPNYYYYGMDV III RSSQSLLHSNGYNYLD LGSNRAS MQALQTPRT Kappa II 
MP1 E2 GFTFDDYAMH LISWDGGSTYYADSVKG PLDIVVVVGVTTGYYGMDV III TRSSGSIDSNYVQ EDNLRPS QSYDDSNHLV Lambda VI 
MP1 E3 GFTFSSYSMN SISSSSSYIYYADSVKG PQEYGDYGMDV III TRSSGGIASNYVQ EDKQRPS QSFDSTNHWV Lambda VI 
MP1 E4 GGNFRNYAIS WINTNTGNPTYAQGFTG DRFEGAIFDY I TGSSGSIASNYVQ EDNQRPS QSYDSNNRV Lambda VI 
MP1 E5 GFTFDDYAMH GISWNSGSIGYADSVED DSADYYYYYMDV III RASQSISSYLN AASSLQS QQSYSTPRT Kappa I 
MP1 E6 GFTFSSYAMS AISGSGGSTYYADSVKG SYSSSVLRWLI III RSSQSLVFSDGNTYLN KVSNRDS MQGTHWPLT Kappa II 
MP1 E9 DELETION DELETION DELETION  RASQGISNRLA AASSLQS QHYYNTPPT Kappa I 
MP1 
E10 
GYSFTNYWIS RIDPSDSYTNYSPSFQG QPSPYSIGYYGMDV I GNNIGSKNVH RDSNRPS QVWDSSTAEVV Lambda 
III 
MP1 
E11 
GYSFTSYWIG IIYPGDSDTNYSPSFQG LYYGGYVDY I GGDNIGGKSVH DTDRPS QVWDDSAHAAI Lambda 
III 
MP1 
E12 
GGTFSSYAIS GIIPIFGTANYAQKFQG DRDLVVANAEALDI I RSSQSLVYSDGNTHLQ KVSKRDS MQGAHWPRT Kappa II 
MP1 F1 GFSLSTSGMRMN RIDWDDDKYYSTSLKT IPPLWWYGMD II TRSSGSIASNYVQ EDNQRPS QSYDSGNEAV Lambda VI 
MP1 F2 GFTFSSYAMH VISYDGSNKYYADSVKG DEWELLGGGAFDI III RASQGIGTYLN AASSLQS QQSYSTPYT Kappa I 
MP1 F3 GYSFTSYWIG IIYPGDSDTRYSPSFQG PRAGTTGGIDY I GGNNIGSKNVH RDSNRPS QVWDSSTAV Lambda 
III 
MP1 F4 GGTFSSYAIS GIIPIFGTANYAQKFQG GRGYCSGGSCYPDY I TRSSGDIASNYVQ EDKQRPP QSYHNDNWI Lambda VI 
MP1 F5 GFTFDDYAMH GISWNSGSIGYADSVKG GGYSSSWYGDY III TRSSGSIASNYVQ EDDERPS QSLDGRDWV Lambda VI 
MP1 F7 GGTFSSYTIS RIIPILGIANYAQKFQG DKYYGSGSYPFDAFDI I TRSSGSIARNYVQ EDNQRPS QSYDSSAVV Lambda VI 
MP1 F8 GFTFDDYAMH GISWNSGSIGYADSVKG EGGGTWAFDY III TRSSGSIASNYVQ EDNQRPS QSYGDNTVI Lambda VI 
MP1 F9 GYTFTGYYMH WINPNSGGTNYAQKFQG ASGSYHNWFDP I TGSRGSIASNYVQ EDDQRPS QSYDSLNPWV Lambda VI 
MP1 
F10 
GFTFDDYAMH GISWNSGSIGYADSVKG AQYSSPLSYFDY III TRSSGSIASNYVH EDSQRPS QSYDSNILV Lambda VI 
 
Table 4.7: Paratope sequences and immunoglobulin subclasses of anti-ADAMTS-5 antibodies (continued). 
 
Figure 4.15 shows the frequency of different combinations of the VH, VL kappa and VL 
lambda subfamilies in the selected repertoire. In agreement with previous work (Schofield et al., 
2007), we observed a disproportionate occurrence of certain germline families, in particular VH1, 
VH3, VL kappa I and VL lambda VI. Since the relative contribution of each germline family was 
normalised during the construction of the library, the over-representation of certain subfamilies in 
the selected repertoire may reflect a greater degree of diversity within these families or may be the 
result of improved expression (Schofield et al., 2007). 
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Figure 4.15: Frequency of VH and VL germline gene combinations in the selected antibody populations. 
 
 
4.4.Secondary screening 
 
4.4.1. Expression and purification of scFv-Fc lead antibodies 
Theoretically, conditioned medium from HEK cells could be directly assayed for inhibitory 
potential. However, functional characterisation requires high concentrations of antibody and I found 
that antibody concentration in the conditioned medium ranged between 10-50 nM (See Section 
4.3.2). Moreover, concentration of medium may also lead to concentration of contaminants which 
can affect functional assays. I then chose to purify individually candidate antibodies. Fifty-four 
different antibodies were expressed in 25-ml transfection scale and affinity-purified by IMAC 
(Figure 4.16). Purified scFv-Fc antibodies displayed different sizes on SDS-PAGE, as predicted on 
the basis of their physical and chemical properties (Table 4.8). Most of the sequences of the 
isolated scFv-Fc antibodies show isoelectric point (pI) values which are slightly acidic (average and 
mode of pI values were 6.2. and 6.5, respectively). Generally, pI values of IgG1 antibodies are basic 
(pI values around 8.6) (Tracy, 1982). Although the scFv-Fc antibodies lack the constant regions 
CH1 and CL of IgGs, these do not significantly affect the overall charge of the antibody molecule. 
Also the presence of the 6x His tag and the acidic triple-FLAG tag sequences (2 6x-His/3xFLAG 
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tags per dimer) does not dramatically affect the pI of the antibody, thus it is possible that observed 
acidity may be antigen-selected (i.e. CDRs on scFv-Fc molecules are responsible for the predicted 
acidity). 
One antibody (1E6) was successfully expressed (supernatant was assayed by ELISA against 
biotinylated ADAMTS-5) but rapidly degraded after purification and was thus discarded from 
analysis; antibodies 2B3 and 1B9 were discarded due to low expression levels. 
 
Figure 4.16: Expression and purification of lead anti-ADAMTS-5 antibodies. scFv-Fc antibodies were expressed in 
HEK293-F cells (25 ml) and purified using Ni-NTA resin. After dialysis in TNC buffer, 580 ng of purified protein were 
loaded under reducing conditions on a 10% Tris-glycine gel and stained with CBB. Variations in size correlate with 
predicted molecular weight. 
 
Clone 1E9 is a “light chain only” antibody. This antibody is a “domain antibody” or (dAb), and 
comprises only the VL chain of an antibody fused to the Fc portion, so the original scFv is half the 
size of an scFv comprising both the VH and VL chains. Individual VH and VL domains can exist in 
vivo in some human diseases such as heavy chain disease (isolated heavy chains) (Hendershot et al., 
1987; Prelli and Frangione, 1992) and as Bence-Jones proteins in multiple myeloma (isolated light 
chains) (Hilschmann and Craig, 1965). Camels naturally produce heavy chain dAbs (Ungar-Waron 
et al., 1987) and these dAbs are usually endowed with excellent biophysical properties such as 
thermostability (Dumoulin et al., 2002). 
Table 4.9 reports the summary of results for phage display selection and mammalian 
screening. 
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CLONE pI MW Number of 
residues 
Extinction coefficient  
cm-1 M-1 (secreted protein) 
2A1 6.20  111415.77 1018 178650 
2A3 6.46  112603.26 1020 191710 
2A7 7.43  111852.67 1018 177730 
2A11 6.02 111539.5 1026 191710 
2B1 5.58  110492.53 1010 157790 
2B3 6.40  111794.36 1020 177730 
2B9 6.46  111017.50 1018 166730 
2C1 5.98  112136.48 1028 177730 
2D3 6.13  113340.43 1034 172690 
2D5 6.49  112056.72 1018 188730 
2D9 5.82  113942.67 1044 194690 
2D11 6.12  112581.53 1020 191710 
2E6 6.20  114565.49 1044 194690 
2E7 6.15  111696.08 1026 201790 
2G9 6.03  110847.21 1020 165810 
1A3 5.95  110426.73 1008 162830 
1A4 6.84  111714.11 1018 180710 
1A5 5.94  112214.59 1020 210730 
1A6 5.33  111174.86 1016 174750 
1A7 6.79  109888.43 1000 193770 
1A9 6.12  109966.07 1008 199730 
1A12 6.36  112965.28 1030 172690 
1B1 6.26  113259.61 1034 175000 
1B2 6.69  112461.24 1022 185750 
1B3 5.70  111521.99 1022 179790 
1B4 6.43  110953.84 1016 179790 
1B6 6.11  111225.98 1020 196750 
1B7 5.86  112837.01 1034 211650 
1B9 6.13  113379.26 1032 181850 
B11 6.33  111808.39 1022 196625 
1C1 6.66  111880.60 1018 196750 
1C2 6.02  110606.81 1008 154810 
1C3 6.52  111087.89 1014 169710 
1C5 6.33  112575.19 1018 171770 
1C6 6.66  111179.81 1016 182770 
1C8 5.61  110850.80 1010 174750 
1D1 6.46  111215.76 1018 166730 
1D6 6.67  113518.83 1038 171770 
1D10 6.02  111449.93 1020 171770 
1D11 6.46  112441.35 1024 204770 
1E2 5.83  113984.79 1040 174750 
1E6 7.07  112888.02 1028 190790 
1E9 6.66  82492.32 740 106660 
1E10 6.33  112356.78 1024 202710 
1E11 6.23  110559.20 1024 199730 
1E12 6.30  113310.57 1032 162830 
1F1 5.90  112967.82 1026 190790 
1F2 6.37  111874.82 1020 174875 
1F3 6.37  110591.13 1014 196750 
1F4 6.03  112402.78 1028 177980 
1F5 5.95  112156.24 1022 193770 
1F7 6.37  114299.14 1048 166730 
1F9 6.15  112504.80 1024 199730 
1F10 6.06  112016.30 1024 177730 
 
Table 4.8: Predicted physical and chemical properties of lead scFv-Fc antibodies. Molecular weight (MW), 
extinction coefficient and isoelectric points (pI) were predicted by Expasy Proteomic Server. 
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Number of selections performed   4 
Total number of analysed clones 308 
Primary hits 116 
Success rate 30% 
 
Confirmed different antibody clones 
(sequencing) 
 72 
Final diversity  69% 
Different antibody clones carried 
forward for secondary screening 
 54 
 
Table 4.9: Summary of selections and mammalian screening results. 
 
4.4.2.  Investigation of the inhibitory potential of scFv-Fc lead antibodies on 
ADAMTS-5 
Fifty-four (54) purified antibodies were then screened for their ability to inhibit ADAMTS-5 
cleavage of a QF peptide and bovine aggrecan (Table 4.10). Although 15 of these antibodies 
(~29%) were found to inhibit ADAMTS-5 cleavage of QF peptide in a dose-dependent manner, 
only 9 antibodies (~17%) showed a certain degree of inhibition of bovine aggrecan cleavage (Table 
4.10 and Figures 4.17 and 4.18). Some antibodies, like 2A3 and 1B11, showed a modest increase 
in aggrecanase activity (2-2.5 folds) (Figure 4.18 D) which was not matched by an equivalent 
increase in peptidolytic activity (Figure 4.17 D). 
Antibodies 2D3, 2D5 and 2D11 were the most potent in the QF peptide cleavage assay and 
retained their activity when tested for inhibition of aggrecan cleavage at the Glu392↓393Ala site. On 
the other hand, antibodies 2B9 and 2D9 inhibited aggrecan cleavage in a dose-dependent manner 
although they did not show any inhibitory potential in the QF peptide cleavage assay. For 
comparison, 10 nM N-terminal domain of TIMP-3 (N-TIMP-3) was sufficient to completely block 
ADAMTS-5 activity in both assay (Figures 4.17 and 4.18).  
We observed a constant increase in Ki app values (about 10-folds) in the aggrecan digestion 
assay compared with the QF peptide cleavage assay (Table 4.10). A possible explanation for this 
phenomenon may be the different Km of ADAMTS-5 for these two substrates. The Km for 
aggrecanase cleavage at Glu392↓393Ala in the bovine aggrecan digestion assay was estimated to be 
around 4 µM (Figure 4.19). The estimated Km value for aggrecan cleavage is much lower than the 
estimated Km calculated for ADAMTS-5 cleavage of the Abz-TESE~SRGAIY-Dpa-KK peptide 
substrate (76 µM) (Troeberg et al., 2009). 
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Clone Inhibition (Ki app nM) Clone Inhibition (Ki app nM) 
QF 
peptide 
Aggrecan 
(Glu392↓393Ala  cleavage) 
 QF 
peptide 
Aggrecan 
(Glu392↓393Ala  cleavage) 
2A1 120 NI 1B7 300 NI 
2A3 NI NI 1B9 ND ND 
2A7 530 NI 1B11 NI NI 
2A11 150 NI 1C1 NI NI 
2B1 NI NI 1C2 NI NI 
2B3 ND ND 1C3 NI NI 
2B9 NI 300 1C5 NI NI 
2C1 NI NI 1C6 500 NI 
2D3 5 30 1C8 NI NI 
2D5 23 300 1D1 NI NI 
2D9 NI 400 1D6 1400 NI 
2D11 60 100 1D10 NI NI 
2E6 NI NI 1D11 NI NI 
2E7 250 NI 1E2 NI NI 
2G9 NI NI 1E6 ND ND 
1A3 NI NI 1E9 1000 NI 
1A4 1040 NI 1E10 1800 NI 
1A5 NI >500 1E11 NI NI 
1A6 NI >500 1E12 NI >500 
1A7 NI >500 1F1 NI NI 
1A9 NI NI 1F2 NI NI 
1A12 NI NI 1F3 NI NI 
1B1 NI NI 1F4 NI NI 
1B2 850 NI 1F5 NI NI 
1B3 NI NI 1F7 NI NI 
1B4 NI NI 1F9 930 >500 
1B6 NI NI 1F10 NI NI 
 
Table 4.10: Inhibition data of scFv-Fc antibodies. Fifty-four antibodies were selected for expression in 25 ml-scale 
transfection, purified by IMAC and tested for their ability to inhibit ADAMTS-5 cleavage of both a QF-peptide and 
bovine aggrecan. NI, not inhibiting at 500 nM concentration; ND, not determined (failed expression or stability issues). 
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Figure 4.17: Inhibition of QF peptide cleavage by scFv-Fc antibodies. ADAMTS5-2 at a concentration of 5 nM was 
incubated alone or with N- TIMP-3 (10 nM) and different concentrations of scFv-Fc antibodies (10, 100 and 500 nM) 
for 2 h. Residual activities against Abz-TESE~SRGAIY-Dpa-KK (1 h, 37°C) were determined. 
 
The estimated Km value for aggrecan cleavage may reflect additional interactions which arise 
between aggrecan and enzyme exosites, such as TS-1 and Sp domains. On the other hand, the 
higher Km value for the peptide substrate appear to reflect a much weaker interaction with the active 
site of ADAMTS-5. As a result, inhibition of ADAMTS-5 by scFv-Fc antibodies is affected to a 
different degree by the presence of the two substrates, with Ki app values reflecting the relative 
affinity between antibody, enzyme and substrate.  
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Figure 4.18: Inhibition of aggrecan cleavage at the Glu392↓393Ala by scFv-Fc antibodies. ADAMTS5-2 at a 
concentration of 0.5 nM was incubated alone (C, control) or with N- TIMP-3 (10 nM) and different concentrations of 
scFv-Fc antibodies (10, 100 and 500 nM) for 2 h. Bovine aggregan (50 µg) was added and the mixture was incubated 
for 2 h at 37°C. The reactions were stopped with 50 mM EDTA and the product was deglycosylated overnight with 
chondroitinase ABC and keratanase and analysed by Western blot for ARGSV-containing fragments using BC3 mAb. 
Representative Western blots and densitometric analysis are shown. 
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Figure 4.19: Estimate of Michaelis-Menten constant for bovine aggrecan cleavage by ADAMTS-5. ADAMTS5-2 
was incubated with bovine aggregan (0-250 µg) for 2 h at 37°C. The reactions were stopped with 50 mM EDTA and the 
products were deglycosylated overnight with chondroitinase ABC and keratanase and analysed by Western blot for 
ARGSV-containing fragments using BC3 mAb (A). Membranes were scanned with a BioRad GS710 calibrated 
imaging densitometer and data were fitted to the Michaelis Menten equation (B). 
 
4.4.3. Recognition of ADAMTS-5 deletion mutants on Western blot 
To evaluate how denatured forms are recognised by scFv-Fc antibodies, ADAMTS5-2 was 
subjected either to reduction/heat denaturation or non-reducing conditions followed by SDS PAGE 
and immunoblotting with isolated scFv-Fc antibodies (Figure 4.20). Bands were visualised with an 
AP-conjugated anti-human IgG antibody. Out of 51 different antibodies tested, 47 showed binding 
to ADAMTS-5 under non-reducing conditions (Table 4.11). Just one antibody (1A6) was able to 
recognise ADAMTS5-2 in both reducing and non-reducing conditions, whereas all the other scFv-
Fc antibodies recognised ADAMTS5-2 only in non-reducing conditions. Thus scFv-Fc performed 
well in ELISA and in Western blotting, despite folded antigen having been used for the selection, 
suggesting that a mixture of linear and conformational epitopes are recognised by these antibodies. 
Alternatively, a positive reaction on Western blot can also be achieved by non-linear epitopes where 
reacting residues are in relatively close proximity. 
scFv-Fc antibodies which scored as positive in Western blots were successively tested for 
their ability to recognise different deletion mutants of ADAMTS-5 (Table 4.11 and Figure 4.20). 
This screening allowed us to map the main epitope of these antibodies. Representative blots for 
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antibodies recognising the different ADAMTS-5 domains are shown in Figure 4.21 and Figure 
4.21 A reports the domain composition of different forms of ADAMTS-5. As a comparison, 
membranes were probed with anti-FLAG mAb and anti-Cat polyclonal antibody. We can exclude 
that the anti-ADAMTS-5 scFv-Fc antibodies recognise the FLAG tag on ADAMTS-5 deletion 
mutants for two main reasons. First, these antibodies showed differential binding on equimolar 
concentrations of FLAG-tagged ADAMTS-5 deletion mutants (Figure 4.21). Moreover, as 
mentioned before, since the scFv-Fc antibodies also contain a triple-FLAG tag, antibodies directed 
against the FLAG sequence would aggregate.  
Under non-reducing conditions, all ADAMTS-5 deletion forms migrated at a molecular 
weight which was in agreement with the predicted molecular weight: ~70 kDa for ADAMTS5-2, 
~50 kDa for ADAMTS5-3, ~40 kDa for ADAMTS5-4. ADAMTS5-5 is present as two distinct 
bands between 30 and 36 kDa that were recognised by the anti-FLAG M2, the polyclonal rabbit 
anti-Cat and by anti-Cat/Dis scFv-Fc antibodies. It has been shown (Gendron et al., 2007) that 
treatment of this deletion form of ADAMTS-5 with N-glycosidase F results in a single band, 
indicating that the higher molecular weight band is a N-glycosylated form of ADAMTS5-5 (See 
Table 3.1). Both forms as well as intermediate bands were recognised by anti-Cat/Dis antibodies as 
well as anti-FLAG and polyclonal rabbit anti-Cat antibodies. In total, 8 antibodies recognised the Sp 
domain, 8 antibodies the CysR domain, 19 antibodies the TS-1 domain and 12 antibodies the 
Cat/Dis domain (Figure 4.22). Domain mapping of lead antibodies 2A11, 2B9, 2D3, 2D5, and 
2D11 is discussed in Chapter 5. 
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Clone ADAMTS5-2 5-3 5-4 5-5 Domain 
Reducing Non-reducing Non-reducing Non-reducing Non-reducing 
2A1 - + + + Faint TS-1 
2A3 - + + + - TS-1 
2A7 - -    - 
2A11 - + + + + Cat/Dis* 
2B1 - + + + + Cat/Dis 
2B9 Faint + + + - Sp* 
2C1 - + + + - TS-1 
2D3 - + + + + Cat/Dis* 
2D5 - + + + - Cat/Dis* 
2D9 - + + + - TS-1 
2D11 - + + + + Cat/Dis* 
2E6 - + + + - TS-1 
2E7 - + + + + Cat/Dis 
2G9 - + + - - CysR 
1A3 - + + + + Cat/Dis 
1A4 - + + - - CysR 
1A5 - + + - - CysR 
1A6 + + + - - TS-1 
1A7  + + - - CysR 
1A9 - + + - - CysR 
1A12 - + + - - CysR 
1B1 - + - - - Sp 
1B2 - + + + - TS-1 
1B3 - + + + - TS-1 
1B4 - + - - - Sp 
1B6 - + - - - Sp 
1B7 - + + + + Cat/Dis 
1B11 - + - - - Sp 
1C1 - Faint    - 
1C2 - + + + - TS-1 
1C3 - + + + - TS-1 
1C5 - + + - - CysR 
1C6 - + + + - TS-1 
1C8 - + + + + Cat/Dis 
1D1 - + + + - TS-1 
1D6 - -    - 
1D10 - + + + + Cat/Dis 
1D11 - + + + - TS-1 
1E2 - + + + - TS-1 
1E9 - + + + - Cat/Dis 
1E10 - + + + - TS-1 
1E11 - + + + - TS-1 
1E12 - + + + - TS-1 
1F1 Faint + - - - Sp 
1F2 - + - - - Sp 
1F3 - + + + + Cat/Dis 
1F4 Faint + - - - Sp 
1F5 - + + - - CysR 
1F7 - Faint    - 
1F9 - + + + - TS-1 
1F10 - + + + - TS-1 
 
Table 4.11: Summary of results obtained by Western blot analysis of ADAMTS-5 deletion mutants using scFv-Fc 
antibodies. Plus signs denotes positive reactivity toward the respective ADAMTS-5 form; minus sign, no signal 
detected Antibodies 2A11, 2B9, 2D3, 2D5 and 2D11 (*) were characterised by SPR ( See Section 5.4). 
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Figure 4.20: Immunoblots with anti-ADAMT-5 scFv-Fc antibodies. ADAMTS5-2 (115 ng) was run on a 10% SDS-
PAGE gel under non-reducing (A) and reducing (B) conditions. Under reducing conditions the samples were boiled at 
90°C for 5 minutes in the presence of β-mercaptoethanol. scFv-Fc antibodies were used to stain the membranes and 
signal was detected with AP-conjugated anti-human IgG. Anti-FLAG M2 antibody was used as a positive control. 
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Figure 4.21 (page 126). Immunoblots with anti-ADAMTS-5 scFv-Fc antibodies. Each purified ADAMTS-5 
deletion mutant (115 ng) was run on a 10% SDS-PAGE gel under non-reducing conditions. A) Domain structure of 
ADAMTS-5 deletion forms B) mouse monoclonal anti-FLAG M2 or rabbit polyclonal anti-cat antibodies were used to 
stain the membranes. J-O): scFv-Fc antibodies were used to stain the membranes and signal was detected with AP-
conjugated anti-human IgG. 
 
 
 
Figure 4.22: Summary of domain mapping results for scFv-Fc antibodies. On top of a schematic representation of 
ADAMTS5-2, the number of antibodies recognizing each domain is reported. See Table 4.11 for details. 
 
4.5.  Discussion 
The purpose of a phage display selection is to isolate a small subset of ligands able to bind a 
desired antigen from huge (diversity ~1010 clones) libraries. Purified ADAMTS5-2 was exposed to 
a human naïve scFv antibody phage-display library for two rounds of solution-phase selections 
(Schofield et al., 2007). From a therapeutic point of view, the use of a human library should 
dramatically reduce the potential for immunogenicity in humans. On the other hand, mouse 
antibodies may generate human anti-mouse antibodies which affect clinical outcomes by 
neutralising therapeutic antibodies, increasing rates of clearance and, ultimately, reducing efficacy 
(Pendley et al., 2003). 
Ligands selected from phage-display libraries can interact specifically with distinct 
conformations of their target antigen. One way to drive the selection against other epitopes on the 
antigen is the epitope masking selection which exploits competitive blocking of epitopes on the 
antigen using antibodies or ligands (Ditzel et al., 1995). In our case exposure of ADAMTS-5 to the 
library was carried out both in the presence and in the absence of a 100-fold excess of the broad-
spectrum metalloprotease inhibitor GM6001 (Grobelny et al., 1992). The presence of the inhibitor 
can stabilise ADAMTS-5 to a particular conformation. Another effect that GM6001 may have on 
phage display selection is competition with phages sharing epitopes deep in the active site cleft. 
Although it is possible that some molecules of ADAMTS-5 are not blocked by GM6001 under 
these conditions, the presence of the competitor for two rounds of selection should bias the selection 
against this kind of antibodies. This strategy has been used before. For example, Nizak et al. (2003), 
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used a GTP-locked form of inactive mutant of Rab6, a small GTPase, as a target antigen to select 
conformation-specific antibody fragments by phage display. Gao et al. (2009) reported a strategy 
for identifying conformation-specific antibodies by using small molecule ligands to lock target 
proteins into the conformation of interest. By this approach, two different Fabs were identified, each 
one recognising a distinct conformation of caspase-1, induced by an irreversible active site and an 
allosteric inhibitor, respectively (Gao et al., 2009). In this case, antibodies binding to the 
catalytically competent conformer were found to increase the catalytic activity of caspase-1, 
whereas antibodies binding to the inactive conformer acted as inhibitors (Gao et al., 2009). Ecotin, a 
macromolecular inhibitor specific for trypsin-fold serine proteases has been used during phage 
display selection to isolate potent allosteric inhibitors of serine protease MTSP1 which did not bind 
to the active site (Sun et al., 2003). Addition of a small molecule active-site inhibitor has been 
shown to be successful in isolating an antibody with preference for TNF-α converting enzyme 
(TACE) ectodomain over the isolated Cat domain (Tape et al., 2011).  
For primary screening, selected libraries are usually subcloned into a vector suitable for 
soluble expression of scFv by bacterial cells. Although bacterial expression is sufficient for most 
purposes, antibody fragments expressed in bacteria show several limits such as stability, lack of 
glycosylation patterns, and poor pharmacokinetics in vivo. Here we chose transient transfection of 
mammalian cells grown in liquid culture to screen libraries selected by phage display, using the 
cationic polymer PEI as a vehicle for the introduction of plasmid DNA (Boussif et al., 1995; 
Durocher et al., 2002). We therefore subcloned selected libraries in pBIOCAM5 vector for 
screening in HEK293-F suspension cells where antibodies were expressed as fusion proteins with 
the crystallizable fragment of human IgG1 (scFv-CH2-CH3 dimers or scFv-Fc) (Chapple et al, 
2006). In parallel, the same eluted polyclonal scFv populations were subcloned into pSANG10-3F 
for expression of soluble scFv (Martin et al., 2006) to compare success rates (i.e. the number of 
positive clones over the total number of screened clones). It was evident that the mammalian system 
gave a superior performance in terms of success rate (~30% vs ~15%), likely due to a combination 
of higher yield and an avidity effect for the presence of two antigen-binding sites on an scFv-Fc 
molecule. The primary screening was therefore performed using the mammalian expression system. 
A similar strategy has been recently reported to isolate antibodies against CD9 by cell panning 
(Yoon et al., 2012), although in our case we took advantage of high-throughput DNA purification 
and transfection to screen a number of clones (308) comparable with those screened when using E. 
coli cells expressing scFvs.  
We were able to exclude general cross-reactivity and non-specific binding of this antibody 
format since randomly-chosen clones did not recognise ADAMTS-4 (aggrecanase-1) in the same 
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ELISA setting (Figure 4.14). Three-hundred-three clones from different selections were ELISA-
screened in HEK293-F cells (Figure 4.13); out of 116 hits, 72 different clones were identified after 
sequencing; among them, 54 were chosen to be expressed in 25-ml transfection scale and affinity-
purified by IMAC for functional characterisation (Table 4.9).  
Antibodies 2D3, 2D5 and 2D11 were the most potent in the QF peptide cleavage assay and retained 
their activity when tested for inhibition of aggrecan cleavage at the Glu392↓393Ala site. On the other 
hand, antibodies 2B9 and 2D9 inhibited aggrecan cleavage in a dose-dependent manner although 
they did not show any inhibitory potential in the QF peptide cleavage assay. These data highlight 
the importance of tailoring the screening strategy to meet the conditions as close as possible to those 
in vivo. To our knowledge, this is the first report of the usage of a native macromolecular substrate 
to screen a relatively high number of inhibitors (54 antibodies tested in functional screening). 
Moreover, the parallel use of QF peptide allowed the identification of both active-site directed and 
exosite-directed antibodies. Characterisation of antibodies 2A11, 2B9, 2D3, 2D5, 2D11 is reported 
in Chapter 5. 
In parallel to inhibitory screening, anti-ADAMTS-5 antibodies were tested for their ability 
to bind to denatured ADAMTS-5 on Western blots. Forty-seven antibodies were able to recognise 
ADAMTS-5 after SDS-PAGE under non-reducing conditions. The fact that just one antibody out of 
47 was able to recognise ADAMTS-5 under both reducing and non-reducing conditions suggests a 
critical role for disulphide bonds in maintaining the epitopes of anti-ADAMTS-5 antibodies. Since 
all the analysed scFv-Fc antibodies were screened for binding to native ADAMTS-5 on a liquid- 
phase ELISA, they may recognise a mixture of linear/conformational epitopes. Antibodies such as 
1E11 (Figure 4.21 G) or 2E6 (Figure 4.21 I) bound strongly to ADAMTS5-2 but not to 
ADAMTS5-3 or 5-4 on Western Blot. This may indicate that the TS-1 domain has a different 
exposure (at least in the presence of SDS under non-reducing conditions) in ADAMTS5-2 
compared to ADAMTS5-3 or 5-4. The same was observed for antibodies such as 1A5 (Figure 4.21 
K) which bound more strongly to ADAMTS5-2 compared to ADAMTS5-3, indicating different 
conformations of the CysR domain under these conditions. On the other hand, antibodies such as 
1A4 (Figure 4.21 J) or 1C5 (Figure 4.21 L) react similarly with ADAMTS5-2 and 5-3, thus the 
epitope recognised by these antibodies likely is not conformational. Domain mapping using 
different deletion mutants of ADAMTS-5 allowed the identification of antibodies targeting different 
domains of this enzyme. These antibodies may represent important tools and useful in-house 
reagents to deepen our knowledge of ADAMTS-5 biology (See Section 6.2). 
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5.1   Introduction 
As was discussed in Chapter 4, antibodies 2B9, 2D3, 2D5, and 2D11 were identified from a 
secondary screening as inhibitors of ADAMTS-5. In particular, antibodies 2D3, 2D5 and 2D11 
inhibited ADAMTS-5 cleavage of both a QF peptide substrate and aggrecan, whereas antibody 2B9 
inhibited cleavage only of the macromolecular substrate. We therefore hypothesised that antibodies 
2D3, 2D5, and 2D11 interfere directly with the catalytic activity of ADAMTS-5, whereas 2B9 may 
represent an allosteric (exosite) inhibitor.  
Our first aim was then the characterisation of these antibodies and the mapping of the 
binding epitope. Inhibition of lead scFv-Fc antibodies was tested against different deletion mutants 
of ADAMTS-5 and interactions between scFv-Fc antibodies and ADAMTS-5 were studied by 
surface plasmon resonance (SPR) studies. I also examined the extent of in vitro inhibition of mouse 
ADAMTS-5, since this information is useful to establish whether these antibodies can be tested in 
in vivo models of OA. Moreover, we were interested in the effects that GM6001 and TIMP-3, a 
small molecule and an endogenous inhibitor of ADAMTS-5, respectively, exert on the inhibitory 
potency of lead scFv-Fc antibodies. Finally, the ability of lead antibodies to inhibit aggrecan 
degradation was tested in an ex vivo model of OA using both porcine articular cartilage explants and 
human knee cartilage explants co-stimulated with IL-1α and OSM. 
 
5.2.   Inhibition of ADAMTS-5 cleavage of QF peptide 
scFv-Fc antibodies 2A11, 2D3, 2D5, and 2D11 showed the ability to inhibit cleavage of a 
QF peptide by ADAMTS5-2 with different potency (Ki app values ranging from 2.8 nM for 2D3 to 
180 nM for 2A11). (Table 5.1 and Figure 5.1). Inhibitory activity was also tested against other 
truncated forms of ADAMTS-5 (Figure 5.1 and Table 5.1). The smallest fragment of ADAMTS-5 
with detectable proteolytic activity consists of Cat/Dis domains (Gendron et al., 2007) and 
crystallographic data shows that these two domains are structurally integrated (Mosyak et al., 2008). 
For this reason, ADAMTS5-5 (comprising Cat/Dis domains) was used as a representative of the Cat 
domain. 
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Clone TS5-2 TS5-3 TS5-4 TS5-5 Mouse TS5-2 TS4-2 MMP-1 
Cat 
MMP-13 MT1-MMP 
2A11 180 ± 38 Nd nd 150 ± 10 360 ± 50 ni nd nd nd 
2B9 ni Ni ni ni ni ni nd nd nd 
2D3 2.5 ± 0.6 3.2 ± 0.2 5.5 ± 0.3 8.3 ± 0.8 14 ± 2 ni ni ni ni 
2D5 20 ± 5 37 ± 2.5 35 ± 2.6 53 ± 2.8 180 ± 30 ni ni ni ni 
2D11 70 ± 8 79 ± 16 73 ± 11 130 ± 31 590 ± 320 ni ni ni ni 
 
Table 5.1: Ki app values (nM) for inhibition of ADAMTS-5, -4 and MMPs by lead antibodies. The QF substrates 
used were Abz-TESE~SRGAIY-Dpa-KK (ADAMTS-5), FAM-AE~LQGRPISIAK-TAMRA (ADAMTS-4) and Mca-
KPLGL-Dpa-AR (MMPs); ni, not inhibiting at 500 nM; nd, not determined. Data are Ki app values of the mean data ± 
S.D. (n = 3-6).  
 
 
 
Figure 5.1: Inhibition of ADAMTS-5 and ADAMTS-4 by scFv-Fc antibodies 2A11 (A), 2D3 (B), 2D5 (C) and 
2D11 (D). Enzyme (5 nM) was incubated with different concentrations of scFv-Fc antibodies for 2 h and residual 
activities against Abz-TESE~SRGAIY-Dpa-KK (ADAMTS-5, 1 h, 37°C) and FAM-AE~LQGRPISIAK-TAMRA 
(ADAMTS-4, 15 min, 37°C) were determined. For 2D3, 0.5 nM of different deletion forms of ADAMTS-5 were 
incubated with substrate for 18 h at 37°C before end-point reading. Representative curves are shown. 
 
Figure 5.2 reports a schematic representation of active forms of FLAG-tagged ADAMTS-5 and 
ADAMTS-4 deletion mutants used to characterise scFv-Fc antibodies. 
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Figure 5.2: Domain structure and nomenclature of active ADAMTS-5 and ADAMTS-4 deletion mutants. F, 
FLAG tag. 
 
With the exception of 2A11, all the lead antibodies showed a 2-3-fold increase in Ki app against 
ADAMTS5-5, with values ranging from 8 nM for 2D3 to 150 nM for 2A11. For 2D3 a ~2-fold 
increase in Ki app was observed against the forms of ADAMTS-5 lacking the CysR domain 
(ADAMTS5-4 and 5-5) (Ki app 5-4 5.5 ± 0.3 nM; Ki app 5-5 8.3 ± 0.8 nM). Similarly, for 2D5 a ~2-fold 
increase in Ki app was observed after removal of the Sp domain (Ki app 5-2 20  ± 5 nM; Ki app 5-3 37 ± 
2.5 nM) and for 2D11 after removal of the TS-1 domain (Ki app 5-4 73 ± 11 nM; Ki app 5-5 130 ± 31 
nM). Thus, although these antibodies recognise the Cat/Dis domain of ADAMTS-5, they establish 
additional interactions with non-catalytic domains such as CysR (2D3), Sp (2D5), and TS-1 (2D11). 
It is also possible that these domains do not interact directly with the antibodies but positively 
modify the structure of their binding site(s). 
Lead scFv-Fc antibodies were tested for their ability to inhibit ADAMTS-4. Unfortunately, 
expression of human recombinant full-length ADAMTS-4 (ADAMTS4-1), which most resembles 
ADAMTS5-2 (38% identity), is very poor (Gendron et al., 2007), thus a form lacking the Sp 
domain was tested for inhibition. Moreover, since all four antibodies are able to inhibit ADAMTS5-
5, the presence of the Sp domain is not necessary for interaction with ADAMTS-5 (Table 5.1). 
Antibodies 2A11, 2D3, 2D5 and 2D11 did not inhibit cleavage of a QF-peptide by ADAMTS4-2 at 
500 nM concentration. Lead scFv-Fc antibodies did not inhibit MMP-1 (Cat domain), -13, and -14, 
thus being selective for ADAMTS-5 over other members of the MA family of metallopeptidases. 
 
5.3.   Inhibition of mouse ADAMTS-5 
In order to assess therapeutic potential for future in vivo applications, the ability of 
antibodies 2A11, 2D3, 2D5 and 2D11 to inhibit mouse ADAMTS-5 was investigated using both the 
QF peptide substrate and bovine aggrecan. When the QF peptide substrate was used, all four 
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antibodies showed the ability to inhibit the murine version of ADAMTS-5, although with decreased 
potency (Ki app values ranging from 14 nM for 2D3 to 590 nM for 2D11) (Table 5.1).  
Mouse ADAMTS5-2 cleaves bovine aggrecan in vitro at the aggrecanase site Glu392↓393Ala, 
thus the ARGSV cleavage products are detectable by the anti-ARGSV neoepitope antibody in 
Western blot. Antibodies 2A11, 2B9, 2D3, 2D5 and 2D11 inhibited mouse ADAMTS5-2 cleavage 
of bovine aggrecan with comparable potency to the human version (Figure 5.3). The non- 
inhibitory antibody 1B3 also showed inhibition of aggrecanase activity of mouse ADAMTS-5. The 
reasons for this discrepancy are not known although we may hypothesise subtle structural 
differences between mouse and human ADAMTS-5. 
 
 
Figure 5.3: Inhibition of mouse ADAMTS-5 by scFv-Fc antibodies. Mouse ADAMTS-5 at a concentration of 1 nM 
was incubated alone (C, control) or with various concentrations of TIMP-3 and scFv-Fc antibodies for 2 h. Bovine 
aggregan (50 µg) was added and the mixture was incubated for 2 h at 37°C. The reactions were stopped with 50 mM 
EDTA and the products were deglycosylated overnight with chondroitinase ABC and keratanase and analysed by 
Western blot for ARGSV-containing fragments using BC3 monoclonal antibody. The result shown is representative of 
three independent experiments. 
 
Figure 5.4 shows alignment of amino acid sequences of mature ADAMTS-5 lacking C-terminal TS  
(TS-2) domain from different species (residues not homologous to human are shown in red). 
ADAMTS-5 sequences are highly conserved between human and cynomolgus monkey (99.3% 
identity), mouse (96.6% identity), rat (96.3% identity), rabbit (96.3% identity), pig (90.7% identity) 
and cow (97.2%).  
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  Catalytic domain	  
Human	   RSISRARQVELLLVADASMARLYGRGLQHYLLTLASIANRLYSHASIENHIRLAVVKVVVLGDKDKSLEVSKNA 
Cynom	   RSISRARQVELLLVADASMARLYGRGLQHYLLTLASIANRLYSHASIENHIRLAVVKVVVLGDKDKSLEVSKNA 
Mouse	   RSISRARQVELLLVADSSMARMYGRGLQHYLLTLASIANRLYSHASIENHIRLAVVKVVVLTDKDTSLEVSKNA 
Rat	   RSISRARQVELLLVADSSMAKMYGRGLQHYLLTLASIANRLYSHASIENHIRLAVVKVVVLTDK--SLEVSKNA 
Rabbit	   RSISRSRQVELLLVADSTMARMYGRGLHHYLLTLASIANRLYSHASIENHIRLAVVKVVVLGDKDKSLEVSKNA 
Pig	   RSISRARQVELLLVADASMARMYGRGLQHYLLTLASIANRLYSHASIENHIRLTVVKVVVLGDKDKTLEVSKNA 
Bovine	   RSISRARQVELLLVADASMARMYGRGLQHYLLTLASIANKLYSHASIENHIRLVVVKVVVLGDKDKSLEVSKNA 
	  
	  
Seq	   	  
Human	   ATTLKNFCKWQHQHNQLGDDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTV 
Cynom	   ATTLKNFCKWQHQHNQLGDDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTV 
Mouse	   ATTLKNFCKWQHQHNQLGDDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTV 
Rat	   ATTLKNFCKWQHQHNQLGDDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTV 
Rabbit	   ATTLKNFCKWQHQHNQLGDDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTV 
Pig	   ATTLKNFCKWQHQHNQLGDDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTV 
Bovine	   ATTLKNFCKWQHQHNQLGDDHEEHYDAAILFTREDLCGHHSCDTLGMADVGTICSPERSCAVIEDDGLHAAFTV 
	  
Seq	   476 477 
Human	   AHEIGHLLGLSHDDSKFCEETFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCLLDLP RKQILG 
Cynom	   AHEIGHLLGLSHDDSKFCEETFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCLLDQP RKQILG 
Mouse	   AHEIGHLLGLSHDDSKFCEENFGTTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCLLDLP RKQILG 
Rat	   AHEIGHLLGLSHDDSKFCEENFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCLLDVP RKQILG 
Rabbit	   AHEIGHLLGLSHDDSKFCEENFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCLLDVP RKQILG 
Pig	   AHEIGHLLGLSHDDSKFCEENFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCLLDLP RKQILG 
Bovine	   AHEIGHLLGLSHDDSKFCEENFGSTEDKRLMSSILTSIDASKPWSKCTSATITEFLDDGHGNCLLDLP RKQIPG 
	  
Seq	   Disintegrin domain 
Human	   PEELPGQTYDATQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTKKLPAVEGTPCGKGRICLQGKCVDKTK 
Cynom	   PEELPGQTYDATQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTKKLPAVEGTPCGKGRICLQGKCVDKTK 
Mouse	   PEELPGQTYDATQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTKKLPAVEGTPCGKGRVCLQGKCVDKTK 
Rat	   PEELPGQTYDATQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTKKLPAVEGTPCGKGRICLQGKCVDKTK 
Rabbit	   PEELPGQTYDATQQCNLTFGPEYTVCPGMDVCARLWCAVVRQGQMVCLTKKLPAVEGTPCGKGRICLQGKCVDKTK 
Pig	   PEELPGQTYDASQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTKKLPAVEGTPCGKGRICLQGKCVDKTK 
Bovine	   PEELPGQTYDASQQCNLTFGPEYSVCPGMDVCARLWCAVVRQGQMVCLTKKLPAVEGTPCGKGRICLQGKCVDKTK 
	  
Seq	   566 567                          TS-1                   622 623 
Human	   KKYYSTSS HGNWGSWGSWGQCSRSCGGGVQFAYRHCNNPAPRNNGRYCTGKRAIYRSCSLMPCP PNGKSFRH 
Cynom	   KKYYSTSS HGNWGSWGSWGQCSRSCGGGVQFAYRHCNNPAPRNNGRYCTGKRAIYRSCGLMPCP PNGKSFRH 
Mouse	   KKYYSTSS HGNWGSWGPWGQCSRSCGGGVQFAYRHCNNPAPRNSGRYCTGKRAIYRSCSVTPCP PNGKSFRH 
Rat	   KKYYSTSS HGNWGSWGPWGQCSRSCGGGVQFAYRHCNNPAPRNSGRYCTGKRAIYRSCSVIPCP PNGKSFRH 
Rabbit	   KKYYSTSS HGNWGSWGPWGQCSRSCGGGVQFAYRHCNNPAPRNSGRYCTGKRAIYRSCSVTPCP ANGKSFRH 
Pig	   KKYYSTSS HGNWGSWGSWGQCSRSCGGGVQFAYRHCNNPAPRNSGRYCTGKRAIYRSCSVTPCP ANGKSFRH 
Bovine	   KKYYSTSS HGNWGSWGSWGQCSRSCGGGVQFAYRHCNNPAPRNNGRYCTGKRAIYRSCSVTPCP ANGKSFRH 
	  
Figure 5.4: Amino Acid Sequences of human ADAMTS-5 and corresponding sequences of other animal species. 
Alignment of human (accession number Q9UNA0), cynomolgus monkey (G8F2G2) mouse (Q9R001), rat (QSTY19), 
rabbit (G1SIH2), pig (F1SHP0) and bovine (F1MRZ2) ADAMTS-5 sequences was performed with Clustal Omega. C-
terminal TS (TS-2) domain is not shown. 
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Seq	   Cys-Rich Domain  
Human	   EQCEAKNGYQSDAKGVKTFVEWVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTDGTECRLYSNSVCVRGKCVR- 
Cynom	   EQCEAKNGYQSDAKGVKTFVEWVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTDGTECRPYSNSVCVRGKCVR 
Mouse	   EQCEAKNGYQSDAKGVKTFVEWVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTDGTECRPYSNSVCVRGRCVR- 
Rat	   EQCEAKNGYQSDAKGVKTFVEWVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTDGTECRPYSNSVCVRGRCVR- 
Rabbit	   EQCEAKNGYQSDAKGVKTFVEWVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTDGTECRPYSNSVCVRGRCVR- 
Pig	   EQCEAKNGYQSDAKGVKTFVEWVPKYAGVLPADVCKLTCRAKGTGYYVVFSPKVTALTRN-----SRCLCEFCIYT 
Bovine	   EQCEAKNGYQSDAKGVKTFVEWVPKYAGVLPGDVCKLTCRAKGTGYYVVFSPKVTDGTECRPYSNSVCVRGKCVR- 
	  
Seq	   731 732 Spacer domain 
Human	   -TGCDGIIGSKLQYDKCGVCGGDNSSC TKIVGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRFTAYL 
Cynom	   -TGCDSIIGSKLQYDKCGVCGGDNSSC TKIVGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRFTAYL 
Mouse	   -TGCDGIIGSKLQYDKCGVCGGDNSSC TKIIGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRFTAYL 
Rat	   -TGCDGIIGSKLQYDKCGVCGGDNSSC TKIIGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRFTAYL 
Rabbit	   -TGCDGIIGSKLHYDKCGVCGGDNSSC TKIIGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRFTAYL 
Pig	   YINHDYLLGSSL---ECHLCGSTGETC RKFLFVYSFVNKGYTDVVRIPEGATHIKVRQFKAKDQTRFTAYL 
Bovine	   -TGCDGIIGSKLQYDKCGVCGGDNSSC TKVVGTFNKKSKGYTDVVRIPEGATHIKVRQFKAKDQTRFTAYL 
	  
Seq	                                            Spacer domain 
Human	   ALKKKNGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILIVQILATDPTKPLDVRYSFFV 
Cynom	   ALKKKNGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILIVQILATDPTKPLDVRYSFFV 
Mouse	   ALKKKTGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILIVQILATDPTKALDVRYSFFV 
Rat	   ALKKKTGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILIVQILATDPTKALDVRYSFFV 
Rabbit	   ALKKKNGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILIVQILATDPTKALDVRYSFFV 
Pig	   ALKKKNGEYLINGKYMISTSETIIDLNGTVMNYSGWSHRDDFLHGMGYAATKEILIVQILATDPTKALDVRYSFFV 
Bovine	   ALKKKNGEYLINGKYMISTSETIIDINGTVMNYSGWSHRDDFLHGMGYSATKEILIVQILATDPTKALDVRYSFFV 
	  
Seq	    Spacer domain   874 
Human	   PKKSTPKVNSVTSHGSNKVGSHT 
Cynom	   PKKSTPKVNSVTSHGSNKVGSHT 
Mouse	   PKKTTQKVNSVISHGSNKVGPHS 
Rat	   PKKTTQKVNSVISHSSNKVGLHS 
Rabbit	   PKKSTQNLNSVTNHGSNKVVSHT 
Pig	   PKKSTPKVNSVTSQGSNKVGSHT 
Bovine	   PKKSAPKANSVTSQGSNKVGSPT 
	  
Figure 5.4  (continued). 
 
5.4.   Determination of dissociation constant (KD) and domain mapping by SPR 
To characterise the kinetics of interactions between ADAMTS-5 and scFv-Fc antibodies, 
antibodies 2A11, 2B9, 2D3, 2D5, and 2D11 were captured by rabbit anti-human IgG amino-
coupled to a CM5 Biacore chip and titrated concentrations of ADAMTS-5 deletion mutants were 
injected (Figure 5.5). As negative controls, two scFv-Fc antibodies selected against unrelated 
antigens were not able to capture ADAMTS5-2 at the highest concentration tested (100 nM) 
(Figure 5.6). 
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Figure 5.5: Binding kinetics of ADAMTS-5 and scFv-Fc antibodies. scFv-Fc antibodies (100 nM) were captured by 
an anti-human IgG antibody immobilised onto a CM5 chip and ADAMTS-5 or -4 deletion mutants were injected at 
different concentrations ranging from 1.2 to 200 nM at a flow rate of 30 µl/min. Representative binding curves are 
shown. 
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Figure 5.6: Control scFv-Fc antibodies do not bind to ADAMTS5-2 in the SPR setting. Two different scFv-Fc 
antibodies (A, B) isolated from phage display selections against unrelated antigens were captured on CM5 chip by 
immobilised anti-Fc IgG and a single (100 nM) concentration of ADAMTS5-2 was injected. 
 
Generally, the dissociation constants (KD) values determined by SPR were found to be in good 
agreement with the Ki app values obtained from steady-state inhibition studies (Table 5.2). For 
2A11, it was not possible to accurately estimate the KD for ADAMTS5-2 (approximate KD: 94 ± 72 
nM) since this approaches the maximum ADAMTS5-2 concentration tested (100 nM). 
Interestingly, 2A11 bound to the Cat/Dis domain with higher affinity (KD 5-5: 35.6 ± 0.21 nM); this 
was mainly due to a substantially higher association rate, suggesting that this interaction might be 
conformation-dependent, with the epitope partially masked in the full-length molecule. The reason 
for the relatively high KD values for the two forms is the poor off rate (koff 5-2: 0.121 sec-1, koff 5-5: 
0.181 sec-1) (Table 5.2). 
Antibody 2B9 was able to bind to ADAMTS5-2 with relatively high affinity (KD 5-2: 6.7 ± 
0.8 nM) but was not able to bind to all the other truncation forms of ADAMTS-5 at the highest 
concentration tested (100 nM) in the SPR setting, indicating the Sp domain as the main epitope 
(Table 5.2 and Figures 5.5 and 5.7). The binding kinetics of 2B9 to ADAMTS5-2 was 
characterised by high values of association and dissociation rate constants (~106 M-1 sec-1 and ~10-2 
sec-1, respectively). 
Antibodies 2D3, 2D5, and 2D11 bound to both ADAMTS5-2 and ADAMTS5-5 but with 
some remarkable differences. Antibody 2D3 bound to ADAMTS5-5 with essentially the same 
affinity as ADAMTS5-2 (KD 5-5: 3.4 ± 1.0 nM; KD 5-2: 2.8 ± 1.2 nM). Although antibody 2D11 
showed a comparable equilibrium dissociation constant for the two enzyme forms (KD 5-2: 22 ± 7.2 
nM; KD 5-5: 24 ± 4.6 nM) both dissociation and association rate constants were 2-fold higher in the 
case of the interaction with ADAMTS5-5 than with ADAMTS5-2. Antibody 2D5 exhibited a 2-fold 
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increase in KD for ADAMTS5-5 (71 ± 29 nM) compared with ADAMTS5-2 (29 ± 11 nM) and this 
was due to a 2 fold increase in dissociation rate constant. 
 
 kon 
(M-1 sec-1) 
koff 
(sec-1) 
KD 
(x 10-9 M) 
ΔG 
(kJ/mol) 
ΔΔG 
(kJ/mol) 
Epitope 
2A11      Dis-Cat 
ADAMTS5-2 1.58 x106  0.121 94 ± 72 -40.6   
ADAMTS5-5 5.11 x 106 0.182 36 ± 0.2  -42.6 ~ -1.9  
2B9      Spacer 
ADAMTS5-2 (2.4 ± 0.3) x 106 (1.6 ± 0.2) x 10-2 6.7 ± 0.8 -46.7   
ADAMTS5-3 - - NB    
ADAMTS5-4 - - NB    
ADAMTS5-5 - - NB    
ADAMTS4-2 - - NB    
2D3      Dis-Cat 
ADAMTS5-2 (2.8 ± 0.8) x 105 (7.0 ± 0.8) x 10-4 2.8 ± 1.2 -48.8   
ADAMTS5-5 (3.3 ± 1.1) x 105 (1.1 ± 0.1) x 10-3 3.4 ± 1.0 -48.3 0.5  
ADAMTS4-2 - - NB    
2D5      Cross-
domain 
ADAMTS5-2 (2.3 ± 0.7) x 105 (5.9 ± 0.2) x 10-3 29 ± 11 -43.0   
ADAMTS5-5 (2.3 ± 1.2) x 105 (1.4 ± 0.5) x 10-2 71 ± 29 -40.8 2.2  
ADAMTS4-2 - - NB    
2D11      Dis-Cat 
ADAMTS5-2 (1.9 ± 1.0) x 106 (4.9 ± 1) x 10-2 22 ± 7.2 -43.7   
ADAMTS5-5 (4.70 ± 1.9) x 106 (0.11 ± 0.2) 24 ± 4.6 -43.5 0.2  
ADAMTS4-2 - - NB    
 
Table 5.2: ADAMTS-5 Surface Plasmon Resonance (SPR). Association (kon) and dissociation (koff) rate constants 
and the equilibrium dissociation constant (KD) were determined by global fitting of the SPR data to a 1:1 binding model. 
ΔΔG is the difference in free energy of binding (calculated from KD) relative to ADAMTS5-2. Free energies of binding 
were calculated from KD according to ΔG = -RTln(1/KD); NB, no measurable binding at 100 nM concentration of 
ADAMTS-5 and 200 nM concentration of ADAMTS4-2. Mean values ± S.D. are reported (n=3). 
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Figure 5.7: Antibody 2B9 does not bind to ADAMTS5-3 and ADAMTS5-4. scFv-Fc antibodies (100 nM) were 
captured by an anti-human IgG antibody immobilised onto a CM5 chip and ADAMTS5-3 or 5-4 were injected at 
different concentrations ranging from 1.2 to 100 nM at a flow rate of 30 µl/min. 
 
To test selectivity, the ability of anti-ADAMTS-5 antibodies to bind to ADAMTS-4 was 
investigated. Antibodies 2B9, 2D3, 2D5, and 2D11 did not bind to ADAMTS4-2 at the highest 
concentration of enzyme tested (200 nM) (Table 5.2 and Figure 5.8). 
 
 
Figure 5.8: scFv-Fc antibodies 2B9, 2D3, 2D5, and 2D11 do not bind to ADAMTS-4. scFv-Fc antibodies (100 nM) 
were captured by an anti-human IgG antibody immobilised onto a CM5 chip and ADAMTS4-2 ( 200nM) was injected 
at a flow rate of 30 µl/min. 
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5.5.   Recognition of ADAMTS-5 on Western blot 
scFv-Fc antibodies 2A11, 2B9, 2D3, 2D5, and 2D11 were able to recognise ADAMTS-5 on 
Western blots only when the protein was run under non-reducing conditions and the sample was not 
previously heat-denatured (Figures 5.9 and 5.10). This implies that the epitopes recognised by 
these antibodies are a mixture of three-dimensional and linear sequences, as reported for other anti-
ADAMTS-5 scFv-Fc antibodies (See Section 4.4.3). With antibody 2B9, a faint band was detected 
under reducing conditions (Figure 5.9). 
Antibodies 2A11, 2D3, 2D5, 2D11 could recognise all the truncated ADAMTS-5 forms, 
thus confirming the SPR data. Interestingly, 2D5 recognised ADAMTS5-5 with much decreased 
sensitivity and this confirms the increase in KD value for ADAMTS5-5 compared to ADAMTS5-2 
as measured by SPR. 2B9 recognised not only ADAMTS5-2 but also ADAMTS5-3 and 
ADAMTS5-4 on a Western blot, and this implies that the antibody, due to its size, shields some 
epitopes in CysR and TS-1 domains, other than in the Sp domain. These epitopes may not be 
exposed in solution and therefore not bound by 2B9 in the SPR setting. The polyclonal rabbit anti-
Cat antibody and the anti-Cat/Dis antibodies 2D3, 2A11 and 2D11 could detect lower bands at 55 
and 36 kDa in the ADAMTS5-2 lane. These bands were not detected by anti-FLAG antibody and 
correspond in size to recombinant truncated forms of ADAMTS-5 consisting of Cat/Dis 
(ADAMTS5-5) and Cat/Dis/TS-1/CysR domains (ADAMTS5-3); they therefore should be products 
of C-terminal truncation, probably due to autolysis. 
All the antibodies showed a certain ability to detect mouse ADAMTS-5 on Western Blot, 
although with decreased sensitivity (an exception being 2D3 and 2D11, Figure 5.10 E, G). The 
polyclonal rabbit anti-ADAMTS-5 Cat domain antibody was raised against the peptide sequence 
426CEETFGSTEDKRL438 which is different from the mouse 426CEENFGTTEDKRL438 (residues 
not homologous to human are shown in red) thus it cannot recognise mouse ADAMTS-5 (Figure 
5.10 B).  
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Figure 5.9: Immunoblots with scFv-Fc antibodies. ADAMTS5-2 (115 nanograms) was run on a 10% SDS-PAGE gel 
under non-reducing and reducing conditions. Under reducing conditions the samples were boiled at 90°C for 5 minutes 
in the presence of β-mercaptoethanol. scFv-Fc antibodies were used to stain the membranes and signal was detected 
with AP-conjugated anti-human IgG. Anti-FLAG M2 antibody was used as a positive control. 
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Figure 5.10. Immunoblots with scFv-Fc antibodies. Purified ADAMTS-5 deletion mutants (115 nanograms) were run 
on a 10% SDS-PAGE gel under non-reducing conditions. A), B) mouse monoclonal anti-FLAG M2 or rabbit polyclonal 
anti-Cat antibodies were used to stain the membranes. C-G): scFv-Fc antibodies were used to stain the membranes and 
signal was detected with AP-conjugated anti-human IgG. M5-2: mouse ADAMTS5-2. 
 
5.6.   Investigation of mechanism of inhibition of QF peptide cleavage 
To investigate the mechanism of inhibition of antibodies 2A11, 2D3, 2D5, 2D11 inhibition 
kinetic studies were performed using the QF-peptide. Dixon plots were used as a graphical method 
for determination of the type of enzyme inhibition and as an independent way to calculate the Ki 
values of the enzyme-inhibitor complexes. In this case the effect on the enzyme rate (1/v) was 
determined at 4 substrate concentrations (10, 20, 40, and 80 µM, corresponding to 0.13, 0.26, 0.53, 
and 1.05 [S]/Km ratios) over a range of scFv-Fc concentrations which produce between 5-70% 
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inhibition. In a plot of the reciprocal of the rate of peptide hydrolysis (1/v) against the inhibitor 
concentration ([I]), data for each substrate concentration fall on straight lines that intersect at a 
concentration of inhibitor equal to the inhibition constant above the x axis ([I] = -Ki and 1/v = 
1/vmax) (competitive inhibition), or on the x axis (1/v = 0) (noncompetitive inhibition). In the case of 
uncompetitive inhibition, these lines are parallel. Examination of the kinetic data by a linearised 
Dixon plot graphic approach suggested a competitive inhibition modality for antibodies 2A11 and 
2D5, and a noncompetitive inhibition modality for antibodies 2D3 and 2D11 (Figure 5.11).  
 
 
Figure 5.11: Dixon Plots for ADAMTS-5 inhibition by 2A11 (A), 2D3 (B), 2D5 (C), and 2D11 (D) scFv-Fc 
antibodies. Enzyme (5 nM) was incubated with different concentrations of scFv-Fc antibodies for 2 h and reciprocal 
rates against Abz-TESE~SRGAIY-Dpa-KK (1 h, 37°C) were determined at 10, 20, 40, and 80 µM substrate 
concentrations. 
 
The Ki values estimated from the intercepts of the plots were found to be in good agreement with the 
values determined by dose-response inhibition at [S]= 20 µM (Table 5.3). In the case of the tight-
binding inhibitor 2D3 (Ki value 2.5 nM), these values were higher because 5 nM enzyme was used 
instead of 0.5 nM due to detection limits at substrate concentrations lower than 20 µM (20 µM 
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substrate should be incubated with 0.5 nM enzyme for approximately 18 h to generate a reasonable 
signal). 
Clone Ki  
(nM) 
2A11 180 ± 12 
2D3 4.4 ± 0.2 
2D5 18 ± 0.7 
2D11 60 ± 1.0 
 
Table 5.3: Ki values for inhibition of ADAMTS-5 by scFv-Fc antibodies as estimated by the intercepts of the 
Dixon plots on the x axis.  
 
However, a limitation of this method is that only low concentrations of substrate relative to the Km 
could be used. This is due to auto-quenching and solubility limits at high substrate concentrations. 
In fact, if we plot the data above in a classical Lineweaver-Burk plot (i.e. the reciprocal of the rate 
of peptide hydrolysis, 1/v, versus the reciprocal of the substrate concentration, 1/[S]), intercepts are 
too close to the origin so accurate determination of both Km (intercept on the x axis) and Vmax 
(intercept on the y axis) is not possible (Figure 5.12 A, C, E, G). This is confirmed by a plot of the 
rate versus the substrate concentration where it is evident that Vmax is not reached at any substrate 
concentration (Figure 5.12 B, D, F, H). 
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Figure 5.12: Dependence of ADAMTS-5 activity on the concentration of the QF peptide substrate in the presence 
of scFv-Fc antibodies. Lineweaver-Burk (A, C, E, G) and rate versus substrate concentration (B, D, F, H) plots are 
shown. 
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5.7.   Dual inhibition studies 
Since the studies described in Section 5.6 did not elucidate unequivocally the mechanism of 
inhibition of anti-ADAMTS-5 antibodies, I chose to test the effect of addition of other ligands such 
as GM6001, heparin and TIMP-3 on the inhibitory potency of scFv-Fc antibodies. These studies 
could help to clarify if these antibodies inhibit ADAMTS-5 through a zinc-chelating mechanism or 
share an epitope deep in the active site cleft (combination with GM6001) and if they are potentially 
affected by TIMP-3 or GAG binding to the enzyme (combination with TIMP-3 or heparin, 
respectively). Therefore, double-inhibitor experiments were conducted as described by Yonetani 
and Theorell (1964). In such experiments, the effect of the concurrent presence of two inhibitors is 
examined by varying the concentration of one inhibitor in the absence or presence of a second 
inhibitor held at a constant concentration. These studies will show zero interaction if the effect of 
the combination is that expected from the dose-response curves of the single inhibitors; synergy if 
the effect is greater than expected and antagonism if the effect is less than expected. Factor γ 
represents the mutual influence of the two inhibitors on the binding of each other. If the binding of 
two inhibitors to the enzyme is mutually exclusive (γ = ∞), plotting 1/v against different 
concentrations of the first inhibitor at a fixed concentration of the second inhibitor would result in 
parallel lines. If the inhibitors can bind simultaneously to the enzyme (γ ≠ 1), the slope will depend 
on the concentration of the inhibitor held at constant concentration and the lines will intersect above 
or below the x axis. In this case the two inhibitors will show positive interaction since use of the 
combination means that the total concentration needed to obtain a certain level of inhibition is less 
than the concentrations of each inhibitor taken separately. When γ = 1, the effects of the two 
inhibitors are independent and the lines in the Yonetani-Theorell plot will converge at the x axis.  
 
5.7.1. Effect of GM6001 
To investigate whether antibodies 2A11, 2D3, 2D5 and 2D11 act via a zinc-binding 
mechanism or share epitopes deep in the active site cleft, we performed dual inhibition kinetics 
using GM6001, a known zinc chelator and competitive inhibitor of many metalloproteinases 
(Grobelny et al., 1992) (Figure 5.13 and Table 5.4).  
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Figure 5.13: Effect of GM6001 on inhibitory potency of anti-ADAMTS-5 scFv-Fc antibodies. Dose-response (left) 
and Yonetani-Theorell plots (right) for ADAMTS-5 inhibition by 2A11 (A, B), 2D3 (C, D), 2D5 (E, F), and 2D11 (G, 
H) scFv-Fc antibodies in the absence and presence of a fixed concentration (600 nM) of GM6001. Concentration of 
enzyme was 5 nM for all scFv-Fc antibodies except 2D3. For 2D3, 0.5 nM of enzyme was incubated with substrate for 
18 h at 37°C before end-point reading. 
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Clone Ki app 
(nM) 
+GM6001 
Ki app (nM) 
Phage display 
selection 
2A11 250 ± 50 140 ± 20 +/- GM6001 
2D3 2.8 ± 0.2 1.6 ± 0.2 + GM6001 
2D5 30 ± 0.6 32 ± 0.5 + GM6001 
2D11 77 ± 10 70 ± 7 + GM6001 
 
Table 5.4: Ki app values (nM) for inhibition of ADAMTS-5 by scFv-Fc antibodies in the presence and absence of 
GM6001 (600 nM). Data are Ki app values of the mean data ± S.E. of the curve fit. In the presence of GM6001, the Ki app 
value for the antibodies was measured by fixing as 100 % the activity from the control reaction containing enzyme and 
GM6001. The presence/absence of GM6001 during the respective phage display selection is reported. 
 
Antibodies 2A11 and 2D3 showed a slight increased inhibitory potency (less than 2-fold) in 
the presence of GM6001 at a concentration corresponding to its Ki app under these conditions, 
whereas no synergistic effect was observed in the case of 2D5 and 2D11. Thus, binding of these 
antibodies and GM6001 is mutually non-exclusive. Since GM6001 is known to bind to zinc (as well 
as S1’ and other active site cleft sites), these antibodies most likely act via a non zinc-binding 
mechanism or do not share an epitope deep in the active site cleft. This can be explained on the 
basis of a noncompetitive/uncompetitive inhibition mode where inhibition of peptide cleavage still 
allows for GM6001 access to the active site cleft. Intriguingly, antibodies 2D3, 2D5 and 2D11 were 
all isolated from phage display selections performed in the presence of GM6001, whereas antibody 
2A11 was isolated in multiple copies independently of the presence/absence of GM6001 (Table 
5.4). This underlies the potency and versatility of phage display conditions for isolation of 
antibodies with desired properties, in this case an allosteric mechanism of inhibition. Exosite 
antibody 2B9, which was isolated from phage display selection in the absence of GM6001, did not 
show any effect in this assay (Figure 5.14). In fact, Ki app values for inhibition of ADAMTS5-2 by 
GM6001 in the presence and absence of 2B9 were 510 ± 40 and 490 ± 34, respectively. In this case, 
2B9 was used at a concentration equivalent to its KD value, as measured by SPR (Table 5.2). 
However, I cannot exclude that higher antibody concentrations may affect the inhibitory potency of 
GM6001 for ADAMTS5-2. 
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Figure 5.14: Dose-response for ADAMTS-5 inhibition by GM6001 in the absence and presence of a fixed 
concentration (6 nM) of 2B9 antibody. Concentration of enzyme was 5 nM.  
 
5.7.2. Effect of heparin 
Inhibition mechanisms determined with a peptide substrate not only suffer from the 
drawbacks discussed in Section 5.6 but also may not correctly describe the mechanism of inhibition 
when the native (macromolecular) substrate is used. This is because potential interactions between 
the substrate and enzyme exosites are abolished. As discussed in Section 1.3.2, interactions 
between GAGs of aggrecan and ADAMTS-5 are important for aggrecan cleavage. To simulate the 
effect of GAGs on antibody activity, heparin was co-incubated with ADAMTS-5 and scFv-Fc 
antibodies prior to adding the QF substrate. The concentration of heparin was 50 µg/ml (assuming a 
molecular weight of 15 kDa, this corresponds to 3.33 µM). At this concentration, heparin did not 
inhibit cleavage of QF peptide by ADAMTS5-2 (Figure 5.15). However, the Ki app value for 
inhibition of ADAMTS-5 cleavage of an IGD substrate by heparin is 20 µg/ml (Troeberg et al., 
2008). 
Addition of heparin at 50 µg/ml did not produce any significant effect on the inhibitory 
potency of scFv-Fc antibodies 2D3, 2D5, 2D11 (Figure 5.16 and Table 5.5). Moreover, 
combination of antibody 2B9 (which does not inhibit cleavage of QF peptide) with heparin did not 
result in any inhibition of ADAMTS-5 in this assay (Figure 5.17).  
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Figure 5.15: Effect of heparin on ADAMTS-5 cleavage of QF peptide. ADAMTS5-2 (5 nM) was incubated with 
different concentrations of heparin for 2 h and residual activity against Abz-TESE~SRGAIY-Dpa-KK (1 h, 37°C) was 
determined.  
 
 
Clone Ki app 
(nM) 
+Heparin 
Ki app (nM) 
2D3 1.7±0.2 1.4 ± 0.3 
2D5 17 ± 1.5 14 ± 0.3 
2D11 72 ± 14 80 ± 14 
 
Table 5.5: Ki app values (nM) for inhibition of ADAMTS-5 by scFv-Fc in the presence and absence of heparin (50 
µg/ml). Data are Ki app values of the mean data ± S.E. of the curve fit. 
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Figure 5.16: Heparin does not affect inhibitory potency of scFv-Fc antibodies on ADAMTS-5. Dose-response (left) 
and Yonetani-Theorell plots (right) for ADAMTS-5 inhibition by 2D3 (A, B), 2D5 (C, D), and 2D11 (E, F) scFv-Fc 
antibodies in the absence and presence of a fixed concentration (50 µg/ml) of heparin. Concentration of enzyme was 5 
nM for all scFv-Fc antibodies except 2D3. For 2D3, 0.5 nM of enzyme was incubated with substrate for 18 h at 37°C 
before end-point reading. 
 
A solid-phase binding assay was used to evaluate whether scFv-Fc antibodies were able to 
bind to heparin-bound ADAMTS-5. Heparin was coated onto multi-well plates (Mahoney et al., 
2004) and subsequent binding of ADAMTS5-2 or ADAMTS5-5 was quantified using an antibody 
against their C-terminal FLAG. ADAMTS5-2 bound strongly to immobilised heparin, whereas 
binding was much reduced in the case of ADAMTS5-5 by deletion of Sp, CysR and TS-1 domains, 
as previously reported (Troeberg et al., 2012) (Figure 5.18 A). The CysR domain of ADAMTS-5 is 
the primary site for interaction with the sulphated polysaccharide chains of aggrecan (Gendron et 
al., 2007). Approximately 40 nM ADAMTS5-5 were necessary to generate the same signal of 10 
nM ADAMTS5-2 on this solid-phase ELISA (Figure 5.18 B).  
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Figure 5.17: Combination of antibody 2B9 with heparin does not affect ADAMTS-5 cleavage of QF peptide. 
ADAMTS5-2 (5 nM) was incubated with different concentrations of 2B9 for 2 h in the absence and in the presence of a 
fixed concentration (50 µg/ml) of heparin and residual activity against Abz-TESE~SRGAIY-Dpa-KK (1 h, 37°C) was 
determined.  
 
Binding of scFv-Fc antibodies to heparin-bound ADAMTS5-2 (10 nM) and ADAMTS5-5 
(40 nM) was then quantified using an HRP-conjugated anti-human IgG antibody. Antibodies 2B9, 
2D3, 2D5, and 2D11 were all able to bind to ADAMTS-5 under these conditions, confirming that 
heparin-binding sites on ADAMTS-5 do not overlap with the respective epitopes on the enzyme 
surface (Figure 5.18 C-F). It is likely that other GAGs such as CS/KS chains which are attached on 
aggrecan would not affect binding of scFv-Fc antibodies to ADAMTS-5, although the effect of the 
aggrecan protein core on antibody binding has not been examined. Some differences between 
antibodies were remarkable. Antibodies 2D3 and 2D11 bound with essentially the same affinity to 
both ADAMTS5-2 and ADAMTS5-5, but antibody 2D5 bound to ADAMTS5-5 with a drastic 
decrease in affinity and antibody 2B9 was essentially unable to bind to ADAMTS5-5. These data 
confirmed Biacore data where antibodies 2D3 and 2D11 recognised the Cat/Dis domains, 2B9 the 
Sp, and antibody 2D5 bound to ADAMTS5-5 with decreased affinity compared with ADAMTS5-2 
(Table 5.2).  
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Figure 5.18: Binding of scFv-Fc antibodies to GAG-bound ADAMTS-5. A) Heparin (10 µg/ml) was immobilised on 
GAG-binding plates and subsequent binding of ADAMTS5-2 or ADAMTS5-5 was detected by anti-FLAG and HRP-
conjugated anti-mouse antibody. B) 10 nM ADAMTS5-2 produced the same signal of 40 nM ADAMTS5-5. C-F) 
Binding of antibodies 2B9, 2D3, 2D5, and 2D11 to ADAMTS5-2 (10 nM), ADAMTS5-5 (40 nM) or heparin (non- 
specific binding) was detected by HRP-conjugated anti-human IgG. OD, optical density. 
 
5.7.3. Effect of TIMP-3 
TIMP-3 is an endogenous inhibitor of ADAMTS-5 and -4 (Gendron et al., 2003); we 
therefore investigated whether lead antibodies share an overlapping epitope with TIMP-3 (Figure 
5.19 and Table 5.6). When antibodies were incubated in the presence of TIMP-3, the Yonetani-
Theorell plot produced non-parallel lines of best fit for 2D5 and 2D11, indicating mutually non-
exclusive binding by TIMP-3 and each of these antibodies, whereas for 2A11 and 2D3 the parallel 
lines indicate mutual exclusive binding with TIMP-3. In the case of 2D11, synergism was observed, 
with an increase in potency in the presence of TIMP-3 of about 2-fold. 
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Clone Ki app 
(nM) 
+TIMP-3 
Ki app (nM) 
2A11 210 ± 70 > 300 
2D3 3.2 ±0.3 > 400 
2D5 15 ± 0.3 11 ± 0.3 
2D11 60 ± 10 35 ± 6 
 
Table 5.6: Ki app values (nM) for inhibition of ADAMTS-5 by scFv-Fc antibodies in the presence and absence of 
TIMP-3. Data are Ki app values of the mean data ± S.E. of the curve fit. In the presence of TIMP-3, the Ki app values were 
measured by fixing as 100 % the activity from the control reaction containing enzyme and TIMP-3. 
 
In order to examine the effect on TIMP-3 potency, titrating concentrations of TIMP-3 were 
incubated in the presence of a fixed concentration of each antibody (Figure 5.20 and Table 5.7). 
The Ki app value for ADAMTS5-2 inhibition by TIMP-3 was in line with the published value of 0.72 
± 0.17 nM (Troeberg et al., 2009). In the presence of 2D3, an antagonist effect was observed, again 
indicating mutually exclusive binding; quite surprisingly, the same was observed also in the case of 
anti-Sp antibody 2B9. On the other hand, antibodies 2D5 and 2D11, at a concentration equivalent to 
their Ki app value, enhanced inhibitory potency of TIMP-3. Accurate determinations of the improved 
Ki app were not possible, as ADAMTS-5 concentrations below 0.5 nM cannot be reliably assayed 
with the currently available QF substrate.  
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Figure 5.19: Dose-response (left) and Yonetani-Theorell plots (right) for ADAMTS-5 inhibition by 2A11 (A, B), 
2D3 (C, D), 2D5 (E, F), and 2D11 (G, H) scFv-Fc antibodies in the absence and presence of a fixed concentration 
(2.5 nM) of TIMP-3 (5 nM ADAMTS5-2). Since 2D3 is a tight-binding inhibitor, 0.5 nM enzyme and 0.5 nM TIMP-3 
were used and rates against Abz-TESE~SRGAIY-Dpa-KK (18 h, 37°C) were determined. 
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Figure 5.20: Effect of antibodies 2B9 (A, 6 nM), 2D3 (B, 2 nM), 2D5 (C, 20 nM), and 2D11 (D, 60 nM) on TIMP-3 
inhibition of ADAMTS-5. ADAMTS5-2 (0.5 nM) was incubated with TIMP-3 (0.2-10 nM) and a fixed concentration 
of scFv-Fc antibodies and residual activity against Abz-TESE∼SRGAIY-Dpa-KK was determined (18 h, 37°C). Note: 
at this antibody concentration residual activity in the absence of TIMP-3 is around 70%. 
 
 Ki app 
(nM) 
TIMP-3 0.70 ± 0.16 
+2B9 2.0 ± 0.4 
+2D3 4.5 ± 1.5 
+2D5 <0.4 
+2D11 ~0.3 
 
Table 5.7: Ki app values (nM) for inhibition of ADAMTS-5 by TIMP-3 in the presence and absence of scFv-Fc 
antibodies. The activity from the control reaction containing the enzyme and the fixed concentration of scFc-Fv (6 nM 
for 2B9, 2 nM for 2D3, 20 nM for 2D5 and 60 nM for 2D11) was fixed as 100 %. 
 
To determine if scFv-Fc antibodies 2B9, 2D3, 2D5 and 2D11 were able to bind to 
ADAMTS-5 in the presence of TIMP-3, a co-immunoprecipitation experiment was performed 
(Figure 5.21). scFv-Fc antibodies were bound to protein G-paramagnetic beads and successively 
incubated with ADAMTS5-2 in the presence and in the absence of TIMP-3 (1:1 enzyme/TIMP-3 
ratio). Both ADAMTS-5 and ADAMTS-5/TIMP-3 complex were precipitated by 2D5 and 2D11 
but not by an isotype scFv-Fc control. 2D3 was able to pull-down ADAMTS5-2 and ADAMTS5-
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2/TIMP-3 complex, but also to a certain degree TIMP-3 alone. Since a faint band was detected also 
in the TIMP-3 alone control in the case of 2D5 by anti-TIMP-3 probing, the observed band is likely 
due to non-specific binding between antibody and TIMP-3. Unfortunately, the anti-Sp antibody 2B9 
underwent degradation under these assays conditions (Figure 5.21) such that it was not possible to 
assess its ability to immunoprecipitate ADAMTS-5 or ADAMTS-5/TIMP-3 complex. The reasons 
for degradation are not known; I cannot exclude that a protease contamination occurred.  
 
Figure 5.21: Co-immunoprecipitation of ADAMTS-5/TIMP-3 complex by anti-ADAMTS-5 scFv-Fc antibodies. 
Antibodies 2B9, 2D3, 2D5, 2D11 and an isotype scFv-Fc control (Iso C) were bound to protein G-coated paramagnetic 
beads and used to pull-down ADAMTS5-2 (100 nM) in the presence and absence of an equimolar concentration of 
TIMP-3 (100 nM). Samples were subjected to SDS-PAGE under reducing conditions and immunoblotting. Membranes 
were probed with anti-FLAG M2 mAb, anti-human IgG antibody, polyclonal rabbit-anti ADAMTS-5 Cat domain 
antibody or anti-TIMP-3 mAb. Arrows indicate protein bands. 
 
5.7.4. Effect of antibody combination 
If two lead scFv-Fc antibodies bind to different epitopes on ADAMTS-5, they will exhibit 
synergism (increase in inhibitory potency which should reflect an increase in affinity) when added 
simultaneously to the enzyme solution. This is particularly important in view of a potential 
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therapeutic application. To investigate if a combination of two anti-ADAMTS-5 scFv-Fc antibodies 
is more effective than a single antibody taken individually, double inhibitor studies were performed 
using the QF peptide substrate. 2B9 is the only antibody among the characterised leads which is not 
able to bind to ADAMTS-5 Cat/Dis domain; moreover, it does not inhibit QF peptide cleavage but 
inhibits the aggrecanase activity of ADAMTS-5. When used at a concentration near its KD value (5 
nM), 2B9 showed a synergistic effect with antibodies 2A11, 2D3, 2D5 and 2D11 (Figure 5.22). 
The increase in inhibitory potency in the presence of 2B9 was ~ 2-fold for 2A11, 2D3 and 2D11 
and ~ 3-fold for 2D5 (Table 5.8). 
 
Clone Ki app 
(nM) 
+2B9 
Ki app (nM) 
2A11 170 ± 22 97 ± 2 
2D3 2.3 ± 0.3 1.2 ± 0.1 
2D5 17 ± 0.6 5.8 ± 0.7 
2D11 61 ± 11 28 ± 3 
 
Table 5.8: Ki app values (nM) for inhibition of ADAMTS-5 by scFv-Fc antibodies in the presence and absence of 
2B9. Data are Ki app values of the mean data ± S.E. of the curve fit. Note: 2B9 does not inhibit cleavage of QF peptide by 
ADAMTS-5. 
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Figure 5.22: Dose-response (left) and Yonetani-Theorell plots (right) for ADAMTS-5 inhibition by 2A11 (A, B), 
2D3 (C, D), 2D5 (E, F), and 2D11 (G, H) scFv-Fc antibodies in the absence and presence of a fixed concentration 
(5 nM) of antibody 2B9. Concentration of enzyme was 5 nM for all scFv-Fc antibodies except 2D3. For 2D3, 0.5 nM 
of enzyme was incubated with QF peptide substrate for 18 h at 37°C before end-point reading. 
 
On the basis of the SPR data (Table 5.2), antibodies 2D5 and 2D3 show a different ability to bind 
to the Cat/Dis domain, with 2D5 showing a preference for ADAMTS5-2 over ADAMTS5-5 and 
2D3 binding with the same affinity to both enzyme forms. I therefore studied the effect that a 
combination of these two antibodies had on the reciprocal inhibitory potency (Figure 5.23). The 
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Yonetani-Theorell plots produced parallel lines of best fit for these two antibodies each in the 
presence of a fixed concentration of the other, indicating mutually exclusive binding. The increase 
in Ki app value for 2D3 was about 3-fold, whereas for 2D5 the increase of Ki app value in the presence 
of 2D3 was modest due to the low concentration of 2D3 (corresponding to the Ki app of 3 nM) 
relative to the enzyme concentration (5 nM) under the conditions used to test inhibitory activity of 
2D5 (Table 5.9). 
 
Clone Ki app 
(nM) 
+2D5 
Ki app (nM) 
+2D3 
Ki app (nM) 
2D3 1.7 ± 0.2 5.2 ± 1.2 - 
2D5 16 ± 0.6 - 19 ± 0.8 
 
Table 5.9: Ki app values (nM) for inhibition of ADAMTS-5 by combination of 2D3 and 2D5 scFv-Fc antibodies. 
The activity from the control reaction containing the enzyme and the fixed concentration of scFc-Fv (20 nM for 2D5 
and 3 nM for 2D3) was fixed as 100 %. 
 
 
Figure 5.23: Dose-response (left) and Yonetani-Theorell plots (right) for ADAMTS-5 inhibition by 2D3(A,B) and 
2D5 (C,D) scFv-Fc antibodies in the absence and presence of a fixed concentration of 2D5 (20 nM) and 2D3 (3 
nM), respectively. Concentration of enzyme was 5 nM for 2D5. For 2D3, 0.5 nM of enzyme was incubated with QF 
peptide substrate for 18 h at 37°C before end-point reading. 
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5.8.   Effect of scFv-Fc antibodies on aggrecan breakdown in cartilage explants treated with 
IL-1 and OSM 
As was discussed in Chapter 1, aggrecanases are the main proteinases involved in cartilage 
degradation in stimulated cartilage explants (Sandy et al., 1991; Arner et al., 1998; Little et al., 
1999). We therefore investigated the ability of ADAMTS-5 inhibitory antibodies 2B9, 2D3, 2D5, 
and 2D11 to inhibit stimulated aggrecanase activity in porcine and human articular cartilage 
explants. As controls, the non-inhibitory anti-ADAMTS-5 antibody 1B3 (See Section 4.4.2) and an 
isotype scFv-Fc antibody (directed against desmin) were used. Donor details for human explants are 
reported in Table 5.10. 
 
Patient Age Sex Pathology OA Explant source 
N104 49 F Spindle cell sarcoma 
Hip replacement 
Moderate Knee 
N108 Data not available Knee 
N110 47 M Chondrosarcoma Absent Knee 
 
Table 5.10: Clinical data for knee explant donors. 
 
Porcine and human articular cartilage explants were stimulated with IL-1α (10 ng/ml) and 
OSM (50 ng/ml) in the presence or absence of scFv-Fc antibodies (1µM) and N-TIMP-3 (0.1 µM) 
for 24 h and then the medium was analysed for the presence of GAGs and aggrecanase-generated 
aggrecan fragments by dimethylmethylene blue (DMMB) assay (Farndale et al., 1986). 
Porcine articular explants treated with IL-1α/OSM alone showed approximately 2-fold 
increase in GAG release over controls after 24 h of stimulation (Figure 5.24 A). In the case of 
human articular explants this increase was approximately 3-fold (Figure 5.24 B).  
The IL-1α-stimulated release from both porcine and human explants was inhibited by N-
TIMP-3 to the basal level as previously reported (Gendron et al., 2003); however, a negative isotype 
control (anti-desmin scFv-Fc), as well as anti-ADAMTS-5 scFv-Fc antibodies 1B3, 2B9, 2D3, 2D5 
and 2D11 were not effective. The basal level of GAG-release was not increased in the presence of 
scFv-Fc antibodies (Figure 5.24).  
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Figure 5.24: Inhibition of GAG release by scFv-Fc antibodies. Porcine (A) and human (B) articular cartilage 
explants were incubated with DMEM with or without 10 ng/ml IL-1α and 50 ng/ml OSM plus scFv-Fc antibodies (1 
µM) or N-TIMP-3 (0.1 µM) for 24 h. The GAG content released into the media was measured using the DMMB assay. 
The results are from 4 (A) or 3 (B) separate experiments ± S.E.M. (three pieces of cartilage for each condition). 
*P<0.05; ***P < 0.001 as compared with the IL-1α/OSM treatment without antibody. Iso C, isotype control.  
 
Conditioned media from these experiments were analysed by Western blot analysis using a 
mAb that recognises the aggrecanase-generated neoepitope ARGSV (Figures 5.25 and 5.26). 
Although Western blot is not as sensitive as methods such as ELISA, the advantage with this 
technique is that it discriminates between different proteolytic fragments carrying the same epitope. 
In concordance with the GAG release data, there was an increase in the amount of aggrecanase-
generated fragments released upon treatment with IL-1α/OSM from both porcine and human 
explants. In both cases, the release of aggrecanase-generated fragments was completely blocked by 
0.1 µM N-TIMP-3. In porcine explants, the isotype antibody control showed approximately 50% 
inhibition of aggrecanase-generated fragments in porcine explants cultures. Although desmin is 
reported as a muscle marker, it is still possible that porcine chondrocytes express an antigen sharing 
homology with desmin and that this antigen is recognised by the anti-desmin antibody. 
Alternatively, we cannot rule out a non-specific effect mediated by the Fc portions of the antibodies 
in porcine explants. On the other hand, the anti-ADAMTS-5 non-inhibitory antibody 1B3, showed 
only a modest (approximately 25%) reduction in aggrecanase-generated fragments and was thus 
used as a control for porcine explants. Antibodies 2B9, 2D3 and 2D5, but not 2D11, showed a 
significant inhibition of aggrecanase-generated fragments compared with antibody 1B3 in porcine 
explants (Figure 5.25). This efficacy is in contrast with the GAG release data (Figure 5.24) and can 
be explained on the basis of specific inhibition of ADAMTS-5. 
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Figure 5.25: Analysis of aggrecan degradation in conditioned media from IL-1α/OSM-stimulated porcine 
articular cartilage. The conditioned media from porcine articular cartilage explants treated with IL-1α/OSM were 
deglycosylated and analysed by Western blotting with anti-ARGSV neoepitope antibody BC3. A) Densitometric 
analysis of Western blot. Intensity of anti-ARGSV reactive band is plotted as percentage of residual activity of 
untreated explants. *P<0.05; **P < 0.005 as compared with the IL-1α/OSM treatment with the control antibody 1B3. 
The results are from 4 separate experiments ± S.E.M. (three pieces of cartilage for each condition). B) A representative 
Western blot is shown. 
 
In the conditioned medium from human samples (Figure 5.26), two main ARGSV-cross 
reactive bands were observed, one at around 310 kDa, corresponding in size to the 393ARGSV---
SELE1564 fragment and a lower band at around 130-160 kDa corresponding to ARGSV-fragments 
produced by multiple cleavage in the CS-1 domain (Struglics et al., 2006). The presence of further 
anti-ARGSV-reactive fragments at low molecular weight is distinctive of human samples. 
Conditioned media from human knee cartilage showed a significant inhibition of the 393ARGSV---
SELE1564 aggrecanase-generated fragment after treatment with IL-1α/OSM in the presence of 
antibodies 2B9 and 2D3 (approximately 60% inhibition), whereas antibodies 1B3, 2D5 and isotype 
control had no effect. Surprisingly, antibody 2D11 showed a highly significant (approximately 2-
fold) increase in the 310-kDa band (Figure 5.26). 
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Figure 5.26 (pag 164): Analysis of aggrecan degradation in conditioned media from IL-1α/OSM-stimulated 
human articular cartilage. The conditioned media from human articular cartilage explants treated with IL-1α/OSM 
were deglycosylated and analysed by Western blotting with anti-ARGSV neoepitope antibody BC3. A) Densitometric 
analysis of Western blot. Intensity of anti-ARGSV reactive band is plotted as percentage of residual activity of 
untreated explants. *P<0.05; **P < 0.005 as compared with the IL-1α/OSM treatment with the control antibody 1B3. 
The results are from 3 separate experiments ± S.E.M. (three pieces of cartilage for each condition). B) A representative 
Western blot for one patient is shown. 
 
 
5.9.   Discussion 
In this chapter, I characterised the inhibitory mechanisms and epitopes of scFv-Fc antibodies 
2A11, 2B9, 2D3, and 2D11 and tested their efficacy in an ex vivo model of cartilage degradation. 
Antibodies 2D3, 2D5 and 2D11 inhibited ADAMTS-5 cleavage both of a QF peptide and bovine 
aggrecan. Notably, no inhibition of ADAMTS-4 or MMPs was observed, indicating that these 
antibodies are specific for ADAMTS-5 (Table 5.1). Antibody 2B9 was only able to inhibit the 
enzyme activity against aggrecan so we speculated that it might act as an exosite inhibitor. 
SPR studies using different deletion mutants of ADAMTS-5 allowed us to map the specific 
domain(s) which constitute(s) the epitope of these antibodies. The absence of binding to ADAMTS-
4 on SPR confirmed that these antibodies are truly specific for ADAMTS-5 (Table 5.2). The 
putative domains of ADAMTS-5 recognised by anti-ADAMTS-5 lead antibodies are reported in 
Figure 5.27. Antibodies 2D3 and 2D11 recognised the Cat/Dis domain of ADAMTS-5; 2D5, 
although still recognising the Cat/Dis domain, showed a preference for ADAMTS5-2. For 2B9 the 
Sp domain is crucial for binding to ADAMTS-5 (Table 5.2 and Figure 5.27). These data were 
essentially confirmed by Western blot analysis of ADAMTS-5 deletion forms where scFv-Fc 
antibodies were used as primary antibodies (Figure 5.10). 2B9 was still able to recognise the 
ADAMTS5-3 and 5-4 on Western blots, suggesting further contacts with CysR and TS-1 domains. 
However, from the SPR data it is evident that binding to these forms of ADAMTS-5 is at least 100-
fold less effective after removal of the Sp domain (Table 5.2). 2B9 is therefore similar to CRB0017 
mAb, developed by the Rottapharm group (Visintin et al., 2012). CRB0017 is specific for the Sp 
domain of ADAMTS-5 with a KD value in the low nanomolar range; moreover, it inhibits 
proteolytic activity of the enzyme in vitro with a Ki app value in the low nanomolar range (Visintin et 
al., 2012) and has been found protective in a murine model of spontaneous OA (Chiusaroli et al., 
2013). 
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Figure 5.27: Schematic representation of domains recognised by anti-ADAMTS-5 antibodies. The figure shows 
crystal structures of ADAMTS-5 Cat (red)/ Dis (salmon) domains (pdb entry 2RJQ) aligned with the TS (green), Cys-R 
(sky blue) and Sp (blue) domains from crystal structure of ADAMTS-13 (pdb entry 3GHN). Main epitopes as well as 
catalytic zinc ion (pink) chelated by GM6001 and calcium ions (green) are outlined.  
 
The ability of exosite antibody 2B9 to inhibit ADAMTS-5 cleavage at the Glu392↓393Ala site 
of bovine aggrecan suggests that this antibody exerts its inhibitory potency by impairing binding of 
ADAMTS-5 to the aggrecan molecule through its Sp domain. At least 32 residues at the N-terminal 
of the cleavage site (P residues of the substrate) and 13 residues at the C-terminal side (P’ residues) 
are required for cleavage at the Glu392↓393Ala bond by aggrecanases (Hörber et al., 2000). Thus 
these sequences serve as further sites of interaction between the enzyme and its substrate. Unlike 
aggrecanases, MMPs require just 8 amino acid N-terminal and 8 amino acids C-terminal to the 
aggrecanase site to cleave efficiently at the Glu392↓393Ala bond (Horber et al., 2000). In the case of 
serine proteases, several works have suggested that interactions between substrate and enzyme far 
away from the active site may be important for catalysis by properly aligning the substrate in the 
active site cleft (Hedström, 2002). These remote interactions can propagate down the peptide chain, 
resulting in significant effects on the stabilisation of the transition state (Hedström, 2002). It may be 
possible that the same effect is produced by anti-ADAMTS-5 exosite antibodies such as 2B9. 
However it would be interesting to test whether 2B9 is able to inhibit cleavage in the CS-2 domain 
of aggrecan. 
I was not able to unequivocally establish the mechanism of inhibition of QF peptide 
cleavage by varying the concentrations of substrate (Figure 5.12). One of the limitations with QF 
peptides is that the solubility of the substrate concentrations well above the Km of the enzyme are 
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difficult to reach and the substrate auto-quenches. Moreover, modulation of enzyme activity is 
substrate-dependent, thus inhibition mechanisms determined with a peptide substrate may not 
correctly describe the mechanism of inhibition when the native (macromolecular) substrate is used 
and enzyme exosites are involved. In the case of several coagulation proteases, where exosites play 
a pivotal role in substrate recognition and specificity, inhibitors competitive with small peptide 
substrates appear noncompetitive with the native pro-enzyme substrates (Krishnaswamy et al., 
2005). In the case of ADAMTS-5, deletion of the Sp or CysR domains severely affects aggrecanase 
activity both at the IGD and CS-2 regions of aggrecan and the Cat domain alone is devoid of 
aggrecanase activity, suggesting a pivotal role for exosites in binding and cleavage of aggrecan 
(Gendron et al., 2007). Wittwer et al. (2007) reported that a hydroxamic acid inhibitor of 
ADAMTS-4 showed competitive inhibition against a peptide substrate but noncompetitive 
inhibition against aggrecan. This observation was explained by the ability of peptide-competitive 
inhibitors to bind both free-enzyme and initial aggrecan-enzyme exosite complex; thus according to 
this model, interactions between the exosite(s) and aggrecan precede those between active site and 
aggrecan (Wittwer et al., 2007). Exosite inhibitors such as 2B9 may prevent the formation of the 
Michaelis complex by blocking the formation of the initial enzyme exosite-substrate complex. 
According to this model, these inhibitors should act as competitive with the native substrate. In my 
case, it was difficult with the current semi-quantitative aggrecan digestion assay used here to 
perform inhibition studies at increasing concentrations of aggrecan. As an alternative, competition 
with aggrecan could be assessed using recombinant aggrecan fragments, such as the gst-IGD 
substrate described by Lim et al. (2010). 
I then chose to study the effect of GAGs such as heparin on the activity and binding of scFv-
Fc antibodies. At 50 µg/ml heparin did not produce any significant effect on inhibition of 
ADAMTS-5 by these antibodies when the QF peptide was used as a substrate (Table 5.5 and 
Figure 5.16); moreover, in a solid-phase ELISA, 2B9, 2D3, 2D5 and 2D11 all show saturating 
binding to ADAMTS-5 bound to heparin-coated wells, suggesting that the epitope recognised by 
these antibodies is not significantly disturbed by GAG binding (Figure 5.18). These results 
therefore indicate that the cartilage environment may not affect the enzyme-antibody complexes. 
Nevertheless, the effects of co-factors such as syndecan-4 (Echtermeyer et al., 2009) and fibulin 
(Lee NV et al., 2005; McCulloch et al., 2009a), as well as competition with protein core 
(deglycosylated protein) of aggrecan should be assessed. For example, calcium pentosan 
polysulphate (CaPPS), a chemically-sulphated xylanopyranose from beechwood, increases the 
affinity of TIMP-3 for ADAMTS-4 and -5 by more than 100-fold, (Troeberg et al., 2008; Troeberg 
et al., 2012). Also Wayne et al. (2007) reported that interaction of full-length TIMP-3 with 
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ADAMTS-4 was enhanced by the presence of aggrecan through binding of GAGs of the substrate 
to TS and Sp domains of the enzyme. It is noteworthy that in this study the effect of aggrecan on 
ADAMTS-4 was analysed directly using a QF peptide substrate. This peptide had a Km value 
around 10 µM and as little as 10 pM of ADAMTS-4 could be reliably used (Wayne et al., 2007). 
Unfortunately, in my case ADAMTS-5 has a Km around 80 µM for its QF peptide substrate, and the 
minimum enzyme concentration to be used is 0.5 nM with 18 h digestion (Troeberg et al., 2012); on 
the other hand, this same enzyme concentration readily cleaves bovine aggrecan within 2 h (See 
Section 3.3.) so it is not possible to follow the effect of the simultaneous presence of the substrates 
on the antibody/enzyme complex. 
In our effort to isolate antibodies specific for ADAMTS-5 we then wished to compare the 
inhibition mechanism of anti-ADAMTS-5 antibodies with that of broad-spectrum hydroxamate 
small molecule inhibitors such as GM6001. Dual inhibitor studies performed with GM6001 
identified antibodies 2A11, 2D3, 2D5 and 2D11 as non-zinc chelating inhibitory antibodies. Zinc-
chelating inhibitory antibodies have been reported before. For example, Sela-Passwell et al. (2011) 
reported the isolation of an anti-gelatinase (MMP-2/MMP-9) antibody SDS3 which was isolated by 
immunisation with a synthetic zinc-histidine complex mimicking the catalytic centre of MMPs. As 
expected, SDS3 bound to the catalytic zinc region of the active form of MMPs. The fact that the 
anti-ADAMTS-5 antibodies here described are not affected by (2D5, 2D11), or show a synergistic 
(i.e. non additive) effect (2A11, 2D3) with GM6001 (Figure 5.13 and Table 5.4), can be explained 
by the fact that they were originally isolated from phage display selections where the active site of 
ADAMTS-5 was blocked with a 100-fold excess of this small molecule inhibitor. This is a proof of 
principle that a careful choice of conditions during phage display selections allows the isolation of 
antibodies with desired properties. 
The next step was to investigate the effect of full-length TIMP-3 on inhibitory potency of 
anti-ADAMTS-5 inhibitory antibodies. Although the inhibitory potency of 2A11 and 2D3 was 
decreased by the presence of TIMP-3, 2D5 and, especially, 2D11, showed improved inhibitory 
potency in the presence of TIMP-3, suggesting non-overlapping binding sites (Figures 5.19 and 
5.20 and Tables 5.6 and 5.7). When concentration of scFv-Fc antibodies was kept constant, TIMP-
3 showed decreased inhibitory potency in the presence of 2D3 but increased inhibitory potency in 
the presence of 2D5 and 2D11. These results were confirmed by co-immunoprecipitation 
experiments where 2D5 and 2D11 were able to pull-down both ADAMTS-5 and ADAMTS-
5/TIMP-3 complexes (Figure 5.21). By contrast, an isotype scFv-Fc control was not able to pull-
down ADAMTS-5 nor ADAMTS-5/TIMP-3 complex. 
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The mechanism of inhibition of metalloproteinases by TIMPs is the bidentate coordination 
of the catalytic zinc ion by the N-terminal α-amino group and the carbonyl group of the first N-
terminal residue (a cysteine), which displaces from the enzyme the water molecule needed for 
peptide bond hydrolysis (Brew and Nagase, 2010). In the complex between full-length TIMPs and 
the catalytic domains of MMPs, it emerges that C-terminal domains of TIMPs establish few 
contacts with the enzyme and these do not appear to make important contributions to complex 
formations since the N-terminal domains of TIMPs have high affinity for the enzyme (Gomis-Rüth 
et al., 1997; Fernandez-Catalan et al., 1998; Maskos et al., 2007). For example, the Ki app value for 
ADAMTS5-2 inhibition by N-TIMP-3 is 0.35 nM, whereas the Ki app value for full-length TIMP-3 is 
0.72 nM (Troeberg et al., 2009). C-terminal domains may be involved in the competitive effect 
exerted by anti-Sp antibody 2B9 on TIMP-3/ADAMTS-5 complex (Figure 5.20 and Table 5.7). 
On the other hand, another possible explanation for the reduced reactivity of TIMP-3 in the 
presence of 2B9 is that C-terminal domains of the enzyme affect the structure around the active site, 
favouring interactions with N-TIMP-3 (Troeberg et al., 2009). If these interactions are abolished by 
2B9, TIMP-3 binding may be disrupted. A model showing ADAMTS-5 regions that are occupied 
by N-TIMP3 or full-length TIMP-3 includes the Dis domain (Figure 5.28). These TIMP-3 contact 
regions are likely to be the epitopes for 2D3 and 2A11, but neither for 2D5 nor 2D11.  
The effects of TIMP-3, GM6001, heparin, and combinations of antibody on inhibitory 
potency of each lead antibody were examined by double inhibition studies. When we examine the 
effects of protein inhibitors such as TIMP-3 and antibodies (not small molecule inhibitors) on a 
single enzyme, we do not expect that binding of any of these inhibitors would be independent 
because the effect of the binding of a single protein ligand can be transduced over the whole 
enzyme molecule. So, even if two proteins bind at different sites of the enzyme, their inhibitory 
effects are not independent since they may influence indirectly the binding of each other and/or they 
may alter the substrate affinity (Palatini, 1983). For example, two independently-bound inhibitors 
might facilitate the binding of each other, since the binding of one of them may increase the affinity 
of the other inhibitor for the enzyme. This would result in an increase in the relative inhibitory 
potency of the two inhibitors. By contrast, if two inhibitors are able to bind independently (for 
example one inhibitor binds to the active site and another one binds to an ancillary domain), it is 
possible that conformational changes in the enzyme molecule may preclude their simultaneous 
binding. 
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Figure 5.28: Models of interactions between ADAMTS-5 and TIMP-3. A) TACE/N-TIMP3 complex from TACE 
3CKI was superimposed on Cat/Dis ADAMTS-5 structure 2RJQ and then residues within 4 angstrom were selected 
(red). B) ADAMTS5 structure 2RJQ was superimposed on TACE 3CKI and then on top of N-TIMP3 structure a model 
of full-length TIMP-3 realised from MMP-3/TIMP-1 complex (1UEA) was super-imposed. Purple, Cat domain; green, 
Dis domain. 
 
Another possibility is that two inhibitors bind to the same site on the enzyme but their binding is 
directed to different forms (Fletcher et al., 1995). This may be the case if ADAMTS-5 exists as an 
ensemble of at least two isomers (Mosyak et al., 2008). Extensive inter-domain flexibility and 
conformational heterogeneity is a feature of MMPs (Bertini et al., 2005), 
ADAM/adamalysin/reprolysin families (Igarashi et al., 2007) and ADAMTSs (Akiyama et al., 
2009). Antibodies 2D3, 2D5 and 2D11 were all able to co-immunoprecipitate ADAMTS-5/TIMP-3 
complexes (Figure 5.21). However, in order to correlate an increase/decrease in inhibitory potency 
of scFv-Fc antibodies in the presence of TIMP-3 with an increase/decrease in affinity between 
scFv-Fc antibodies and ADAMTS-5, SPR studies investigating the affinity of scFv-Fc antibodies 
for ADAMTS-5/TIMP-3 complex should be performed. 
Model systems of cartilage degradation include IL-1α, retinoic acid or IL-1α/OSM–
stimulated bovine nasal, porcine articular and human articular cartilage. In our study we decided to 
focus our efforts in examining the effects of scFv-Fc antibodies on the IL-1α/OSM-stimulated 
porcine and human articular cartilage on the basis of the availability of these samples. Each species 
responded in a different way to the stimulation by IL-1α/OSM. For example, we observed 
consistently a 2-fold increase in GAG release from porcine-explants after incubation with IL-
1α/OSM, whereas in the case of human articular cartilage this increase was about 3-fold.  
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We did not find a correlation between detection of ARGSV fragments by Western blot and 
GAG release. Pratta et al. (2006) reported that there was no good correlation between the levels of 
ARGSV fragments (detected by sandwich ELISA) and the release of the total GAG levels in SF of 
individuals without joint diseases. It is still not known if ADAMTS-5 is the main aggrecanase in 
porcine and human cartilage. Treatment with OSM in combination with either IL-1α or TNF-α in 
human chondrocytes or cultured human cartilage explants led to a marked induction of ADAMTS-4 
gene expression and some induction of ADAMTS-5; siRNA-mediated knock down suggested that 
both enzymes are involved in stimulated aggrecan degradation (Song et al., 2007). OSM is a potent 
catabolic cytokine which is involved not only in release of aggrecanase-generated fragments but 
also link protein and HA degradation in bovine cartilage (Durigova et al., 2008a,b). In bovine 
cartilage explants, treatment for 2 days with IL-1β induces a dramatic up-regulation of Adamts-4 
gene expression and only a modest up-regulation of Adamts-5, although the mRNA levels of 
ADAMTS-5 are always higher than ADAMTS-4 (Durigova et al., 2011b). Another possible 
mechanism by which catabolic cytokines regulate aggrecan degradation is stimulation of C-terminal 
processing of aggrecanases (Patwari et al., 2005; Durigova et al., 2011b). In any case, under 
stimulated conditions both ADAMTS-5 and ADAMTS-4 contribute to aggrecan degradation, as 
detected by ARGSV-neoepitope antibodies. 
N-TIMP-3 inhibits both ADAMTS-4 and ADAMTS-5, and hence is efficient in blocking 
GAG release (Figure 5.24) and aggrecan degradation (Figures 5.25 and 5.26) from porcine and 
human articular cartilage explants under stimulated conditions. On the other hand, anti-ADAMTS-5 
inhibitory antibodies were not able to inhibit GAG release (Figure 5.24). It is possible that this lack 
of efficacy is partly due to lower affinity of the antibodies. However, an aggrecanase-independent 
pathway for GAG-release has been observed in bovine and porcine explants after stimulation by IL-
1α and retinoic acid (Gendron et al., 2003), so the cumulative GAG-release observed in the 
presence of IL-1 α/OSM may be due to ADAMTS-4 as well as other activities (for example 
hyaluronidases, Sztrolovics et al., 2002a,b).  
Anti-ADAMTS-5 scFv-Fc antibodies 2D3 and 2B9 were able to inhibit aggrecan 
degradation (as measured by generation of ARGSV neoepitope) from both porcine and human 
articular cartilage explants. In the case of human explants, only a decrease in the intensity of the 
393ARGSV---SELE1564 band was observed, likely due to an excessive response of human 
chondrocytes to IL-1α/OSM stimulus (Figure 5.26). It is noteworthy that studies with human OA 
cartilage explants described by GlaxoSmithKline in US Patent 2012/0095193 (Burden et al., 2012) 
followed spontaneous cartilage degradation for a 2-3 week period ex vivo in the absence of 
stimulation; this was possible due to sensitive methods (such as ELISA) used to detect ARGSV 
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neoepitope generation. Anti-ADAMTS-5 specific antibodies described in this patent produced a 
70% inhibition of ARGSV neoepitope at the concentration of 670 nM (Burden et al., 2012). After 
removal of the treatment media, the effect on ARGSV generation lasted as long as 23 days. The 
results described in this patent provide evidence of the extended duration of the therapeutic effect of 
ADAMTS-5 inhibition in human OA cartilage and indicate a low turnover rate of ADAMTS-5 in 
diseased tissue, thus confirming an impairment of ADAMTS-5 endocytosis in OA cartilage 
(Yamamoto et al., 2013). ADAMTS-5 endocytosis is mediated by LRP-1 (See Section 1.2.4.3) and 
addition of receptor-associated protein (RAP) to porcine cartilage explants increases the basal level 
of aggrecan degradation, as well as ADAMTS-5-mediated aggrecan degradation (Yamamoto et al., 
2013). Therefore, the ability of anti-ADAMTS-5 antibodies to inhibit aggrecan degradation in 
cartilage explants should be assessed under unstimulated conditions in the presence of RAP in order 
to exclude ADAMTS-4 interference with this system.  
The specific inhibition of aggrecanase-generated fragments reported here is potentially 
beneficial in disease treatment. In particular, side effects such as MSS associated with broad-
spectrum MMP inhibitors (See Section 1.4.1) should be abolished. In the case of antibody 2D11, an 
increase in aggrecan degradation was observed in all three human samples examined. Since the 
same phenomenon was not observed for porcine articular explants, more human samples needed to 
be analysed by this method.  
Generally, aggrecanase inhibitors are much more potent in in vitro than in ex vivo systems. 
For example, in our study, the concentration of scFv-Fc antibodies used to test inhibitory effect on 
stimulated cartilage explants was 1 µM (i.e. from 20 to 500-fold higher than the Ki app). One reason 
for the observed decrease in potency may be competition with aggrecan. Since high levels of 
aggrecan are present in the cartilage matrix (>10 mg/ml, ~ 10 µM for nasal cartilage, Wittwer et al., 
2007), when inhibitors are tested in explants cartilage systems their Ki app will increase according to 
the Cheng and Prusoff equation (i.e. Ki = Ki app /(1+ [S]/Km)) (Cheng and Prusoff, 1973). As 
discussed before, since the anti-ADAMTS-5 antibodies described here do not act through a zinc-
chelating mechanism and therefore likely act through a noncompetitive/uncompetitive mechanism 
of inhibition, but the exact inhibitory mechanisms of these antibodies against aggrecan were not 
elucidated. 
Other factors that may affect antibody performances in explants studies are antibody 
stability, ability to reach the target, isoelectric point (pI) and affinity for polyanionic components of 
the ECM, and epitope masking by interactions of ADAMTS-5 with ECM molecules. The pI values 
of the antibodies described here is very similar, ranging from 5.70 for 1B3 to 6.46 for 2B9, and 
these values should be compared with the basic pI of N-TIMP-3 (9.27) (Gendron et al., 2003). Few 
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studies have so far examined the permeability of this tissue to large macromolecules such as 
antibodies. It is still a matter of debate whether IgGs can penetrate the cartilage. Maroudas (1976) 
reported that variations in GAG content between different joints and between different zones of the 
same joint lead to large differences in the penetration of IgGs (~ 160 kDa), but with a partition 
coefficient of the same order of magnitude of serum albumin (~69 kDa). Anti-ADAMTS-5 
antibodies described in US Patent 2012/0095193 (IgGs) are capable of penetrating mouse cartilage 
in vivo even when administered by a non-articular route of administration (intravenous, 
intramuscular, subcutaneous, oral, intranasal and intraperitoneal administration) (Burden et al., 
2012). In the same patent, the ability of mAbs to penetrate human cartilage was tested on ex vivo 
tissues. Irrespective of target specificity, mAb penetration was observed to be a concentration and 
time-dependent process primarily originating from the synovial surface of the cartilage and 
proceeding to full thickness penetration within 3-4 days; an isotype control (non-specific for any 
cartilage target) failed to penetrate the cartilage (Burden et al., 2012). Also, in vivo assessment of 
cartilage penetration was performed using near-infrared (NIR) dye-labelled mAbs, administered 
intraperitoneally to mice that had undergone surgical DMM 6 weeks prior to the test. Again, within 
4 days after systemic mAb administration, full-thickness cartilage penetration was observed for 
anti-ADAMTS-5 and anti-ADAMTS-4 mAbs, but no staining for an isotype control (Burden et al., 
2012). This indicates that cartilage penetration by mAbs is antigen-specific. The anti-ADAMTS-5 
mAb CRB0017 (IgG) is effective in delaying cartilage breakdown in STR/ort mice (which 
spontaneously develop age-related OA) when administered intra-articularly, although no 
quantitative bioanalytical methods have been used to assess cartilage penetration (Chiusaroli et al. 
2013). 
Penetration of scFv-Fc antibodies (~ 110 kDa) may thus be a combined result of molecular 
size, isoelectric point, and affinity for the target antigen. Immunohistochemistry will be needed to 
assess the extent and deepness of cartilage penetration by these lead antibodies. Taking into account 
the relevance of the ex vivo systems to the human disease and the observed efficacy, the data 
presented in this chapter strongly support further therapeutic validation of the anti-ADAMTS-5 
antibodies described here. However, dose-response inhibition as well as cytotoxicity studies should 
be performed in order to establish conditions for in vivo treatment. 
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6.1. Mechanisms of action of inhibitory antibodies  
Developing selective and potent inhibitors of proteases is difficult because a target protease 
is frequently co-expressed with other similar proteases that differ only slightly in sequence, global 
fold and even substrate specificity. One example is the metallopeptidase clan MA that includes 
matrix metalloproteinases (family M10), astacins, ADAMs, ADAMTSs and snake venom 
metallopeptidases (family M12). More than 200 structures of metallopeptidases have been 
deposited in the Protein Data Bank so far. This huge complexity and similarity traditionally 
hampered the therapeutic development of small molecule inhibitors which generally targeted the 
conserved catalytic zinc ion of these families and therefore lacked selectivity (Coussens et al., 
2002). Since the first studies showing protection of Adamts-5 knock out mice from cartilage 
degradation (Glasson et al., 2005; Stanton et al., 2005), a lot of effort has been spent to develop 
small molecule inhibitors targeting this enzyme. Generally, these compounds contained a zinc-
chelating group such as hydroxamate (Yao et al., 2001; Cappelli et al., 2010; Nuti et al., 2013), 
carboxylate (Shiozaki et al., 2001) or acylthiosemicarbazide (Maingot et al., 2013). Due to the 
paucity of structural informations, so far few examples of non-zinc chelating aggrecanase inhibitors 
have been reported (Ding, 2010; Deng et al., 2012). As discussed in Section 1.4.1, zinc-chelating 
small molecule inhibitors, although potent, are generally thought to be associated with MSS. 
The antibody scaffold is an attractive alternative for the development of highly potent and 
selective inhibitors of metallopeptidases since it can immunologically distinguish between 
structurally closely related proteins. Phage display of antibody fragments is a well-established 
technology which, by exploring the huge diversity of natural antibody repertoire, has enabled the 
isolation of inhibitory antibodies against complex extracellular proteins (Hoogenboom, 2005). 
However, despite the ability of the antibody repertoire to generate specific binders against virtually 
all antigens, the number of antibodies acting as enzyme inhibitors is low. A possible explanation for 
this scarce representation lies in the surface topography of both enzyme active site and the antigen-
binding site of antibodies. The active site of most enzymes is found usually in the largest cleft on 
the protein surface (Laskowski et al., 1996). In the case of ADAMTS-5, the catalytic site has the 
shape of a funnel that opens up at the zinc site at its widest point and then forms an L-shaped 
hydrophobic channel through the S1’pocket and out to solvent at its distal end (Shieh et al., 2008). 
On the other hand, the antigen-binding surface of conventional antibodies frequently forms a flat 
surface when interacting with other protein antigens (Webster et al., 1994). Large protruding 
flexible loops are not frequently observed at the antigen-binding site (Wu et al., 1993; Padlan, 
1996). This may be due to the loss of degrees of freedom upon binding to the antigen. A 
consequence is that, unlike canonical inhibitors which present a convex surface and target the 
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protease cleft to inhibit the enzyme in a substrate-like manner (Laskowski and Kato, 1980), 
conventional antibodies may preferentially bind to protruding loops at the rim of the substrate-
binding cleft with flat or concave paratopes (Wu et al., 2007). 
One important exception is represented by heavy chain antibodies (hcAbs) from camels and 
sharks. The immune system of these species seems to possess an inherent propensity for forming 
enzyme-blocking antibodies. hcAbs are formed only by a single domain, designated VHH in 
camelids and VNAR (shark variable new antigen receptor) in sharks, and so lack a light chain. The 
CDR3 region of hcAbs possesses the ability to form long extensions that can fit into cavities of 
antigens such as the active sites of enzymes (De Genst et al., 2006). A serious disadvantage of the  
use of the hcAbs in therapy is their potential immunogenicity, which represents a major concern for 
repeated and long-term treatments. However, humanisation may help to limit immunogenicity.  
For the most part, the inhibitory antibodies of proteases reported in the literature have been 
mAbs raised from hybridomas which act through two different mechanisms: active-site inhibition 
(where the antibody inserts a loop in a substrate-like manner into the active site and produces steric 
hindrance) (Farady et al., 2007) and allosteric inhibition (where the antibody occludes substrate 
binding or causes conformational changes of the enzyme) (Petersen et al., 2001, Matias-Roman et 
al., 2005; Xuan et al., 2006). Allostery is a basic principle of control of enzymatic activities based 
on the interaction of a protein or small molecule at a site distinct from an enzyme active centre. An 
advantage of antibodies over small molecules when an allosteric modulation is desired is their size. 
Proteins that interact with other proteins generally use contact surfaces (1500-3000 angströms) 
(Jones and Thornton, 1997) much larger than the average contact area between a small molecule 
and its protein target (1000 angströms) (Cheng et al., 2007).  
Historically, allostery was initially thought to be restricted to oligomeric proteins. It is now 
widely recognised that the native states are ensembles of pre-existing populations; thus, an allosteric 
effector leads to an equilibrium shift of pre-existing conformational and dynamic states 
(Gunasekaran et al., 2004). According to this view, allostery is an intrinsic property of all dynamic 
proteins, including monomeric proteins (Gunasekaran et al., 2004). Enzymes can adopt several 
conformations, some of them catalytically active, with others being inactive. Equilibria exist 
between these different states, and these can be shifted upon reversible ligand binding or 
irreversible trapping at the allosteric binding sites to result in redistribution of the conformation 
ensembles (Volkman et al., 2001). For example, there are peptidic allosteric regulators that induce a 
switch from the ordered active protease conformation to the disordered zymogen-like conformation, 
thereby following a mechanism similar to that of the allosteric zymogen activators (Dennis et al., 
2000). 
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Antibodies can behave as allosteric effectors, giving rise to kinetic effects such as activation, 
noncompetitive inhibition and/or hyperbolic (i.e. partial) inhibition of enzymes and receptors 
(Pollock, 1964; Saerens et al., 2004; Shapira and Arnon, 1967; Barlow et al., 2009; Oyen et al., 
2011). A common mechanism by which allosteric activators increase kcat is enhancing product 
release, which is a rate-determining step commonly observed in enzymes (Suzuki et al., 1969; 
Barlow et al., 2009). Most allosteric effectors appear preferentially to target native low-energy 
conformations such as those found in the zymogen or active protease structure since it is easier to 
shift the protein conformation equilibrium into a low-energy conformation than into high-energy 
structures. 
Allosteric antibody inhibitors show peculiar inhibitory profiles where they cannot inhibit the 
hydrolysis of peptide substrates or have different levels of inhibition against different substrates 
(Petersen et al., 2001; Xuan et al., 2006). Usually, allosteric inhibitors act by restricting the 
conformational flexibility in the enzyme active site and blocking substrate binding (Desmyter et al., 
1996; Goodey and Benkovic, 2008). Auto-antibodies (i.e. antibodies that recognise self rather than 
foreign proteins) are a class of antibodies which can act according to the latter mechanism and are 
implicated in immune diseases (Makita et al., 2007; Scheiflinger et al., 2003; Colwell et al., 1998). 
An example is provided by auto-antibodies which occur in patients diagnosed with thrombotic 
thrombocytopenic purpura (TTP) (See Section 1.2.2). These auto-antibodies react with the non-
catalytic ancillary domain of ADAMTS-13 and inhibit enzyme cleavage of von Willebrand factor 
(vWF) (Soejima et al., 2003). vWF acts by anchoring platelets at sites of injured vessel walls under 
high shear stress. The result of impaired vWF cleavage is the accumulation of unprocessed high 
molecular weight-vWF on endothelial vessel walls, thus provoking microvascular thrombus 
formation and consequent haemolytic anaemia, renal failure, neurological dysfunction and fever 
(Moake et al., 1982). Epitope mapping studies have shown that the CysR/Sp domains represent the 
major antigenic determinant for human anti-ADAMTS-13 antibodies (Soejima et al., 2003; Klaus et 
al., 2004; Luken et al., 2005). Residues within Y658-Y665 of ADAMTS-13 Sp domain that are 
targeted by auto-antibodies in TTP directly interact with a complementary exosite within the vWF 
A2 domain (Pos et al., 2010). These auto-antibodies thus block initial binding of ADAMTS-13 to 
vWF (Zheng et al., 2003). As discussed below, this mechanism likely occurs in the case of the anti-
ADAMTS-5 Sp antibody 2B9. 
Other than active-site inhibition and allosteric inhibition, another mechanism by which 
antibodies can inhibit protease function is by targeting zymogen activation as reported for the serine 
protease urokinase-type plasminogen activator (uPA) activity (Blouse et al., 2009). An anti-uPA 
mAb reported by Blouse et al. (2009) not only interferes with the cleavage of pro-uPA but also 
Chapter 6  General discussion and future prospects 
178 
stabilises the active two-chain enzyme in a non-catalytic conformation by restricting the 
conformation flexibility of the activation domain. Antibodies targeting protease multimerisation and 
subsequent activation have been reported for HIV-proteases (Rezacova et al., 2001), cysteine 
proteases (Puchi et al., 2006), and the serine protease beta tryptase (Fukuoka and Schwartz, 2006). 
The ability of the antibodies to interfere with the biological activity of their target protein at 
a distance from the epitope could arise from the induced-fit (Schechter et al., 1971) or selection of 
distinct conformational states (Berger et al., 1999). In the context of antigen-antibody recognition, 
the expression “induced-fit” implies that the binding reaction induces conformational changes 
leading to a better complementarity between epitope and paratope. Ganesan et al. (2009) reported a 
phage display-derived antibody which, although being a competitive inhibitor of serine protease 
hepatocyte growth factor activator (HGFA), bound to an epitope distant from the active site and 
induced a conformational change which switched the enzyme to a non-competent state, thus 
actually acting as an allosteric inhibitor. Conformational changes can be detected by NMR 
relaxation dispersion techniques (Brüschweiler et al., 2009). However, large conformational 
changes in proteins upon complex formation with antibodies are rarely observed by X-ray 
crystallography (Sundberg and Mariuzza, 2002). An alternative way for antibodies to modulate 
protein function is by altering protein dynamics. The rates of amide hydrogen exchange in some 
proteins are reduced upon antibody binding for amides at considerable distances from the epitope 
and without any evident change in crystal structure (Williams et al., 1996; Dumoulin et al., 2003). 
Conformational selection is an alternative mechanism which does not need conformational 
changes during the binding reactions. In this case the antibody selects those antigen molecules 
whose epitope is already in a fitting conformational state (Leder et al., 1995; Berger et al., 1999) or, 
in the reciprocal case, the antigen selects the antibody which happens to be in the complementary 
conformation (Foote and Milstein, 1994). Popovych et al. (2006) presented direct experimental 
evidence illustrating that allostery can be mediated solely by changes in protein dynamics without 
any conformational change. This absence of conformational change leads to a definition of allostery 
in pure thermodynamic terms: allostery can be controlled by enthalpy, by enthalpy and entropy, or 
solely by entropy (Tsai et al., 2008; Tsai et al., 2009). A free energy change without conformational 
change is defined as entropy-dominated (Tsai et al., 2008; Tsai et al., 2009).  
An hydroxamate-based succinamide derivative, which showed significant inhibitory activity 
towards many MMPs, including MMP-2, MMP-8, MMP-9 and MMP-13, was proved to inhibit 
ADAMTS-5 by inducing a conformational change in the S1’ loop of the active site (Shieh et al., 
2011). However, this flexibility of ADAMTS-5 active site may lead to allosteric inhibition by anti-
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ADAMTS-5 antibodies which is entropy dominated and that will not produce detectable 
conformational changes. 
The work described so far confirms that solution-phase scFv phage display is a suitable 
method to identify and isolate potent and specific inhibitory antibodies of ADAMTS-5. Sequences 
of lead antibodies are reported in Table 6.1, together with sequences for anti-ADAMTS-5 
antibodies described by GlaxoSmithKline (GSK) in USA Patent 2012/0095193 (Burden et al., 
2012). Sequences of anti-ADAMTS-5 antibodies described here differ widely from each other and 
from those described in the US Patent.  
 
Clone Variable Heavy Variable Light 
CDR-1 CDR-2 CDR-3 CDR-1 CDR-2 CDR-3 
MP2 A11 GYSFTSYWIS RIDPSDSYTNYSPSFQG GGDSSSLYDAFDI TGTSSDVGGYNYVS EGSKRPS SSYTSTNSVV 
MP2 B9 GFTFSSYAMS AISGSGGSTYYADSVKG DQTPLGGFYFDY RASQSISSYLN AASSLQS QQSYSTPGT 
MP2 D3 GGTFSSYAIS GIIPIFGTANYAQKFQG EGRLVVGATTDYYYYYGMDV RASQNINTYLN KASSLES QQYDNLPIT 
MP2 D5 GFTFDDYAMH GISWNSGSIGYADSVKG ESSSWYLRYFDY RASQSISSYLN AASSLQS QQSYSTPFT 
MP2 D11 GFTFTDYYMS YIDTGSGGTYTKYADSVKG LWTLGGWYFDL QASQDISNYLN DASNLET QQYDNLRLT 
US Patent 
20120095193 
DAWMD EIRNKANNHARHYAESVKG TYYYGSSYGYCDV RTSENIYSYLA NAKTLAE QHHYGTPWT 
US Patent 
20120095193 
DAWMD EIRHKANDHAIFYDESVKG PFAY KASQNVGTAVV SASNRHT QQYTSYPFT 
 
Table 6.1: Sequences of lead antibodies and comparison with sequences described in US Patent 20120095193 
(Burden et al., 2012). 
 
The antibodies characterised here show different epitopes (Table 6.2). Inhibitory potency of 
antibody 2A11 is affected by TIMP-3. However, the interaction with GM6001 is positive. NMR 
studies indicate that the binding mode between TIMPs and MMPs are similar to zinc-chelating 
MMP inhibitors. The N-terminal side-chains of TIMP-1 (Thr2) and TIMP-2 (Ser2) (Fernandez-
Catalan et al., 1998) have both been shown to extend into the S1’pocket containing the catalytic 
zinc ion of MMP-3. Hydroxamate inhibitors such as GM6001 also target the catalytic zinc ion 
within the S1’ pocket; however, the number of interactions established with enzyme subsites is 
considerably less. It is thus likely that 2A11 binds to the Cat/Dis domain of ADAMTS-5 without 
chelating the zinc ion. Competition with TIMP-3 may occur through overlapping contacts in the 
catalytic site cleft or in the Dis domain (Figure 5.28). 
Similar interactions with GM6001 and TIMP-3 are observed in the case of 2D3. Thus, 
binding of this antibody does not compete with small molecule inhibitors but competes with the 
macromolecular protein inhibitor TIMP-3 which has extended contact sites with the enzyme. 2D3 
(like 2A11) acts therefore as an allosteric orthosteric inhibitor since it competes with the 
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endogenous ligand for access to the enzyme. Interestingly, 2D3 has a long (20 residues) heavy 
chain CDR3 loop, whereas 2A11, 2B9, 2D5 and 2D11 have smaller heavy chain CDR3 loops (11-
13 residues) (Table 6.1). The main chain conformations are determined not only by the primary 
amino acidic sequence but also by the length of the antigen-binding loop, with longer loops 
associated with active-site inhibition (De Genst et al., 2006). 
 
Clone Ki app  
QF 
peptide 
(nM) 
Ki app 
Aggrecan 
(nM) 
KD 
(nM) 
Epitope Interaction  
with GM6001 
Interaction 
with TIMP-3 
Interaction  
with heparin 
Interaction 
with 2B9 
2A11 180 ni 94 Dis-Cat + - 0 + 
2B9 ni 300 6.7 Sp 0 - 0 na 
2D3 2.5 30 2.8 Dis-Cat + - 0 + 
2D5 20 300 29 Dis-Cat 0 + 0 + 
2D11 70 100 22 Dis-Cat 0 + 0 + 
 
Table 6.2: Summary of characterisation of anti-ADAMTS-5 antibodies. Data for ADAMTS5-2 are reported. ‘+’ 
indicates positive interaction, ‘- ‘negative interaction and ’0‘, null interaction in the QF peptide cleavage assay. Ni, not 
inhibiting, na, not applicable. KD values were measured by SPR. 
 
We can compare the epitopes of anti-ADAMTS-5 antibodies with those of the anti-
ADAMTS-5 antibodies described by GSK in US Patent 2012/0095193 (Burden et al., 2012). GSK 
antibodies were isolated by hybridoma technology and bind simultaneously to both Cat and Dis 
domains. The Cat and Dis domains of ADAMTS-5 are separated by a connecting peptide that may 
give some flexibility between the domains and act to regulate the substrate localisation to the 
catalytic site. GSK anti-ADAMTS-5 antibodies likely lock the Cat and Dis domains, thus impairing 
the flexibility between these regions. It thus seems that the effect of antibody binding on 
ADAMTS-5 is entropy-dominated. It is possible that antibodies directed against the Cat/Dis domain 
of ADAMTS-5 such as 2A11 and 2D3 may bind at the interface between the Cat/Dis domain and 
follow a similar mechanism of inhibition. 
A different mechanism may characterise inhibition of ADAMTS-5 by 2D5 and 2D11 scFv-
Fc antibodies. Inhibitory potency of 2D5 is not affected by GM6001 and only slightly increased in 
the presence of TIMP-3 (an increase in inhibitory potency of TIMP-3 was observed in the presence 
of 2D5, see Figure 5.20 and Table 5.7). Also, the higher KD shown for ADAMTS5-5 compared 
with ADAMTS5-2 confirms that crucial interactions with ancillary domains happen in this case. 
This behaviour recalls that of an anti-ADAM-17 cross-domain inhibitory antibody described by 
Tape et al. (2011). We can speculate that 2D5 binds to the back of the Cat/Dis domain of 
ADAMTS-5 opposite to the catalytic site cleft. Antibody 2D11 showed the most peculiar 
mechanism of inhibition. This antibody shows increased inhibitory potency in the presence of 
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TIMP-3 and binds to ADAMTS5-2 and ADAMTS5-5 with similar affinity. Again, a possibility is 
that 2D11 binds to the back of the enzyme. Synergism with TIMP-3 has not been previously 
reported with antibody inhibitors. For example, the cross-domain anti-ADAM17 inhibitory 
antibody D1(A12) shares a partially overlapping catalytic-cleft with TIMP-3 so it may simply block 
access of macromolecular substrate to the active site (Tape et al., 2011). Thus, 2D5 and 2D11 act as 
allosteric modulators which do not compete with endogenous ligands and therefore can exert their 
effect even if the active-site ligand (TIMP-3) is bound. Mechanistically, this may involve an 
undescribed mechanism of inhibition. In vivo synergism with TIMP-3 may represent a way to 
increase inhibitory potency and treatment efficacy, and to reduce therapeutic dose. 
A totally different mechanism is exerted by anti-Sp antibody 2B9. It induces allosteric 
effects that are more detrimental to the cleavage of the macromolecular substrate (aggrecan) but not 
to the peptide substrate. A similar trend was observed with a Fab inhibitory antibody of the trypsin-
like hepatocyte growth factor activator (HGFA) (Wu et al., 2007), although in our case no inhibition 
of peptide substrate cleavage was observed at all. Also, monoclonal antibodies mAb 5, mAb 16 and 
mAb394 which bind to the serine protease domain of uPA do not inhibit the peptidolytic activity of 
uPA (Petersen et al., 2001). However these antibodies block plasminogen activation. So the active 
site cleft is still accessible to small molecule synthetic substrate in the presence of bound 
monoclonal antibodies (Petersen et al., 2001). Therefore, the inhibitory effects observed with 
peptide substrates do not always reflect those observed with macromolecular substrates. This 
indicates that peptide substrates are inadequate surrogates of natural protein substrates, which 
require precise alignment of the scissile bond involving interactions with exosites (Gendron et al., 
2007). Recently, an inhibitory antibody of ADAMTS-5 directed against the Sp domain, CRB0017,  
has been reported by Visintin et al. (2012). The mechanisms of 2B9 and CRB0017 can be compared 
to those of auto-antibodies present in patients with TTP, that mainly target the Sp domain of 
ADAMTS-13 and impair initial binding of the enzyme to the substrate (Zheng et al., 2003). Ability 
of 2B9 to inhibit only aggrecan cleavage with no effect in QF peptide cleavage, together with 
Biacore data, defined this antibody as a truly exosite antibody and may challenge the use of 
synthetic substrates during drug screening. In this instance, our use of both QF peptide and the 
physiological substrate aggrecan allowed the identification of both active-site directed and exosite-
directed antibodies.  
Potentially, antibodies that bind to the exosites of ADAMTSs are attractive as they could 
modulate enzyme activity for the natural substrates with high-specificity. In fact they either 1) mask 
scissile bonds on the substrate; 2) compete with the substrate for protease binding at exosites; 3) 
reduce the binding and cleavage of specific substrates while still allowing for proteolysis of other 
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substrates of the same enzyme. For example, anti-ADAMTS-5 Sp antibodies such as 2B9 may 
spare versicanase activity of ADAMTS-5 while still inhibiting aggrecanase activity. This is 
particularly important given the increasing evidence of ADAMTS-5 as a versicanase and the 
importance of this activity in vasculature since decreased cleavage of versican in arterial smooth 
muscle cells and pericardial cavities is involved in myxomatous valve disease (Dupuis et al., 2011) 
and development of aortic lesions (Didangelos et al., 2012). 
In conclusion, we may hypothesise that binding of antibodies to the Cat/Dis domain of 
ADAMTS-5 finally distorts active site structure, resulting in a loss of binding affinity to substrate, 
products and possibly transition states; on the other hand, the effect on catalysis by anti-Sp antibody 
2B9 may be mediated by blocking or hampering accessibility of macromolecular substrates. 
Ultimately, description of the exact mechanism of inhibition may require X-ray crystallography. 
 
6.2. Therapeutic development of anti-ADAMTS-5 scFv-Fc antibodies 
Owing to their human origin, scFv-Fc antibodies could go straight into therapeutic 
development as lead compounds, for example by reconstituting a full IgG or by fusion to another 
antibody to generate a bispecific antibody. However, efficacy, clearance and toxicity in mouse 
models of OA should be assessed.  
Species cross-reactivity allows better assessment of therapeutic efficacy and toxicity in 
animal models. We have shown the ability of anti-ADAMTS-5 antibodies to inhibit the mouse 
orthologue. It is noteworthy that cross-reactive antibodies are often difficult to obtain by hybridoma 
methods owing to tolerance. In contrast, phage display libraries are unaffected by immune tolerance 
and antibodies targeting conserved sites across species have proved to be more the rule than the 
exception (Carter, 2006). 
In view of a potential therapeutic application, we have also shown that scFv-Fc antibodies 
2B9, 2D3, 2D5 and 2D11 inhibit the mouse version of ADAMTS-5 (Table 5.1 and Figure 5.3). 
Altogether, these encouraging results suggest that a future line of research should focus on using 
animal models of OA such as the DMM model or the spontaneous OA model with STR/ort mice 
(Mason et al., 2001) to test the therapeutic efficacy of anti-ADAMTS-5 antibodies. However, the 
effect of anti-ADAMTS-5 scFv-Fc antibodies on cell viability of isolated chondrocytes needs to be 
assessed before further development. 
Another argument which should be addressed for therapeutic development of anti-
ADAMTS-5 antibodies is the antibody format. In vivo half-lives of about 2-3.5 h are reported for 
scFvs (Powers et al., 2001; Holliger and Hudson, 2005) but these increase up to 93 h for scFv-Fc 
fusions (Powers et al., 2001). The reason for this prolonged serum half-life lies in the increased size 
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of the scFv-Fc dimer (approximately 110 kDa versus 25 kDa for scFv), which is well above the 
renal cut-off (50 kDa) (Powers et al., 2001; Holliger and Hudson, 2005). Moreover, the Fc domain 
recruits cytotoxic effector functions through complement and/or through interactions with Fcγ 
receptors (Fc receptors for gamma globulins) and can provide long serum half-lives (>10 days) 
through interaction with the neonatal Fc receptor (FcRn). FcRn acts as a salvage receptor by 
binding to and transporting IgGs in intact form both within and across cells, and rescuing them from 
a default degradation pathway (Woof and Burton, 2004). A reason for the diminished in vivo half-
life from IgGs to scFv-Fc fusions is that in the latter case the linker residues can be exposed and 
thereby result in increased protease degradation. In conclusion, although scFv-Fc fusions could be 
tested directly for in vivo efficacy, eventually they may need to be reformatted in the standard IgG 
format. However, reformatting into an IgG may lead to a decrease in affinity of the molecule due to 
lack of degrees of freedom. In fact, although the Fv shares similar antigen-binding properties as the 
Fab or IgGs, the relative orientation of the VL and the VH domains in the Fv is not necessarily the 
same as that found in the IgG, owing to the lack of the constant regions and the presence of the 
linker. As a consequence, all residues of the IgG variable/constant domain interface become 
solvent-exposed in scFv. In an analysis of 30 non-redundant Fab structures it was found that in the 
region of the Fv fragment that originally in the IgGs constitutes the variable/constant domain 
interface the frequency of exposed hydrophobic residues is much higher than in the rest of the Fv 
fragment surface (Nieba et al., 1997). It is very likely that the success of reformatting from scFv-Fc 
to IgG is largely paratope-dependent. 
Another issue to address is affinity. The antigen-binding affinity of current antibody 
therapeutics ranges from a KD of 0.08 nM to 32 nM (Carter, 2006). Average monovalent affinities 
of primary hits from phage display libraries are usually distributed in the double-digit nanomolar 
range, matching the monovalent affinities of animal-derived mAbs (Carter, 2006). Affinity of lead 
antibodies such as 2D3 and 2B9 falls into the low nanomolar range (KD 2 nM and 6 nM, 
respectively). However, depending on their efficacy in mouse models, this affinity may need to be 
improved by affinity maturation. Antibodies such as 2B9, which are characterised by a relatively 
high dissociation rate constant (See Section 5.4), are particularly amenable to improvements by 
affinity maturation. For example, cloning of the VH domain into a phage display library consisting 
only of VL domains (a process termed “light-chain shuffling”) will generate an antigen-biased 
phage display library containing a large repertoire of alternative VL domains in combination with 
the VH domain of the candidate scFv which can be selected and re-screened for improved affinity 
(Marks et al., 1992). Light-chain shuffling is limited to antibodies whose VH domains contribute 
significantly to define the paratope. Error-prone PCR may be used to introduce random mutations 
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throughout the variable domains. This method has minimal bias toward any specific class of 
substitutions and allows mutations in CDR and in scaffold regions (Hoogenboom, 2005).  
It is noteworthy that for some applications, such as virus neutralisation (Wu et al., 2005) and 
tumour targeting (Rudnick and Adams, 2009), there is no strict correlation between affinity and 
efficacy above a certain threshold. Engineered high-affinity antibodies have been shown to not 
necessarily have superior tumour-targeting efficacy compared with low-affinity variants, but on the 
contrary, may display diminished penetration into solid tumours (Thurber et al., 2008; Rudnick et 
Adams, 2009). 
As a comparison, anti-ADAMTS-5 antibodies deposited in the US Patent 2012/0095193 
(Burden et al., 2012) show KD values between 0.9 nM and 0.08 nM with the ability to block 
aggrecanase activity at Glu392↓393Ala (as measured by ELISA) in the range of 0.05-2.5 nM. Mice 
which received a single dose (0.5 mg) of anti-ADAMTS-5 antibodies 3 days prior to surgical DMM 
were protected against cartilage degradation, thus mimicking the protection exhibited by Adamts-5 
knock out mice (Burden et al., 2012; Glasson et al., 2005). Similarly, CRB0017 mAb, which binds 
to the Sp domain of ADAMTS-5 with affinity in the low nanomolar range, delays cartilage 
breakdown in STR/ort mice when administered intra-articularly, thus proving that exosite antibody 
inhibitors may be effective as therapeutic tools (Chiusaroli et al., 2013).  
It would be interesting to test the effects of co-administration of two anti-ADAMTS-5 
antibodies on the same mouse. An alternative to co-administration is represented by bispecific-
antibodies. Bispecific antibodies are hybrid molecules that comprise two specificities. To increase 
the binding avidity to a target; bispecific antibodies have been constructed by combining two 
antibodies or their fragments directed against different epitopes on the same target (Cheong et al., 
1990; Holliger et al., 1993). Frequently, the antigen-binding avidity of the bispecific molecule is 
shown to be 1 to 2 logs higher than its individual constituents (Cheong et al., 1990). This increased 
avidity is probably due to the fact that the bispecific antibody, although monovalent to each epitope, 
is in fact bivalent to its target since both of its epitopes are located within the same molecule, 
providing that these epitopes are not overlapping. 
Methods described to produce bispecific antibodies involve hybrid hybridomas (Milstein 
and Cuello, 1983), minibodies (Hu et al., 1996), diabodies (Holliger et al., 1993), chelating 
recombinant antibodies (Neri et al., 1995) and bisFvs (Atwell et al., 1996). BisFvs are dimers of 
two scFvs with different specificities: each scFv has a short linker (5 aa) which prevents the pairing 
of VH and VL domains on the same molecule and favours the formation of non-covalent dimers 
(Atwell et al., 1996). Chelating recombinant antibodies are bispecific scFv composed by two scFvs 
specific for two non-overlapping epitopes on the same antigen molecule connected by a flexible 
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polypeptide linker (Neri et al., 1995). The production of bispecific IgGs by co-expressing two 
different antibodies is not very efficient as a result of unwanted pairings between the component 
heavy and light chains (Suresh et al., 1986). Engineering of the interaction interface in antibody 
variable and constant domains can provide an efficient alternative way to drive heterotypic pairing 
(Carter, 2001). 
As an alternative to create bispecific IgGs, Bostrom and co-workers (2009) obtained dual 
specific antibodies derived from a monospecific antibody through mutations in the periphery of the 
antigen binding site in the light chain CDRs. An antigen-binding site is thus potentially able of 
interacting with two unrelated antigens with high affinity.  
In our case we have shown that combination of an antibody directed against the Cat/Dis 
domains of ADAMTS-5 (such as 2D3) with the anti-Sp antibody 2B9 produces a greater inhibitory 
effect than the single antibody. Thus an alternative approach to increase efficacy of anti-ADAMTS-
5 antibodies would be the creation of a bispecific anti-ADAMTS-5 antibody recognising different 
domains on the antigen. However, before undertaking the creation of such antibodies, other 
experiments are mandatory. For example, one antibody such as 2B9 can be chemically immobilised 
and the affinity for the ADAMTS-5/2D3 complex can be measured by SPR. In this way it would be 
possible to establish if 2B9 and 2D3 do not indeed share an overlapping epitope. 
 
6.3.  Other applications of anti-ADAMTS-5 antibodies 
In this work we described the characterisation of 54 anti-ADAMTS-5 antibodies. These 
antibodies were screened not only for their inhibitory potential (Section 4.4.2) but also for their 
ability to bind to ADAMTS-5 in a semi-solid-phase ELISA (Section 4.3.4). Although they were 
selected and screened against a native mature form of the enzyme, they were generally able to 
recognise ADAMTS-5 in SDS PAGE when the protein was not previously heat-denatured under 
non-reducing conditions (Section 4.4.3). By blotting different deletion forms of ADAMTS-5 it was 
possible to assign each antibody to a specific domain of the enzyme. It is evident that the anti-
ADAMTS-5 antibodies here described may provide a toolbox to deepen our knowledge of 
ADAMTS-5 biology and its functional role in OA setting. Usage of scFv-Fc antibodies for Western 
blotting and immunostaining has been previously shown (Moutel et al., 2009). We report here some 
applications of anti-ADAMTS-5 antibodies. 
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i) Effect on ADAMTS-5 endocytosis 
Acquired TTP has been linked to severe deficiency of ADAMTS-13 activity caused by 
inhibitory auto-antibodies (Levy et al., 2001; Soejima et al., 2003). However, it has been reported 
that some of these antibodies found in patients with TTP failed to inhibit ADAMTS-13 activity, 
suggesting they may influence the half-life of the enzyme, thereby compromising the regulation of 
its activity in vivo (Scheiflinger et al., 2003; Shelat et al., 2006). These non-neutralising auto-
antibodies may reduce the absolute amount of target at different anatomical sites by antibody-
mediated clearance. ADAMTS-5 has been shown to be regulated by endocytosis and this process is 
mediated by exosites (Yamamoto et al., 2013). Specifically, since the TS-1 domain is necessary but 
the Sp domain increases the rate of clearance (Yamamoto et al., 2013), it will be interesting to 
investigate the effect of antibodies directed against specific ADAMTS-5 domains on endocytosis. 
Antibodies able to increase clearance of ADAMTS-5, even if they are not able to inhibit catalytic 
activity, may have a potential for therapeutic use in the OA setting. 
 
ii) Extracellular localisation of ADAMTS-5 
Our lab has shown the extracellular localisation of ADAMTS-5 in human chondrosarcoma 
HTB-94 cell line (Gendron et al., 2007). The CysR domain is critical for ADAMTS-5 binding to the 
cell surface and ECM. However, a limitation of this study was that recombinant ADAMTS-5 was 
used, due to the lack of sensitive and specific anti-ADAMTS-5 mAbs. It will be therefore 
interesting to test the ability of anti-ADAMTS-5 antibodies here described to detect endogenous 
ADAMTS-5. Moreover, due to the availability of antibodies directed specifically against different 
domains of ADAMTS-5, it would be possible to test which ADAMTS-5 form predominates in 
different cell lines or, eventually, in sections from in vivo tissues or in patients with degenerative 
cartilage pathologies such as OA or RA. The specificity of monoclonal anti-ADAMTS-5 antibodies 
should be tested by immunoprecipitation from lysates of Adamts-5 knock out and wild-type cells. 
 
iii) Resolution of ADAMTS-5 structure 
To accurately describe the interactions between antibodies and ADAMTS-5 the 
antibody/enzyme complex could be structurally resolved by co-crystallisation, followed by X-ray 
crystallography. In protein crystallography, Fab and scFv antibody fragments that bind to their 
antigens with high affinity and specificity have been employed as crystallisation chaperones, thus 
permitting successful structure determination of several “difficult” protein targets (Iwata et al., 
1995; Koide, 2009). Backbone flexibility and conformational heterogeneity are a feature of MMP 
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structures in general (Bertini et al., 2005) and of ADAMTS-5 in particular (Shieh et al., 2011), so it 
may be worth obtaining complexes between ADAMTS-5 and different antibodies. mAbs are able to 
discriminate between different conformations of the same antigen (Gao et al., 2009), thus it would 
be interesting to check if the anti-ADAMTS-5 antibodies reported here are directed against different 
conformations of ADAMTS-5. Crystallisation of Fab/ADAMTS-5 complex may identify allosteric 
regions which are currently not predicted by modelling and help to elucidate the mechanisms of 
ADAMTS-5 catalysis.  
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